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ABSTRACT 
 
 The Cephalotaxus esters are a class of alkaloids extracted from plants of the 
Cephalotaxus genus and have been shown to be potent inhibitors of P-388 murine leukemia 
cells.  While direct acylation of cephalotaxine has been reported to be difficult, the construction 
and acylation of cephalotaxine using a β-lactone acyl chain surrogate in the synthesis of 
anhydroharringtonine, deoxyharringtonine, homodeoxyharringtonine, and homoharringtonine is 
described.  The natural esters as well as several non-natural analogues were tested against 
various human cancer cell lines not previously challenged by these alkaloids.  Variations in the 
structure of the ester chain were found to confer differing activity profiles against vincristine 
resistant HL-60/RV+. 
The Aconitum and Delphinium alkaloids comprise a family of compounds isolated from 
the Aconitum and Delphinium genera.  Several compounds within this class show potent Na+ ion 
channel activity ranging from the ion channel activation of aconitine to the ion channel blocking 
of lappaconitine.  The completed synthesis of the skeleton of the C19-diterpenoid alkaloids is 
described.  Key steps include a Diels–Alder cycloaddition of a cyclopropene with a                  
2,5-dioxycyclopenta-1,3-diene, a second Diels–Alder cycloaddition with a 2,5-dihydroazepine 
2π component, an intramolecular N-acyliminium cyclization, and a radical conjugate addition. 
 
 ii
ACKNOWLEDGEMENTS 
 
 
 First and foremost, I would like to thank my lovely and intelligent wife Laura. I look 
forward to sharing the fruits of this labor with her for the rest of our lives. I would also like to 
thank my parents, Cindy and Terry, for doing their best with what they had. My sisters, Jessica 
and Melissa, have always been there for me through the tough times as well as the good.  
 I would like to thank my advisor, Professor David Y. Gin. He has taught me to face 
challenges head-on and to develop new strategies when the known ones fail. I also appreciate the 
time and effort he has expended in helping me to achieve all of my goals.  He has really gone 
above and beyond the requirements of a thesis advisor. I would also like to thank the other 
members of my committee: Professor Paul J. Hergenrother, Professor Martin D. Burke, and 
Professor Benjamin J. McCall. I would particularly like to thank them for agreeing to continue in 
their roles despite my relocation to New York City and all of the difficulties associated with 
teleconferencing.  
 I also acknowledge my past and present colleagues in the Gin Group: Dr. Danica P. 
Galonic, Dr. Kyle D. Bodine, Dr. Nathan D. Ide, Dr. Kevin M. Peese, Dr. Daniel A. Ryan, Dr. 
Michael A. Arnold, Dr. Ryan J. Carra, Dr. Michelle M. Adams, JohnMark Derryberry, Hahdi H. 
Perfect, Nathan S. Werner, Annie Won, Dr. Pengfei Wang, Dr. Kai Deng, Dr. Jianfeng Hang, Dr. 
Timothy A. Boebel, Dr. Joseph D. Eckelbarger, Dr. Michael S. Bultman, Eric Chea, Dr. Roman 
Ivanov, Dr. Jun Ma, Dr. Nicholas Perl, Dr. Matthew Volgraf, Dr. Bryan Cowen, Dr. Alberto 
Fernandez, Rashad Karimov, Dr. Mike Krout, Dr. Pingfan Li, Dr. Lars Nordstrom, Nathan Park, 
Dr. Daniel Pla, Sudeep Prajapati, Dr. Troy Reynolds, Yuan Shi, and Bill Walkowicz. In 
particular I would like to thank two people with whom I have worked on the projects described 
 iii
herein: Dr. Joseph Eckelbarger and Yuan Shi. I would also like to thank my friends Dr. Michael 
Bultman and Dr. Timothy Boebel for all of their support and friendship throughout the years. 
 iv
TABLE OF CONTENTS 
 
CHAPTER 1. SYNTHESIS OF CEPHALOTAXUS ESTERS........................................................1 
1.1 Introduction to the Cephalotaxus Esters........................................................................1 
1.2 Previous Approaches for the Acylation of Cephalotaxine.............................................2 
1.3 Synthetic Strategy for the Synthesis of Cephalotaxus Esters........................................4 
1.4 Cephalotaxine Synthesis Improvement..........................................................................5 
1.5 Synthesis of an Acyclic Acyl Chain..............................................................................6 
1.6 Synthesis of (–)-Anhydroharringtonine.........................................................................9 
1.7 Synthesis of (–)-Deoxyharringtonine...........................................................................10 
1.8 Synthesis of (–)-Homoharringtonine and (–)-Homodeoxyharringtonine....................11 
1.9 Synthesis of Non-natural Cephalotaxus Ester Bis(demethyl)deoxyharringtonine......15 
1.10 Antiproliferative Activity of Natural and Non-natural Cephalotaxus Esters............16 
1.11 Summary....................................................................................................................19 
1.12 Experimental..............................................................................................................20 
1.13 References..................................................................................................................47 
 
CHAPTER 2. INTRODUCTION TO THE C19-DITERPENOID ALKALOIDS.........................50 
2.1 History and Characterization.......................................................................................50 
2.2 Biological Activity and Structure Activity Relationships...........................................52 
2.3 Previous Synthetic Approaches to the Aconitum and Delphinium Alkaloids..............53 
2.4 Summary......................................................................................................................58 
2.5 References....................................................................................................................58 
 v
 CHAPTER 3. RETROSYNTHETIC ANALYSIS OF THE ACONITINE SKELETON.............60 
3.1 General Approach........................................................................................................60 
3.2 Retrosynthetic Analysis...............................................................................................61 
3.3 References....................................................................................................................63 
 
CHAPTER 4. SYNTHESIS AND EXPLORATORY RADICAL CYCLIZATIONS OF A KEY 
CYCLOPROPYLCARBINYL RADICAL PRECURSOR...........................................................64 
4.1 Synthesis of the [2.1.1.0]-Tricylic Ring System..........................................................64 
4.2 Cyclopropylcarbinyl Radical Model Study.................................................................72 
4.3 Synthesis of the [5.4.0]-Bicycloazepine System..........................................................76 
4.4 Undesired 5-Endo Cyclization of a C8 Radical onto C1.............................................80 
4.5 Summary......................................................................................................................82 
4.6 Experimental................................................................................................................84 
4.7 References..................................................................................................................138 
 
CHAPTER 5. EXPLORATION OF A CATION-Π CYCLIZATION CASCADE TO ACCESS 
THE ACONITINE ALKALOIDS...............................................................................................143 
5.1 Addition of an Enol-ether onto an N-Acyliminium to Form the C11–C17 Bond.....143 
5.2 Attempts at Enol-ether Hydrolysis.............................................................................149 
5.3 Summary....................................................................................................................155 
5.4 Experimental..............................................................................................................156 
5.5 References..................................................................................................................173 
 vi
 CHAPTER 6. CONCLUSIONS AND PROSPECTUS...............................................................175 
6.1 Innovations Resulting from the Cephalotaxus Esters Syntheses...............................175 
6.2 Innovations Resulting from the Current Approach to the Aconitine Alkaloids........176 
 vii
CHAPTER 1. SYNTHESIS OF CEPHALOTAXUS ESTERS 
1.1 Introduction to the Cephalotaxus Esters 
A new family of alkaloids was isolated from plants of the Cephalotaxus genus in 1963.1 
The structure of cephalotaxine (1), the major constituent of these compounds, was elucidated in 
1969 using 1H NMR, IR, MS, and X-Ray analysis.2,3 Several minor constituents have also been 
isolated. These include deoxyharringtonine (2),4 anhydroharringtonine (3),5 homoharringtonine 
(4),6 and homodeoxyharringtonine (5).7 Through spectroscopic, degradation, and partial 
synthesis studies, these compounds were found to differ from 1 only by the presence of an acyl 
chain attached via a C3-O-ester linkage at the cephalotaxine hydroxyl group.4-7 These acyl chains 
vary in the length and oxidation of an alkyl substituent at C2', while a β-hydroxy ester at C2' and 
C4'' is a common feature to the side chains. Anhydroharringtonine (3) is unique in that its C2' 
hydroxyl has been incorporated into a furan ring. Although cephalotaxine (1) itself has been 
found to be biologically inactive, the esters are remarkably cytotoxic against P388 and L1210 
leukemia cells.8,9 For instance, deoxyharringtonine (2), homoharringtonine (4), and 
homodeoxyharringtonine (5) exhibit IC50 values of 7.5, 17, and 56 ng mL-1, respectively, against 
murine P388 leukemia cells. Likewise, anhydroharringtonine (3) has been reported to induce 
98% growth inhibition of murine P388 leukemia cells at 1 μg mL-1,9 an activity that is 
comparable to that of deoxyharringtonine (2). In particular, homoharringtonine (4) has reached 
Phase III clinical trials in the U. S. for the treatment of chronic myelogenous leukemia and has 
also gained considerable interest in China and Europe.10-13 The cytotoxicity of the Cephalotaxus 
esters is the result of reversible inhibition of protein synthesis14 via induction of rapid breakdown 
of the polyribosome, with concomitant release of the polypeptide chain.15 Despite production 
difficulties, hematologic toxicity, and susceptibility to multidrug resistance (MDR),16 
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homoharringtonine (4) has maintained interest as a component of combination therapy in the 
treatment of chronic myeloid leukemia. 
 
 The development of the Cephalotaxus esters as a viable cancer therapy has been hindered 
by their relative scarcity from natural sources in comparison to that of cephalotaxine (1) itself. 
Typically, complex Cephalotaxus esters are attainable in only <0.1% of the plant dry weight. 
Therefore, a primary goal of the efforts described herein was the design and execution of a 
method for the production of both natural and non-natural bioactive Cephalotaxus esters that is 
distinct from previous efforts.  
1.2 Previous Approaches for the Acylation of Cephalotaxine 
A synthesis of cephalotaxine (1) has recently been completed within our group,17 
however the biological activity of the esters provide incentive for investigations into their 
synthesis. The major challenge has been shown to be direct esterification 1 with a fully 
functionalized acyl chain due to steric encumberance at C2' of the acyl chain combined with the 
location of the cephalotaxine C3-OH within the concave face of the ring system.4 Previously, the 
few reported esterifications of cephalotaxine (1) have utilized either partially constructed acyl 
chains with sp2 hybridization at C2' to provide steric relief or fully elaborated lactonized acyl 
chains,18 however even these efforts have met with limited success (Scheme 1). For example, 
acylation of cephalotaxine (1) with α-ketoacyl chloride 6 provided α-ketoester 7, which was 
treated with the lithium enolate of methyl acetate to yield deoxyharringtonine (2) in just 6% yield 
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over two steps (Scheme 1A).19 This use of an achiral acyl chain equivalent resulted in a C2' 
epimeric mixture of compounds with a consequent reduction in yield. To our knowledge, no 
efficient synthesis of 2 has been reported. A similar method was utilized by Hudlicky and co-
workers20 in a synthesis of homoharringtonine (4). Cephalotaxine (1) was treated with α-ketoacyl 
chloride 8 to provide an unstable α-ketoester 9. A subsequent Reformatsky21 reaction installed 
the C2' β-hydroxyester 10, and finally methyl Grignard addition to the C6 carbonyl yielded 
homoharringtonine (4) in 25% yield over three steps (Scheme 1B). In contrast to the lithium 
enolate addition mentioned in the previous example, Hudlicky reports the Reformatsky reaction 
to stereoselectively generate a single C2' diastereomer. However, the reported instability of the 
α-ketoester intermediate and poor yields of the Grignard addition limit the utility of this method. 
A notable deviation from these known strategies was introduced by Kelly and co-workers,18 who 
demonstrated the ability to attach a fully elaborated acyl chain equivalent with an sp3 center at 
C2' using activated macrolactone 11 to produce ester 12. It was postulated that the lactone favors 
a conformation which reduces the impact of the sterically large substituents and allows for more 
facile acylation. Subsequent methanolysis of lactone 12 produced methyl ester 13 and 
deprotection of the benzyl ether yielded harringtonine (14) in 19% yield over three steps 
(Scheme 1C).  
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 1.3 Synthetic Strategy for the Synthesis of Cephalotaxus Esters 
In the development of an efficient synthetic strategy for attaching the acyl chains, 
evaluation of the existing methods proved useful to the formulation of a new strategy. Kelly’s 
use of a macrolactone demonstrates the ability to attach the acyl chain by simply incorporating 
C2' into a cyclic structure. As anhydroharringtonine (3, Figure 1) naturally constrains C2' within 
a ring, direct attachment of an appropriately activated acid should be possible.22 However, a 
more rewarding solution would be the attachment of an acyl chain that would directly lead to any 
of the esters, even those with no C5'/C6' hydroxyl, such as deoxyharringtonine (2) and 
homodeoxyharringtonine (5). A novel and general solution would be to transform the β-hydroxy 
ester at C2' and C4'', a structural feature common to many potent Cephalotaxus esters, into a β-
lactone such as 16 (Scheme 2). This lactone was hypothesized to sufficiently reduce congestion 
at C1' to allow effective acylation to occur. Further retrosynthetic analysis reveals the use of 
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Seebach’s self reproduction of stereocenters (SRS)23 alkylation to set the tetrasubstituted 
stereocenter at C2'.24 The carbon skeleton and chiral information can then be provided by 
commercially available D-malic acid. The benefits of this strategy include asymmetry from 
cheap, commercially available starting materials, no reliance on C5'/C6' oxidation, and 
consequently, many natural and unnatural cephalotaxus esters would be available by simply 
varying the electrophile used in the alkylation. 
 
1.4 Cephalotaxine Synthesis Improvement 
Prior to embarking on acylation studies of cephalotaxine (1), an improvement upon the 
recently completed synthesis of 1 itself was desired. Chloroenone 18 was a key intermediate in a 
synthesis of 1, however, the synthesis of this compound was somewhat lengthy at 10 steps 
(Scheme 3). Previous efforts to more directly access 18 by chloroselenylation of the previously  
 
reported enone 1925 had met with failure (Scheme 4), possibly due to the electron poor nature of 
the olefin.  It was thought 1,2-reduction to the allylic alcohol would increase the electron density 
of the alkene to render it more susceptible to electrophilic attack by selenium. Indeed, Lüche 
reduction26 of the enone in 19 followed by treatment of the resulting allylic alcohol 21 with 
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phenylselenenyl chloride successfully generated chloroselenide 22. Selenium oxidation with m-
chloroperbenzoic acid produced a mixture of diastereomeric selenoxides. While one 
diastereomer underwent spontaneous syn elimination at 20 °C, the other required extensive 
heating in the presence of triethylamine, likely due to unfavorable 1,3-diaxial interactions of the 
phenyl group in the conformation required for 1,2-syn elimination, to yield allylic alcohol 23 
(Scheme 5).* Oxidation of the hydroxyl group in 23 was effected with Dess–Martin Periodinane 
(98%) to yield chloroenone 18 in 65% yield over four steps from enone 19; a significant 
improvement over the previous 10 step route. 
 
 
1.5 Synthesis of an Acyclic Acyl Chain 
With an improved route to cephalotaxine (1) in hand, attention was directed toward the 
synthesis and attachment of the acyl chains. In order to test the feasibility of the Seebach SRS 
                                                 
* Inversion of the selenoxide at elevated temperatures to the diastereomer more favorable for elimination cannot be 
discounted. 
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approach, a synthesis of the enantiomer of the deoxyharringtonine side chain was conducted 
(Scheme 6). The enantiomer selected for this proof-of-principle study was chosen due to the 
lower cost of natural L-malic acid over the unnatural D-malic acid required for the correct C2' 
stereochemistry. The synthesis began with the preparation of known dioxolanone 24 by 
treatment of the tris-trimethylsilyl protected derivative of L-malic acid with 
trimethylacetaldehyde in the presence of catalytic trimethylsilyl trifluoromethanesulfonate 
(TMSOTf) (82%).27 In our planned divergent step to the various acyl chains, alkylation of the 
lithium dianion of 24 with 3,3-dimethylallyl bromide was somewhat problematic following the 
known procedure,23 resulting in variable yields. However, mediation of the exotherm caused by 
the initial deprotonation of the free carboxylic acid by addition of the base in two portions 
allowed for a reproducible 66% yield of alkene 25. The SRS method has the additional benefit of 
carboxylic acid differentiation, as the α-hydroxyacid portion is protected as the dioxolanone, 
leaving the other acid free for manipulation. Thus, methyl esterification of the free acid to 
provide ester 26 was effected with trimethyldiazomethane in 92% yield. Subsequent olefin 
hydrogenation over palladium (>99%) generated diester 27 that was one step away from the 
target. Unfortunately, selective dioxolanone deprotection in the presence of the methyl ester 
proved to be difficult due to facile overhydrolysis to the diacid. A screen of acidic and basic 
hydrolysis conditions revealed aqueous acetic acid as the highest yielding hydrolysis reagent, 
however the yield was an unacceptable 37% of the requisite mono-ester 28. Alternatively, the 
desired mono-ester has also previously been shown by Mikolajczak and co-workers to be 
available from diacid 30, available by hydrogenation of 25 to give 29 followed by acidic 
hydrolysis, via selective Fisher esterification of the less hindered acid (Scheme 7).4 However, 
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long reaction times (14 days) combined with moderate yield (57%) made this method 
unattractive.  
 
As an alternative to hydrolysis, dioxolanones are known to be susceptible to methanolysis 
with sodium methoxide.28,29 Although chemoselective hydrolysis of the resulting dimethyl ester 
would be difficult, chemical differentiation could be achieved through the use of benzyl 
alkoxide, resulting in a benzyl ester that could be selectively cleaved by hydrogenolysis in the 
presence of a methyl ester. As anticipated, treatment of dioxolanone 25 (Scheme 8) with benzyl 
alcohol and sodium hydride afforded benzyl ester 31 in 88% yield. Methyl esterification of the 
carboxylic acid with trimethylsilyldiazomethane (32, 100%) was followed by hydrogenation of 
the alkene with concomitant hydrogenolysis of the benzyl ester (100%) to yield acyl-chain 28 in 
five steps and 48% yield from malic acid. This synthesis is also advantageous due to its highly 
modular nature. The β-hydroxyacid intermediate 27 would be a viable precursor to the β-lactone 
required for deoxyharringtonine (2) and β-hydroxyalkene 28 could undergo an intramolecular 
Markovnikov hydration to generate the tetrahydrofuran required for anhydroharringtonine (3). 
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 1.6 Synthesis of (–)-Anhydroharringtonine 
 As intermediate 32 from the model study (see Scheme 8) contains an unprotected            
β-hydroxyolefin, it is an ideal candidate for an intramolecular Markovnikov30 hydration. The 
resulting furan would be instrumental in the synthesis of anhydroharringtonine (3). Thus, 
treatment of ent-32 (Scheme 9) with mercury acetate and capture of the transient mercurinium 
ion by the C2' hydroxyl followed by reductive demercuration with NaBH4 produced cyclic 
diester 33 in 85% yield, with no detection of uncylized product. Subsequent benzyl ester 
hydrogenolysis (100%) provided the key furan acid 34. As anticipated, acylation of 
cephalotaxine (1) with an activated mixed Yamaguchi31 anhydride prepared from 34 proceeded 
well to complete the synthesis of the alkaloid (–)-anhydroharringtonine (3, 88%). 
ent-32
Hg(OAc)2;
NaBH4/NaOH
OMe
Me
OMeO
OBn
O
33 (85%)
H2, Pd/COBn
O
HO
Me
Me
O OMe
Scheme 9
OMe
Me
OMeO
OH
O
34 (100%)
Cl
OCl
ClCl
; 1, DMAP
O
O
N
OMe
O
O
CO2Me
OMe
Me
Anhydroharringtonine
3 (88%)
H
H
Et3N
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1.7 Synthesis of (–)-Deoxyharringtonine 
Although the successful completion of anhydroharringtonine (3) was welcome, the true 
test of the strain-accelerated acylation strategy was the attachment of a β-lactone acyl chain 
surrogate to cephalotaxine (1). The strain energy arising from the endocyclic bond compression 
within the β-lactone ring would necessarily induce exocyclic bond angle expansion, thereby 
relieving local steric congestion at the electrophilic C1' carbonyl. In addition, the angle strain 
resulting from the four-member ring imparts additional hybrid orbital s-character in the exocyclic 
bonds, an effect that could result in increased C1' electrophilicity through induction. Despite 
these potential advantages, the high strain energy inherent in the β-lactone could induce 
alternate, undesired, ring expansion pathways.  
An appropriate β-lactone acylation partner was prepared from ent-31 in the following 
manner (Scheme 10). Activation of the unprotected carboxylic acid under Yamaguchi 
conditions31 and subsequent intramolecular nucleophilic attack by the C2' hydroxyl group 
provided β-lactone 35 (50%). Hydrogenolysis of the benzyl ester with concomitant alkene 
reduction furnished key carboxylic acid 36 (99%). This β-lactone was ideal to test our hypothesis 
of strain-accelerated acylation of cephalotaxine (1). Fortunately, activation of 36 as the 
Yamaguchi mixed anhydride did not result in β-lactone decomposition and allowed for the 
efficient acylation of 1 to form the ester 37 (81%). This achievement marks the first acylation of 
cephalotaxine with a β-lactone as the coupling partner to overcome the steric encumberance at 
C1'. Methanolysis of the β-lactone then concluded the synthesis of (–)-deoxyharringtonine (2, 
76%). To our knowledge, this is the most efficient synthesis of 2 from cephalotaxine (1). To 
understand better the benefits of the β-lactone moiety in the acylation step, an analogous acyclic 
acyl chain 38 was prepared from ent-32 (Scheme 11). Acylation of the C2' hydroxyl was 
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followed by benzyl ester hydrogenolysis to furnish carboxylic acid 38 (>99%), which lacked the 
ring strain elements present in β-lactone 36. Attempts at acylating cephalotaxine with 38 under 
otherwise identical conditions resulted in the detection of only trace quantities of protected 
deoxyharringtonine. Heating the reaction mixture did not improve conversion, thus confirming 
the beneficial effects of the β-lactone moiety.  
 
Scheme 11
ent-32
OBn
O
HO
Me
Me
O OMe
OH
O
AcO
Me
Me
O OMe
1) Ac2O, pyridine
2) H2, Pd/C
38 (74%, 2 steps)
Cl
OCl
ClCl
; 1, DMAP
No observed
acylation.
Et3N
 
1.8 Synthesis of (–)-Homoharringtonine and (–)-Homodeoxyharringtonine 
As homoharringtonine (4) has gained intense interest within the medical community for 
treatment of chronic myeloid leukemia,10-13 it was also chosen as a target with which to further 
demonstrate the utility of β-lactone-accelerated esterification. Initially, synthesis of a suitable 
coupling partner was envisioned by Seebach alkylation23 of dioxolanone 24 with propargyl 
 11
bromide 43, previously prepared by graduate student colleague Joseph Eckelbarger from 
propargyl alcohol in five steps and 22% overall yield via the route outlined in Scheme 12. The 
synthesis of 43 began with the protection of propargyl alcohol as the tetrahydropyran acetal by 
treatment with 2,3-dihydropyran and p-toluenesulfonic acid to provide acetal 39 (81%). 
Deprotonation of the alkynyl proton with n-butyllithium was followed by nucleophilic attack 
onto acetone to give propargyl alcohol 40 (89%). Benzyl protection of the tertiary alcohol was 
accomplished with NaH and BnBr (41, 76%). The THP protecting group was cleaved under 
acidic conditions to reveal alcohol 42 (76%).  The propargyl alcohol was activated as the 
oxophosphonium and displaced with bromide under Appel conditions32 to give the propargyl 
bromide 43 (98%). The SRS protocol was then applied with 43 as the electrophile (Scheme 13). 
Although alkylation of the common intermediate dioxolanone 24 proceeded to produce alkyne 
44 in moderate yield (42%), transesterification of the dioxolanone with NaH and BnOH (45, 
38%) and Yamaguchi lactonization provided β-lactone 46 in only 6% yield over two steps.  
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HO
O
O H O
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H
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78 °C
NaH, BnOHO
O
O
HO O
t-Bu
H
Me
BnO
Me
OBn
O
HO
Me
BnO
Me
OHO
44 (42%)
45 (38%)
Cl
OCl
ClCl
DMAP, Et3N
4 h addition
OBn
O
O
Me
BnO
Me
O
46 (17%)
Scheme 13
24
 
Optimization of these steps may have been possible, however the long route to propargyl 
bromide 43 provided incentive to instead explore another strategy. Alternatively, the required 
one-carbon homologation and oxygen functionality installation were envisioned to be 
accomplished by olefin cross-metathesis as outlined in Scheme 14. As the alkylation of 
dioxolanone 24 with allyl bromide23 and olefin cross metathesis with a TBS protected version of 
5033 have been demonstrated by Seebach and Grubbs, respectively, the success of this strategy 
seemed very likely. Thus, alkylation of the dianion of dioxolanone ent-24 with allyl bromide 
yielded the previously prepared terminal alkene 47 (59%).23 Transesterification of the 
dioxolanone to the benzyl ester with sodium hydride and benzyl alcohol (48, 85%) and β-lactone 
formation from the β-hydroxy acid (67%) under Yamaguchi conditions provided 49 (67%), an 
appropriate partner for olefin cross-metathesis. Cross-metathesis with previously prepared benzyl 
protected allylic alcohol 5034 was more difficult than anticipated, requiring 22 equivalents of 50 
as a neat mixture with 49 and Hoveyda-Grubbs 2nd generation catalyst (56) to disfavor 
homodimerization of 49. Ultimately, 52 was obtained in 61% yield, but even under these forcing 
conditions, 23% of homodimer 51 was also isolated. Re-equilibration of 51 in the presence of 56 
provided additional quantities of 52. Chemoselective cleavage of the benzyl ester was effected 
by transfer hydrosilylation with palladium acetate and triethylsilane. The carboxylic acid group 
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was then revealed by silyl ester hydrolysis during aqueous work-up to afford key carboxylic acid 
53 (85%)35 with no detectable reduction of either the alkene or benzyl ether. Acylation of (–)-
cephalotaxine (1) under Yamaguchi conditions again proceeded in excellent yield to generate 
ester 54 (97%). The ease of this acylation further exemplified the generality of the strain-assisted 
acylation of the cephalotaxine C3 hydroxyl group. Methanolysis of the β-lactone with NaOMe 
proceeded smoothly to afford the penultimate intermediate 55 (79%).  
 
 Allylic benzyl ether 55 could be advanced to either homoharringtonine (4) or 
homodeoxyharringtonine (5) depending on the hydrogenation/hydrogenolysis conditions chosen. 
When intermediate 55 was subjected to hydrogenation conditions with Pd/C in glacial acetic 
acid, (–)-homodeoxyharringtonine (5, Scheme 15) was isolated as the major product in 69% 
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yield, presumably by elimination of the benzyl ether followed by hydrogenation of the resulting 
olefin. Deoxygenation could be inhibited by hydrogenation of the internal olefin in methanol as 
the solvent, with addition of acetic acid in the latter stages to complete C6'-O-debenzylation and 
provide (–)-homoharringtonine (4, 79%). 
 
1.9 Synthesis of Non-natural Cephalotaxus Ester Bis(demethyl)deoxyharringtonine 
 The efficient synthesis and acylation of fully-functionalized acyl chains onto 
cephalotaxine (1) to produce natural Cephalotaxus esters also provided an opportunity to prepare 
a non-natural analogue for biological evaluation with a minimum of deviation from the synthetic 
sequence. This analogue took the form of bis(demethyl)deoxyharringtonine (58, Scheme 16). 
Although much simpler than the natural Cephalotaxus esters, this analogue was also anticipated 
to also show potent antiproliferative activity. The synthesis of 58 began with interception of β-
lactone 49, an intermediate in the synthesis of both homoharringtonine (4) and 
homodeoxyharringtonine (5, refer to Scheme 14). Reduction of the terminal olefin with 
concomitant benzyl ester hydrogenolysis were accomplished with Pd/C under a hydrogen 
atmosphere to yield acid 56 (97%). Activation of 56 as the Yamaguchi mixed anhydride allowed 
acylation of cephalotaxine (1) to provide β-lactone-ester 57 (81%). Methanolysis then completed 
the synthesis of the non-natural Cephalotaxus ester bis(demethyl)deoxyharringtonine 58 in 93% 
yield. 
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1.10 Antiproliferative Activity of Natural and Non-natural Cephalotaxus Esters 
 The completed synthesis of several natural and unnatural Cephalotaxus esters outlined 
above combined with our relocation to Memorial Sloan Kettering Cancer Center (MSKCC) 
allowed us form a collaboration with the MSKCC High Throughput Screening facility to 
evaluate the antiproliferative activity of these alkaloids against a variety of cell lines. A selected 
subset of these data is summarized in Table 1. Those cell lines include HL-60 (acute 
promyelocytic leukemia), HL-60/RV+ (a P-glycoprotein over-expressing multidrug resistant HL-
60 variant which was selected by continuous exposure to vinca alkaloid vincristine), JURKAT (T 
cell leukemia), ALL3 (acute lymphoblastic leukemia recently isolated from a patient treated at 
MSKCC and characterized as Philadelphia chromosome positive), NCEB1 (Mantle cell 
lymphoma), SKNLP (neuroblastoma), Y79 (retinoblastoma), PC9 (adenocarcinoma), TC71 
(Ewing's sarcoma), HTB-15 (glioblastoma), and WD0082 (well-differentiated liposarcoma). 
From these data, we were able to deduce that the unprotected C2' hydroxyl moiety is necessary 
for potent antitumor activity. In contrast with previous reports that anhydroharringtonine (3) is as 
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potent as deoxyharringtonine (2) against P388 murine leukemia cells, this alkaloid proved 
ineffective against the majority of human cancer cell lines. In addition, while β-lactone 
intermediates 37, 54, and 57 were potent antitumor agents, their activity was around 10-fold less 
than that of their acyclic counterparts 2, 55, and 58. It could be argued that even the attenuated 
activity observed for the β-lactone analogues could be mostly due to hydrolysis of the strained 
lactone under physiological conditions to expose the C2' hydroxyl group. The relative lack of 
antitumor activity for anhydroharringtonine (3) substantiates this hypothesis, as the C2' oxygen is 
protected within the hydrolytically stable furan. Thus, the C2' hydroxyl group would not be 
revealed under physiological conditions. 
Cell Line
3
IC50 ( M)
HL-60
HL-60/RV+
JURKAT
ALL3
NCEB1
SKNLP
Y79
PC9
TC71
HTB-15
WD0082
22.67
>100
42.99
>100
>100
5.34
>100
29.08
>100
>100
>100
0.01
0.16
0.04
<0.1
0.07
<0.1
70.59
0.03
0.06
0.20
0.10
2.68
21.80
5.71
1.47
8.62
6.46
>100
4.23
12
52
5
0.01
0.10
0.03
<0.1
0.06
<0.1
>100
0.04
0.03
0.10
0.05
3.68
28.25
7.32
1.84
22.92
8.83
42.28
9.66
12
73
13
0.08
0.8
0.19
0.16
0.15
0.11
>100
0.13
0.20
0.50
0.20
5.73
40.3
12.01
4.24
39.24
10.04
>100
11.29
24
58
11
2
IC50 ( M)
37
IC50 ( M)
55
IC50 ( M)
54
IC50 ( M)
58
IC50 ( M)
57
IC50 ( M)
Table 1. Cytotoxicity of Various Cephalotaxus Esters.
 
 The completion of the syntheses of natural Cephalotaxus esters 2–5 as well as non-
natural analogues bis(demethyl)deoxyharringtonine (58) and benzyldehydrohomoharringtonine 
(55) allowed the comparison of their antiproliferative activity against multi-drug resistant (MDR) 
cell line HL-60/RV+ relative to the "sensitive" HL-60 cell line (Figure 2). Although all natural 
and non-natural Cephalotaxus ester derivatives were highly potent against the sensitive HL-60 
cell line (IC50 < 0.08 um), stark differential response levels were observed within this collection. 
In particular, homoharringtonine (4) displayed a 125-fold decrease in activity against the HL-
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60/RV+ cell line relative to that of the HL-60 cell line, resulting in a resistance index of 125. By 
contrast, much lower resistance indices of 12, 11, 3.3, and 19 were observed for 55, 2, 5, and 58, 
respectively. That homoharringtonine (4) is much less effective against the MDR cell line is 
surprising given that 4 is the favored Cephalotaxus ester for advancement in the clinic. In 
contrast with 4, homodeoxyharringtonine (5) has a resistance index of 3, so the MDR cell line 
can be considered "sensitive" toward 5. One possible explanation for the medical community's 
focus on 4 is that of availability. That is, homoharringtonine (4) is both the most naturally 
abundant Cephalotaxus ester and until now was the only ester produced semi-synthetically based 
on the work of Kelly (refer to Scheme 1C), wherein only those acyl chains with oxidation at C6' 
would be amenable to acylation of cephalotaxine (1). Fortunately, the strategies outlined herein, 
namely the strain-assisted acylation of cephalotaxine (1), do not rely on C6' oxidation and thus 
allow access to many Cephalotaxus esters such as homodeoxyharringtonine (5). 
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Figure 2. Resistance index of homoharringtonine (4), bis(demethyl)deoxyharringtonine (55), 
deoxyharringtonine (2), homodeoxyharringtonine (5), and benzyldehydrohomoharringtonine 
(58). 
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1.11 Summary 
 The development of a novel synthetic strategy has enabled the synthesis of potent anti-
tumor C3-O-esters of cephalotaxine (1). Construction of strained C2'–C4'' β-lactone acyl chain 
derivatives was accomplished though a Seebach SRS alkylation of dioxolanone 24, readily 
available from D-malic acid. The ring strain inherent in the β-lactone moiety reduced the steric 
encumbrance of the tetrasubstituted C2' carbon to allow a strain assisted acylation of the 
sterically congested C3 hydroxyl group of cephalotaxine (1). This technology allowed access to 
numerous natural and non-natural Cephalotaxus esters that were tested to determine their 
cytotoxicity against a range of human cancer cell lines. It was concluded that an unprotected C2' 
hydroxyl group is necessary for potent antitumor activity as evidenced by the lack of 
antiproliferative activity of anhydroharringtonine (3) as well as the 10-fold lower activity for the 
β-lactone intermediates relative to the final Cephalotaxus esters. In addition, despite the focus of 
the medical community on homoharringtonine (4), it was found that homodeoxyharringtonine (5) 
is much less susceptible to MDR than 4 (resistance index of 3 for 5 vs. 125 for 4). Until now, 
deoxyharringtonine (2) and homodeoxyharringtonine (5) were not as readily available as 
homoharringtonine (4) due to the lack of efficient synthetic strategies for those esters lacking a 
C5'/C6' oxygen functionality. These advancements should facilitate future endeavors to prepare 
novel Cephalotaxus esters that are more potent, less toxic, and less susceptible to cellular MDR 
mechanisms than the current state-of-the-art treatments. 
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1.12 Experimental 
General Procedures.  All reactions were performed in flame-dried modified Schlenk (Kjeldahl 
shape) flasks fitted with a glass stopper under a positive pressure of argon, unless otherwise 
noted.  Air- and moisture-sensitive liquids and solutions were transferred via syringe or stainless-
steel cannula.  Organic solutions were concentrated by rotary evaporation below 30 °C.  Flash 
column chromatography was performed employing 230-400 mesh silica gel under a positive 
pressure of nitrogen.  Thin-layer chromatography (analytical and preparative) was performed 
using glass plates pre-coated to a depth of 0.25 mm with 230-400 mesh silica gel impregnated 
with a fluorescent indicator (254 nm). Visualization was achieved using UV light, iodine, para-
anisaldehyde, or ceric ammonium molybdenate. Buffered silica gel was prepared by agitating a 
10% by weight mixture of commercial pH 7.0 buffer in silica gel for at least 30 m. 
Materials.  Dichloromethane (CH2Cl2), tetrahydrofuran (THF), acetonitrile, diethyl ether, 
hexane, toluene, and benzene were purified by passage through two packed columns of neutral 
alumina under an argon atmosphere.  Methanol was distilled from magnesium turnings under a 
nitrogen atmosphere at 760 mm Hg. 1,2-Dichloroethane, N,N-dimethylformamide (DMF), 
dimethylsulfoxide, and 1,4-dioxane were dried over activated 4Å molecular sieves.  
Triethylamine, 2,6-lutidine, pyridine, Hünig's base, and diisopropylamine were distilled from 
CaH2 under a nitrogen atmosphere at 760 mm Hg.  Lithium bis(trimethylsilyl)amide (LHMDS) 
was purchased as a solid from Aldrich and handled under an intert atmosphere. Benzyl alcohol 
was distilled from CaO under an argon atmosphere at 760 mm Hg. Dess-Martin periodinane was 
prepared by published methods.36
Instrumentation.  Infrared (IR) spectra were obtained using a Perkin Elmer Spectrum BX 
spectrophotometer or a Bruker Tensor 27 referenced to a polystyrene standard. Data are 
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presented as the frequency of absorption (cm-1).  Proton and carbon-13 nuclear magnetic 
resonance (1H NMR or 13C NMR) spectra were recorded on a Varian 400, a Varian 500, Varian 
Inova 500 NMR, a Bruker Avance III 500, or a Bruker Avance III 600 spectrometer; chemical 
shifts are expressed in parts per million (δ scale) downfield from tetramethylsilane and are 
referenced to the residual protium in the NMR solvent (CHCl3: δ 7.26 for 1H NMR, δ 77.16 for 
13C NMR; C6D6: δ 7.16 for 1H NMR, δ 128.06 for 13C NMR; CD3OD:  δ 3.30 for 1H NMR, δ 
49.00 for 13C NMR).  Data are presented as follows: chemical shift, multiplicity (s = singlet, bs = 
broad singlet, d = doublet, bd = broad doublet, t = triplet, dd = doublet of doublets, ddd = doublet 
of doublet of doublets, td = triplet of doublets, dt = doublet of triplets, m = multiplet and/or 
multiple resonances). 
O
O
O
Me
Me
O
O
OH
Me
Me
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O
OH
Me
Me
SePh
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19 21 22  
6(3aR,4S,5S,6S,6aR)-6-chloro-2,2-dimethyl-5-(phenylselanyl)tetrahydro-3aH-
cyclopenta[d][1,3]dioxol-4-ol (22) (II-JTW-010) 
To a solution of enone 19 (246 mg, 1.60 mmol, 1.00 equiv) in MeOH (16 mL) was added 
CeCl3.7H2O (715 mg, 1.92 mmol, 1.20 equiv).  The solids were allowed to dissolve completely 
and then NaBH4 (72.6 mg, 1.92 mmol, 1.20 equiv) was added in several small portions.  After 
the vigorous bubbling had subsided, the reaction was quenched with H2O (15 mL) and poured 
into CH2Cl2 (16 mL).  The phases were separated and the aqueous phase was extracted with 
CH2Cl2 (2x 16 mL).  The combined organic phases were dried over MgSO4 and concentrated 
under a stream of N2 to a volume of 16 mL.  Allylic alcohol 21 was not isolated to avoid loss due 
to its volatility.  This solution was then cooled to 0 ºC and PhSeCl (337 mg, 1.76 mmol, 1.10 
equiv) was added and the resulting orange solution was stirred at 0 ºC for 1 h.  The solvent was 
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then removed by rotary evaporation and the orange residue was purified by silica gel column 
chromatography (gradient; 4:1-1:1 Hex:EtOAc) to yield selenide 22 (403 mg, 73% over 2 steps). 
Rf = 0.5 (2:1 hex:EtOAc); 1H NMR (500 MHz, C6D6) δ 7.55 (m, 2H), 6.94 (m, 3H), 4.68 (s, 1H), 
4.42 (pentet, 1H, J=5.5 Hz), 4.34 (d, 1H, J=5.8 Hz), 4.12 (t, 1H, J=5.5), 3.70 (d, 1H, J=6.0 Hz), 
3.28 (d, 1H, J=11.2 Hz), 1.48 (s, 3H), 0.95 (s, 3H); 13C NMR (125 MHz, C6D6) δ 185.13, 
133.74, 133.69, 133.65, 132.93, 129.403, 111.99, 85.82, 78.88, 71.59, 63.76, 57.71, 25.50, 
23.45; IR (neat film) 3509 (m), 3057 (w), 2987 (m), 2940 (m), 1579 (m), 1384 (s), 1208 (s), 972 
(m); HRMS (EI) m/z calcd for C14H17O3ClSe (M+) 348.0031 observed 348.0027; [α]D = +14.1º 
(c 2.19, CHCl3). 
O
O
OH
Me
Me
SePh
Cl
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23  
(3aR,4R,6aR)-6-chloro-2,2-dimethyl-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-ol (23) 
(II-JTW-012) 
To a solution of selenide 22 (402 mg, 1.16 mmol, 1.00 equiv) in CH2Cl2 (12 mL) was added 
washed m-CPBA37 (220 mg, 1.28 mm, 1.10 equiv).  This solution was stirred for 15 m and then 
triethylamine (323 μL, 2.32 mmol, 2.00 equiv) was added via syringe and the solution was 
heated to 40 ºC for 17 h.  The solution was then allowed to cool, partitioned between saturated 
aqueous NaHCO3 solution (15 mL) and CH2Cl2 (15 mL).  The phases were separated and the 
aqueous phase was extracted with CH2Cl2 (2x 15 mL) and the combined organic phases were 
dried over MgSO4.  Solvent removal by rotary evaporation yielded a bright orange oil that was 
purified by silica gel column chromatography (2:1 hex:EtOAc) to yield allylic alcohol 23 (201 
mg, 91%) as a white, crystalline solid. 
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Rf = 0.25 (2:1 Hex:EtOAc); 1H NMR (400 MHz, C6D6) δ 5.51 (m, 1H), 4.24 (d, 1H, J=5.3 Hz), 
4.06 (m, 2H), 2.68 (d, 1H, J=9.8 Hz), 1.22 (s, 3H), 1.15 (s, 3H); 13C NMR (125 MHz, C6D6) δ 
136.55, 132.08, 113.03, 84.27, 77.76, 71.96, 27.49, 26.85; IR (neat film) 3322 (m), 2989 (m), 
2939 (m), 1632 (m), 1380 (m), 1371 (m), 1213 (m), 1125 (s), 1064 (s); HRMS (EI) m/z calcd for 
C8H12O3Cl (M+ + H) 191.0475 observed 191.0471; [α]D = -37º (c 1.98, CHCl3). 
 
6(3aS,6aR)-6-chloro-2,2-dimethyl-3aH-cyclopenta[d][1,3]dioxol-4(6aH)-one (18) (II-JTW-
014) 
To a solution of alcohol 23 (30.0 mg, 0.157 mmol, 1.00 equiv) in CH2Cl2 (1.6 mL) was added 
Dess-Martin Periodane (100 mg, 0.236 mmol, 1.50 equiv).  The resulting suspension was stirred 
at 23 ºC for 2 h at which time the suspension was loaded directly onto a plug of silica gel (1 g) 
and flushed with CH2Cl2 (15 mL).  Solvent removal by rotary evaporation yielded chloroenone 
18 (29 mg, 98%) as a white, crystalline solid. 
Rf = 0.35 (25% ethyl acetate in hexane); 1H NMR (500 MHz, C6D6) δ 5.54 (s, 1H), 4.21 (d, 1H, 
J=5.5 Hz), 3.94 (d, 1H, J=5.5 Hz); 1.19 (s, 3H), 1.10 (d, 3H, J=0.3 Hz); 13C NMR (125 MHz, 
C6D6) δ 196.82, 145.39, 131.16, 115.65, 81.01, 79.00, 27.30, 26.31; IR (neat film) 2987 (w), 
2933 (w), 1722 (s), 1582 (s) cm-1; HRMS (EI) m/z: Calcd for C8H9ClO3 (M+) 188.0240, 
observed 188.0242. 
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2–((2R,4R)-2-tert-butyl-4-(3-methylbut-2-enyl)-5-oxo-1,3-dioxolan-4-yl)acetic acid (ent-25) 
(I-JTW-164) 
A solution of LHMDS (413 mg, 2.47 mmol, 1.00 equiv) in THF (5 mL) at –78 ºC was 
transferred via cannula to a stirred solution of acid ent-24 (500 mg, 2.47 mmol, 1.00 equiv) in 
THF (25 mL) at –78 ºC.  The resulting solution was stirred at –78 ºC for 15 minutes.  A solution 
of LHMDS (496 mg, 2.96 mmol, 1.20 equiv) in THF (5 mL) at –78 ºC was then added via 
cannula and the resulting solution was stirred for 20 min at –78 ºC.  3,3 dimethylallyl bromide 
(316 μL, 2.72 mmol, 1.10 equiv) was then added via syringe and the resulting solution was 
stirred at –78 ºC for 19 h, at which time the reaction was quenched with saturate aqueous NH4Cl 
solution (25 mL), removed from the cold bath, and allowed to warm to 20 °C.  The solution was 
then poured into 1 N aqueous HCl (75 mL), extracted with CH2Cl2 (3x 75 mL), the combined 
organic phases were dried over MgSO4 and concentrated via rotary evaporation to yield an oily 
solid.  Purification by silica gel column chromatography (19:1 MeOH:CH2Cl2) yielded ent-25 
(438 mg, 66%) as a white powder. 
Rf = 0.51 (19:1 CH2Cl2:MeOH); 1H NMR (400 MHz, CDCl3) δ 5.16 (m, 2H), 2.83 (m, 2H),  
2.50 (d, 2H, J=7.7 Hz), 1.74 (d, 3H, J=0.8 Hz), 1.64 (d, 3H, J=0.8 Hz), 0.93 (s, 9H); 13C NMR 
(100mhz, CDCl3) δ 174.91, 173.84, 137.96, 115.55, 108.42, 80.54, 39.44, 34.28, 32.40, 25.97, 
23.60, 18.03;  IR (neat film) 2973 (m), 2916 (m), 1800 (s), 1710 (s), 1181 (m), 1156 (m) cm-1; 
HRMS (ESI) m/z calcd for C14H23O5 (M+) 271.1545, observed 271.1553; [α]D = –266º (c 2.98 
CHCl3). 
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Methyl 2-((2R,4R)-2-tert-butyl-4-(3-methylbut-2-enyl)-5-oxo-1,3-dioxolan-4-yl)acetate (26) 
(I-JTW-046).   
A solution of acid 25 (150 mg, 0.56 mmol, 1.00 equiv.) in 7:2 benzene:MeOH (5.5 mL) was 
treated with a 2 M solution of trimethylsilyl diazomethane in Et2O (416 μL, 0.83 mmol, 1.50 
equiv.).  The resulting solution was stirred under air for 15 m then concentrated by rotary 
evaporation. The residue was purified by flash column chromatography (15:1 hexanes:EtOAc) to 
yield 26 (145 mg, 92%) as a colorless oil that solidified into a white solid upon standing.  
1H NMR (400 MHz, CDCl3) δ 5.17 (m, 1H), 5.16 (s, 1H), 3.66 (s, 3H), 2.81 (s, 2H), 2.50 (d, 2H, 
J=7.8 Hz), 1.74 (d, 3H, J=0.8 Hz), 1.64 (d, 3H, J=0.8 Hz), 0.94 (s, 9H)  13C NMR (100 MHz, 
CDCl3) δ 173.96, 168.83, 137.78, 115.71, 108.32, 80.70, 51.93, 39.70, 34.16, 32.51, 25.97, 
23.59, 18.02; HRMS (ESI) m/z calcd for C15H25O5 (M+) 285.1702, observed 285.1713. 
 
methyl 2-((2S,4S)-2-tert-butyl-4-isopentyl-5-oxo-1,3-dioxolan-4-yl)acetate (27) (I-JTW-055).  
A solution of alkene 26 (123 mg, 0.43 mmol, 1.00 equiv.) in EtOAc (6 mL) was suspended with 
10% Pd/C (12 mg, 10 wt%).  The flask was equipped with a rubber septum, evacuated through a 
needle until the solvent begins to boil.  A needle attached to an H2 filled balloon was then 
inserted, and the flask evacuated until the pitch of the sound  of the pump became high.  The 
suspension was then stirred under balloon pressure H2 overnight.  The suspension was then 
filtered through a plug of celite and concentrated by rotary evaporation to yield 27 (125 mg, 
100%) of a colorless oil.  
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 1H NMR (400 MHz, CDCl3) δ 5.14 (s, 1H), 3.65 (s, 3H), 2.80 (s, 2H) 1.79 (m, 2H), 1.52 (septet, 
1H, J=6.6 Hz), 1.28 (m, 2H), 0.93 (s, 9H), 0.88 (d, 6H, J=6.6 Hz);  13C NMR (100 MHz, CDCl3) 
δ 174.01, 168.77, 108.12, 80.27, 51.91, 39.61, 34.25, 32.01, 31.73, 28.11, 23.56, 22.37, 22.26; 
IR (neat film) 2959 (s), 2873 (s), 1799 (s), 1748 (s), 1367 (s), 1163 (br, s) cm-1 ; HRMS (ESI) 
m/z calcd for C15H27O5 (M+) 287.1858, observed 287.1866. 
 
(R)-3-(benzyloxycarbonyl)-3-hydroxy-6-methylhept-5-enoic acid (ent-31) (I-JTW-157) 
A solution of dioxolanone ent-25 (120 mg, 0.444 mmol, 1.00 equiv) in THF (4.5 mL) was cooled 
to 0 ºC and benzyl alcohol (69 μL, 0.67 mmol, 1.5 equiv) was added via syringe followed by a 
60% dispersion of NaH in mineral oil (45 mg, 1.1 mmol, 2.5 equiv) which resulted in vigorous 
evolution of gas.  The solution was allowed to stir at 0 ºC for 30 min, at which time the reaction 
was quenched with saturated aqueous NaHCO3 solution, removed from the cold bath and 
allowed to warm to 20 °C.  The solution was then poured into H2O (4.5 mL), washed with 
CH2Cl2 (1x 6 mL), acidified to pH <5 with 1 N HCl, and then extracted with Et2O (4x 6 mL).  
The combined ethereal phases were dried over MgSO4 and concentrated by rotary evaporation to 
yield a white solid. Purification by silica gel column chromatography (70:28:2 
hex:EtOAc:HOAc) to provided ent-31 (114 mg, 88%) as a white solid. 
Rf = 0.39 (60:38:2 EtOAc:Hex:HOAc); 1H NMR (500 MHz, CDCl3) δ 7.35 (m, 5H), 5.20 (s, 
2H), 5.07 (m, 1H), 3.00 (d, 1H, J=16.7 Hz), 2.76 (d, 1H, J=16.7 Hz), 2.41 (m, 2H), 1.67 (d, 3H, 
J=0.7 Hz3), 1.54 (d, 3H, J=0.7 Hz); 13C NMR (100 MHz, CDCl3) δ 176.43, 174.60, 136.79, 
135.21, 128.71, 128.64, 128.61, 116.45, 75.41, 67.95, 42.69, 38.14, 26.06, 18.09; IR (neat film) 
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3483 (br m), 2968 (m), 1736 (s), 1498 (w), 1195 (s) cm-1; HRMS (ESI) m/z calcd for 
C16H20O5Na (M+ + Na+) 315.1208, observed 315.1214; [α]D = –18º (c 2.98, CHCl3). 
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(R)-1-benzyl 4-methyl 2-hydroxy-2-(3-methylbut-2-enyl)succinate (ent-32) (II-JTW-151) 
To a solution of acid ent-31 (49.8 mg, 0.171 mmol, 1.00 equiv) in 7:2 PhH:MeOH (170 μL) was 
added a 2.0 M solution of TMSCHN2 (128 μL, 0.257 mmol, 1.50 equiv.).  After the resulting gas 
evolution had subsided, the solvent was removed by rotary evaporation to yield methyl ester ent-
32 (52.0 mg, 100%) as a clear, colorless oil. 
Rf = 0.55 (2:1 hex:EtOAc); 1H NMR (500 MHz, CDCl3) δ 7.36 (m, 5H), 5.23 (d, 1H, J=12.1 
Hz), 5.19 (d, 1H, J=12.1 Hz), 5.08 (m, 1H), 3.68 (s, 1H), 3.62 (s, 3H), 2.95 (d, 1H, J=16.2 Hz), 
2.72 (d, 1H, J=16.3 Hz), 2.41 (m, 2H), 1.67 (s, 3H), 1.54 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 
174.84, 171.43, 136.54, 135.46, 128.70, 128.66, 128.60, 116.75, 75.65, 67.79, 51.93, 42.81, 
38.11, 26.06, 18.09; IR (neat film) 3514 (m), 3034 (w), 2955 (m), 1742 (s), 1498 (w), 1439 (s), 
753 (m), 699 (m) cm-1; LRMS (ESI) calc’d for C17H22O5Na (M + Na+) 329.2, found 329.1. 
 
(S)-2-hydroxy-2-(2-methoxy-2-oxoethyl)-5-methylhexanoic acid (28) (I-JTW-159).  A 
solution of diester 32 (105 mg, 0.34 mmol, 1.00 equiv) in EtOAc (3.5 mL) was suspended with 
10% Pd/C (11 mg, 10 wt%).  The flask was equipped with a rubber septum, evacuated through a 
needle until the solvent begins to boil.  A needle attached to an H2 filled balloon was then 
inserted, and the flask evacuated until the pitch of the sound  of the pump changed.  The 
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suspension was then stirred under balloon pressure H2 overnight.  The suspension was then 
filtered through a plug of celite and concentration by rotary evaporation yielded 28 (74 mg, 
100%) of a clear, colorless oil.  
 1H NMR (500 MHz) 3.709 (s, 3H) 2.99 (d, 1H, J=16.6 Hz) 2.74 (d, 1H, J=16.6 Hz) 1.72 (m, 
2H) 1.51 (septet, 1H, J=6.6 Hz),  1.38 (m, 1H), 1.12 (m, 1H), 0.89 (d, 3H, J=2.6 Hz), 0.87 (d, 
3H, J=2.6 Hz) 
 
(R)-benzyl 2-(2-methoxy-2-oxoethyl)-5,5-dimethyltetrahydrofuran-2-carboxylate (33) (II-
JTW-156) 
To a solution of alcohol ent-32 (29.8 mg, 0.0979 mmol, 1.00 equiv)  in 1:1 THF:H2O (1.5 mL) 
was added Hg(OAc)2 (60.6 mg, 0.196 mmol, 2.00 equiv).  The resulting solution was stirred at 
20 °C for 30 minutes. A 0.5 M solution of NaBH4 in 3 M NaOH (196 μL, 0.0979 mmol, 1.00 
equiv) was then added by syringe, resulting in an immediate precipitation of Hg0.  After stirring 
for 5 m, the suspension was partitioned between saturated aqueous NH4Cl solution (10 mL) and 
EtOAc (10 mL).  The phases were separated and the aqueous phase was extracted with EtOAc 
(2x 10 mL).  The combined organic phases were dried over MgSO4 and solvent removal yielded 
a grey suspension that was redissolved in CH2Cl2 and filtered through celite.  Concentration by 
rotary evaporation yielded crude product (27.4 mg, 92%).  A portion of this product (18.3 mg) 
was purified by silica gel column chromatography (6:1 hex:EtOAc) to yield tetrahydrofuran 33 
(17.7 mg, 76%) as a clear, colorless oil. 
Rf = 0.58 (2:1 hex:EtOAc); 1H NMR (500 MHz, CDCl3) δ 7.34 (m, 5H), 5.21 (d, 1H, J=12.3 
Hz), 5.17 (d, 1H, J=12.3 Hz), 3.59 (s, 3H), 2.91 (d, 1H, J=15.4 Hz), 2.81 (d, 1H, J=15.4 Hz), 
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2.41 (m, 1H), 2.16 (m, 1H), 1.85 (m, 1H), 1.78 (m, 1H), 1.30 (s, 3H), 1.24 (s, 3H); 13C NMR 
(125 MHz, CDCl3) δ 173.70, 170.54, 135.93, 128.59, 128.43, 128.32, 84.26, 83.96, 67.10, 51.80, 
43.93, 37.88, 35.58, 29.09, 28.33; IR (neat film) 3036 (w), 2973 (m), 1743 (s), 1500 (w), 1458 
(m), 1440 (m), 701 (m) cm-1; LRMS (ESI) calc’d for C17H22O5Na (M+Na+) 329.2, found 329.1. 
 
(R)-2-(2-methoxy-2-oxoethyl)-5,5-dimethyltetrahydrofuran-2-carboxylic acid (34) (II-JTW-
157) 
To a solution of benzyl ether 33 (17.7 mg, 0.0578 mmol, 1.00 equiv) in EtOAc (550 μL) was 
added 10% Pd/C (2.0 mg).  The atmosphere in the vessel was replaced with H2 and the reaction 
was stirred at 20 °C for 2 h, at which time it was filtered through a plug of celite.  Solvent 
removal by rotary evaporation provided acid 34 (12.4 mg, 99%) as a white solid. 
Rf = 0.07 (2:1 hex:EtOAc); 1H NMR (500 MHz, CDCl3) δ 3.69 (s, 3H), 3.13 (d, 1H, J=15.9 Hz), 
2.67 (d, 1H, J=15.9 Hz), 2.43 (m, 1H), 2.22 (m, 1H), 1.87 (m, 2H), 1.39 (s, 3H), 1.31 (s, 3H); 13C 
NMR (125 MHz, CDCl3) δ 175.72, 170.03, 85.91, 84.23, 52.08, 43.66, 37.67, 36.16, 28.69, 
28.55; IR (neat film) ~3100-2800 (br m), 2983 (s), 1753 (s), 1733 (s), 1459 (w), 1370 (w), 1265 
(s), 1192 (m), 1106 (m), 778 (w) cm-1; LRMS (ESI) calc’d for C10H16O5Na (M + Na+) 239.1, 
found 239.0. 
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Anhydroharringtonine (3) (II-JTW-158) 
To a solution of acid 34 (4.2 mg, 0.019 mmol, 2.0 equiv) and triethylamine (8.7 μL, 0.063 mmol, 
6.6 equiv) in CH2Cl2 (100 μL) was added 2,4,6-trichlorobenzoyl chloride (3.3 μL, 0.021 mmol, 
2.2 equiv) via syringe.  The resulting colorless solution was stirred at 23 ºC for 1 h, then 
transferred via syringe to a solution of cephalotaxine (1) (2.95 mg, 0.00935 mmol, 1.00 equiv) 
and N,N-dimethylaminopyridine (DMAP) (1.46 mg, 0.0120 mmol, 1.28 equiv) in CH2Cl2 (100 
μL).  This solution was then stirred for 2 hours then loaded directly onto a silica gel column.  The 
column was eluted with 2% Et3N in 9:1 toluene:EtOAc to yield 3 (4.26 mg, 88%) as a light 
yellow oil. 
Rf = 0.31 (2% Et3N in 9:1 toluene:EtOAc on plates pretreated with 5% Et3N in pentane); 1H 
NMR (500 MHz, CDCl3) δ 6.58 (s, 1H), 6.56 (s, 1H), 5.87 (m, 3H), 5.02 (s, 1H), 3.80 (d, 1H, 
J=9.8 Hz), 3.68 (s, 3H), 3.58 (s, 3H), 3.18-3.06 (m, 2H), 2.93 (m, 1H), 2.58 (m, 2H), 2.33 (m, 
1H), 2.32 (d, 1H, J=15.1 Hz), 2.26 (d, 1H, J=15.2 Hz), 2.03 (m, 2H), 1.87 (m, 2H), 1.75 (m, 2H), 
1.65 (m, 2H), 1.24 (s, 3H), 1.14 (s, 3H); IR (neat film) 2965 (m), 2880 (m), 2796 (w), 1740 (s), 
1654 (s), 1503 (m), 1487 (s), 1223 (s), 1036 (s) cm-1; LRMS (ESI) calc’d for C28H36NO8 (M + 
Na+) 514.2, found 514.2. 
 
(R)-benzyl 2-(3-methylbut-2-enyl)-4-oxooxetane-2-carboxylate (35) (I-JTW-262) 
A solution of hydroxyester ent-31 (100 mg, 0.342 mmol, 1.00 equiv) and triethylamine (166 μL, 
1.20 mmol, 3.50 equiv) in CH2Cl2 (14 mL) was added via syringe pump over 4 h to a solution of 
2,4,6-trichlorobenzoyl chloride (80 μL, 0.51 mmol, 1.5 equiv) and N,N-dimethylaminopyridine 
(DMAP) (46 mg, 0.38 mmol, 1.1 equiv) in CH2Cl2 (3.4 mL).  The solution was then allowed to 
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stir for 1 h after complete addition after which time it was quenched with H2O (10 mL).  The 
phases were separated and the aqueous phase was extracted with CH2Cl2 (2x 10 mL).  The 
organic phases were combined, dried over Na2SO4, and the solvent was removed via rotary 
evaporation to yield a red solid which was purified by silica gel column chromatography 
(CH2Cl2) to yield 35 (47 mg, 50%) as a pale yellow oil. 
Rf = 0.79 (60:38:2 Hex:EtOAc:HOAc); 1H NMR (500 MHz, CDCl3) δ 7.37 (m, 5H), 5.25 (s, 
2H), 5.09 (m, 1H), 3.61 (d, 1H, J=16.4 Hz), 3.36 (d, 1H, J=16.4 Hz), 2.79 (m, 2H), 1.70 (d, 3H, 
J=0.8 Hz), 1.60 (d, 3H, J=0.8 Hz); 13C NMR (100 MHz, CDCl3) δ 169.21, 165.84, 138.67, 
134.67, 128.68, 128.38, 114.24, 76.28, 67.84, 45.56, 33.43, 25.87, 17.99; IR (neat film) 2966 
(m), 2914 (m), 1842 (s), 1737 (s), 1452 (m) 962 (m) cm-1; HRMS (EI) m/z calcd for C16H18O4 
(M+) 274.120509, observed 274.120646; [α]D = +1.2º (c 2.92, CHCl3). 
 
(R)-2-isopentyl-4-oxooxetane-2-carboxylic acid (36) (I-JTW-229) 
To a solution of benzyl ester 35 (220 mg, 0.802 mmol, 1.00 equiv) in EtOAc (8 mL) was added 
Pd/C (10 wt% on C, 44 mg, 20% by weight).  The resulting suspension was stirred under H2 (1 
atm) for 23 h, then filtered through a plug of celite.  Solvent removal by rotary evaporation 
yielded an oil which showed alkene peaks by 1H NMR, so the residue was resubjected to the 
reaction conditions to yield carboxylic acid 36 (150 mg, >99%) as a clear, colorless oil. 
Rf = 0.11 (60:38:2 hex:EtOAc:HOAc); 1H NMR (400 MHz, CDCl3) δ 10.30 (br s, 1H), 3.71 (d, 
1H, J=16.6 Hz), 3.45 (d, 1H, J=16.6 Hz), 2.19 (ddd, 1H, J=14.2, 12.3, 4.8 Hz), 2.04 (ddd, 1H, 
J=14.2, 12.3, 4.8 Hz), 1.61 (septet, 1H, J=6.6 Hz), 1.40 (m, 1H), 1.27 (m, 1H), 0.92 (d, 6H, 
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J=6.6 Hz); 13C NMR (400 MHz, CDCl3) δ 174.96, 165.69, 76.43, 46.78, 33.17, 32.109, 27.89, 
22.27, 22.20; IR (neat film) 3514 (br m), 3184 (br s), 2958 (s), 1828 (s), 1729 (s), 1408 (m), 
1173 (s) cm-1; [α]D = 22.1º (c 1.67, CHCl3). 
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Deoxyharringtonine, β-lactone (37) (I-JTW-286) 
To a solution of β-lactone 36 (8.9 mg, 0.048 mmol, 1.5 equiv) and triethylamine (19.9 μL, 0.143 
mmol, 4.50 equiv) in CH2Cl2 (320 μL) was added 2,4,6-trichlorobenzoyl chloride (8.2 μL, 0.052 
mmol, 1.7 equiv) via syringe.  The resulting dark purple solution was stirred at 23 ºC for 1 h.  
This solution was then transferred via syringe to a solution of cephalotaxine (1) (10 mg, 0.032 
mmol, 1.0 equiv) and N,N-dimethylaminopyridine (DMAP) in CH2Cl2 (320 μL).  This solution 
was then stirred for 15 m, concentrated under a stream of N2, and loaded directly onto a silica gel 
column that had been packed with 5% triethylamine in hexanes.  The column was eluted with 1:1 
hex:EtOAc to yield 37 (12.4 mg, 81%) as an oil. 
Rf = 0.39 (1:1 hex:EtOAc on plates pretreated with 5% Et3N in pentane); 1H NMR (500 MHz, 
CDCl3) δ 6.60 (app d, 2H), 5.91 (dd, 1H, J=9.6, 0.7 Hz), 5.86 (dd, 2H, J=4.1, 1.4 Hz), 5.08 (s, 
1H), 3.81 (d, 1H, J=9.5 Hz), 3.69 (s, 3H), 3.10 (m, 2H), 2.98 (d, 1H, J=16.5 Hz), 2.93 (m, 1H), 
2.73 (d, 1H, J=16.5 Hz), 2.58 (m, 2H), 2.35 (dd, 1H, J=14.3, 6.9), 2.04 (m, 1H), 1.88 (m, 2H), 
1.75 (m, 2H), 1.62 (m, 1H), 1.47 (septet, 1H, J=6.7 Hz), 1.15 (m, 1H), 1.02 (m, 1H), 0.85 (dd, 
6H, J=6.7, 1.2 Hz); 13C (500 MHz, CDCl3) δ 171.03, 168.57, 166.25, 113.17, 109.96, 109.91, 
101.11, 76.53, 75.62, 65.63, 57.36, 54.05, 48.60, 46.31, 41.74, 33.21, 31.97, 27.91, 22.46, 22.14, 
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20.39; IR (neat film) 2958 (m), 1842 (s), 1750 (s), 1656 (m), 1504 (m), 1488 (s), 1037 (m) cm-1; 
HRMS (EI) m/z calcd for C27H33NO7 (M+) 483.225703 found 483.224659; [α]D = -95º (c 2.77, 
CHCl3). 
 
Deoxyharringtonine (2) (II-JTW-015) 
To a solution of β-lactone 37 (18 mg, 0.0372 mmol, 1.00 equiv) in MeOH (370 μL) was added a 
freshly prepared solution of 0.5 M NaOMe in MeOH (82 μL, 0.0409 mmol, 1.10 equiv).  After 
15 min the solution was quenched with ½ saturated aqueous NH4Cl solution (300 μL) and 
partitioned between H2O (10 mL) and CH2Cl2 (10 mL).  The phases were separated and the 
aqueous phase was extracted with CH2Cl2 (2x 10 mL), the combined organic phases were dried 
over MgSO4, and concentrated by rotary evaporation to yield a yellow oil that was purified by 
silica gel column chromatography (70:28:2 benzene:hex: Et3N) to yield 2 (14.6 mg, 76% after 
correction for residual benzene) as a clear, colorless oil.  Residual benzene was very difficult to 
remove.  Several iterations of dissolution in CH2Cl2 followed by several hours of high vacuum 
did not eliminate it. 
Rf = 0.24 (9:1 benzene:EtOAc on plates pretreated with 5% Et3N in pentane); 1H NMR (500 
MHz, CDCl3) δ 6.62 (s, 1H), 6.53 (s, 1H), 5.99 (dd, 1H, J=9.8, 0.7 Hz), 5.86 (dd, 2H, J=11.8, 1.5 
Hz), 5.04 (d, 1H, J=0.6 Hz), 3.77 (d, 1H, J=9.8 Hz), 3.67 (s, 3H), 3.57 (s, 3H), 3.48 (s, 1H), 3.12 
(m, 2H), 2.94 (td, 1H, J=11.1, 7.1 Hz), 2.58 (m, 2H), 2.37 (dd, 1H, J=14.3, 7 Hz), 2.27 (d, 1H, 
J=16.6 Hz), 2.04 (m, 1H), 1.91 (m, 1H), 1.88 (d, 1H, J=16.2 Hz), 1.75 (m, 2H), 1.42 (m, 3H), 
 33
1.29 (m, 1H), 0.97 (m, 1H), 0.84 (d, 3H, J=7.0 Hz), 0.83 (d, 3H, J=7.0 Hz) 13C NMR (400 MHz, 
CDCl3) δ 174.19, 170.57, 157.87, 146.75, 145.92, 133.43, 128.55, 128.46 (residual benzene), 
112.75, 109.80, 100.94, 100.16, 74.83, 74.69, 70.70, 57.25, 55.98, 54.12, 51.63, 48.82, 43.54, 
42.89, 36.87, 31.70, 31.48, 28.13, 22.83, 22.38, 20.42; IR (neat film) 3527 (w), 2955 (m), 1748 
(s), 1653 (m), 1504 (m), 1488 (s), 1225 (s), 1036 (m), 754 (m); HRMS (ESI) calcd for 
C28H38NO8 (M+ + H) 516.2597 observed 516.2581; [α]D = -110º (c 1.46, CHCl3). 
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(R)-1-benzyl 4-methyl 2-acetoxy-2-(3-methylbut-2-enyl)succinate (S1).  
To a solution of tertiary alcohol ent-32 (33.0 mg, 0.109 mmol, 1.00 equiv) in dry pyridine (500 
μL) at 0 ºC was added acetic anhydride (114 μL, 1.09 mmol, 10.0 equiv) and N,N-
dimethylaminopyridine (DMAP) (3.0 mg, 0.0246 mmol, 0.23 equiv).  The solution was then 
stirred at 23 ºC for 17 h at which time further DMAP (13.0 mg, 1.09 mmol, 1.00 equiv) and 
acetic anhydride (22 μL, 0.21 mmol, 1.9 equiv) were added.  After 1 h the solution was diluted 
with H2O (10 mL) and extracted with CH2Cl2 (3x 10 mL).  The combined organic extracts were 
washed with 0.1 M aqueous CuSO4 soln, dried over MgSO4, and concentrated by rotary 
evaporation to yield a dark red oil.  Purification by silica gel column chromatography (5:1 
hexanes:EtOAc) provided S1 (28.1 mg, 74%) as a colorless oil.  
Rf = 0.32 (5 : 1 hexanes : ethyl acetate, CAM stain); 1H NMR (500MHz, CDCl3) δ 7.35 (m, 5H), 
5.14 (m, 2H), 5.00 (tt, 1H, J=7.5, 1.3 Hz), 3.64 (s, 3H), 3.27 (d, 1H, J=14.7 Hz), 2.96 (d, 1H, 
J=14.7 Hz), 2.80 (dd, 1H, J=14.6, 7.6 Hz), 2.69 (dd, 1H, J=14.6, 7.6 Hz), 2.06 (s, 3H), 1.67 (s, 
3H), 1.56 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 170.34, 170.10, 169.79, 137.21, 135.45, 
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128.64, 128.50, 128.46, 115.89, 80.51, 67.48, 51.85, 37.41, 34.35, 26.11, 21.09, 18.00; IR (neat 
film) 3067 (w), 2955 (w), 1746 (s), 1441 (m), 1371 (m), 1227 (m); LRMS (ESI) 371.11 (M+Na). 
 
(R)-2-acetoxy-2-(2-methoxy-2-oxoethyl)-5-methylhex-4-enoic acid (38). To a solution of 
benzyl ester S1 (28.0 mg, 0.0804 mmol, 1.00 equiv) in ethyl acetate (1.5 mL) was added 10% 
Pd/C (3.5 mg, 13 wt %).  The resulting suspension was stirred under H2 (1 atm) for 15 h and 
filtered through a plug of celite.  Solvent removal by rotary evaporation yielded carboxylic acid 
38 (20.9 mg, 100%) as a clear, colorless oil.  
 1H NMR (500MHz, CDCl3) δ 10.34 (br s, 1H), 3.68 (s, 3H), 3.29 (d, 1H, J=14.8 Hz), 3.00 (d, 
1H, J=14.8 Hz), 2.09 (s, 3H), 2.02 (m, 2H), 1.54 (septet, 1H, J=6.6 Hz), 1.22 (m, 2H), 0.89 (d, 
6H, J=6.6 Hz); 13C NMR (125 MHz, CDCl3) δ 175.83, 170.18, 169.84, 80.49, 52.02, 37.55, 
33.54, 31.89, 28.11, 22.55, 22.39, 21.08; IR (neat film) 3182 (v br m), 2958 (m), 2873 (m), 1746 
(s), 1440 (m), 1370 (m), 1209 (s), 645 (w); LRMS (ESI) 283.01 (M + Na). 
 
2-((2R,4R)-4-allyl-2-tert-butyl-5-oxo-1,3-dioxolan-4-yl)acetic acid (47) (II-JTW-072) 
A solution of LHMDS (413 mg, 2.47 mmol, 1.00 equiv) in THF (5 mL) at –78 ºC was 
transferred via cannula to a stirred solution of acid ent-24 (500 mg, 2.47 mmol, 1.00 equiv) in 
THF (25 mL) at –78 ºC.  The resulting solution was stirred at –78 ºC for 10 m.  A solution of 
LHMDS (621 mg, 3.71 mmol, 1.50 equiv) in THF (7 mL) at –78 ºC was then added via cannula 
and the resulting solution was stirred for 20 m at –78 ºC.  allyl bromide (439 μL, 5.19 mmol, 
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2.10 equiv) was then added via syringe and the resulting solution was stirred at –78 ºC for 21 h, 
at which time the reaction was partitioned between 1 N aqueous HCl (75 mL) and CH2Cl2 (75 
mL), the phases were separated and the aqueous phase was extracted with CH2Cl2 (2x 50mL). 
The combined organic phases were dried over MgSO4 and concentrated via rotary evaporation to 
yield an oily solid.  Purification by silica gel column chromatography (19:1 MeOH:CH2Cl2) 
yielded 47 (344 mg, 59%) as a clear, colorless oil. 
Rf = 0.69 (60:38:2 EtOAc:Hex:HOAc); 1H NMR (500 MHz, CDCl3) δ 5.77 (m, 1H,), 5.22 (m, 
3H), 2.86 (d, 1H, J=16 Hz), 2.81 (d, 1H, J=16.0 Hz), 2.55 (m, 2H), 0.92 (s, 9H); 13C NMR (125 
MHz, CDCl3) δ 174.96, 173.49, 130.11, 121.34, 108.47, 79.90, 39.62, 38.18, 34.45, 23.66; IR 
(neat film) ~3500-2500 (br s), 2966 (s), 1793 (s), 1718 (s), 1165 (m) cm-1; LRMS (ESI) calcd. 
for C12H18O5Na (M + Na+) 265.1, observed 264.9. 
 
(R)-3-(benzyloxycarbonyl)-3-hydroxyhex-5-enoic acid (48) (II-JTW-096) 
A solution of dioxolanone 47 (1.10 g, 4.54 mmol, 1.00 equiv) in THF (45 mL) was cooled to 0 
ºC and benzyl alcohol (564 μL, 5.45 mmol, 1.20 equiv) was added via syringe followed by a 
60% dispersion of NaH in mineral oil (454 mg, 11.35 mmol, 2.50 equiv) which resulted in 
vigorous evolution of gas.  The solution was allowed to warm to 20 °C over 90 m, at which time 
the reaction was again cooled to 0 ºC, quenched with 1 N aqueous HCl (45 mL), poured into 
EtOAc (45 mL).  The phases were separated and the aqueous phase was extracted with a further 
EtOAc (3x 45 mL). The combined organic phases were dried over MgSO4 and solvent removal 
by rotary evaporation yielded an oil which was purified by silica gel column chromatography 
(60:40:2 hex:EtOAc:HOAc) to yield 48 (1.02 g, 85%) as a clear, colorless oil. 
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Rf = 0.60 (38:60:2 hex:EtOAc:HOAc); 1H NMR (500 MHz, CDCl3) δ 7.37 (m, 5H), 5.74 (m, 
1H), 5.22 (d, 1H, J=10.1 Hz), 5.18 (d, 1H, J=10.1 Hz), 5.11 (d, 1H, J=8.8 Hz), 5.06 (d, 1H, 
J=17.1 Hz), 2.99 (d, 1H, J=16.6 Hz), 2.76 (d, 1H, J=16.6 H), 2.45 (d, 2H, J=7.2); 13C NMR (125 
MHz, CDCl3) δ 176.19, 174.34, 135.14, 131.13, 128.74, 128.68, 120.01, 74.98, 68.08, 43.83, 
42.74; IR (neat film) ~3500-2500 (br m), 3077, 1737 (s), 1641 (w), 1219 (m) cm-1; LRMS (ESI) 
calcd. for C14H16O5Na (M + Na+) 287.1, observed 286.9. 
 
(R)-benzyl 2-allyl-4-oxooxetane-2-carboxylate (49) (II-JTW-100) 
A solution of hydroxyester 48 (1.02 g, 3.86 mmol, 1.00 equiv) and triethylamine (519 μL, 17.37 
mmol, 4.50 equiv) in CH2Cl2 (77 mL) was added via syringe pump over 4 h to a solution of 
2,4,6-trichlorobenzoyl chloride (904 μL, 5.79 mmol, 1.50 equiv) and N,N-
dimethylaminopyridine (DMAP) (519 mg, 4.25 mmol, 1.10 equiv) in CH2Cl2 (39 mL).  The 
solution was then allowed to stir for 30 m after complete addition after which it was quenched 
with H2O (100 mL).  The phases were separated and the aqueous phase was extracted with 
CH2Cl2 (2x 100 mL).  The organic phases were combined, dried over MgSO4, and the solvent 
was removed via rotary evaporation to yield a black oil which was purified by silica gel column 
chromatography (CH2Cl2) to yield 49 (639 mg, 67%) as a yellow oil. 
Rf = 0.52 (CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.38 (m, 5H), 5.76 (m, 1H), 5.26 (s, 2H), 5.22 
(m, 2H), 3.65 (d, 1H, J=16.5 Hz), 3.42 (d, 1H, J=16.5 Hz), 2.89 (dd, 1H, J=14.6, 6.8 Hz), 2.80 
(dd, 1H, J=14.6, 6.8 Hz); 13C NMR (125 MHz, CDCl3) δ 169.03, 165.61, 134.75, 129.10, 
128.95, 128.89, 128.59, 121.82, 75.65, 68.17, 45.86, 39.06; IR (neat film) 3034 (w), 1843 (s), 
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1741 (s), 1644 (w), 1456 (m) cm-1; LRMS (ESI) calcd. for C14H14O4Na (M + Na+) 269.1, 
observed 269.1. 
 
(R,E)-benzyl 2-(4-(benzyloxy)-4-methylpent-2-enyl)-4-oxooxetane-2-carboxylate (51) (II-
JTW-204) 
A solution of alkene 49 (58.8 mg, 0.239 mmol, 1.00 equiv) in benzyl ether 50 (842 mg, 4.78 
mmol, 20 equiv) was subjected to two freeze-pump-thaw cycles.  Grubbs catatalyst, 2nd 
generation (20.1 mg, 0.0237 mmol, 0.10 equiv) was then added and the resulting solution was 
subjected to one more freeze-pump-thaw cycle then allowed to stir at 20 ºC for 16 h.  Another 
portion of catalyst (10.3 mg, 0.0121 mmol, 0.051 equiv) was then added and the solution was 
again subjected to one freeze-pump-thaw cycle and allowed to stir at 20 ºC for 8 h.  A third 
portion of catalyst (10.2 mg, 0.0120 mmol, 0.050 equiv) was added and the solution was 
subjected to one freeze-pump-thaw cycle then allowed to stir at 20 ºC for 25 h.  The crude 
reaction mixture was then loaded directly onto a pH 7.0 buffered silica gel (10 wt% buffer) 
column which was eluted with a gradient eluant (1:1 hex:CH2Cl2 to CH2Cl2) to yield 52 (57.6 
mg, 61%) as a yellow oil and 51 (11.5 mg 22%) as a yellow oil. 
Rf = 0.28 (CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.4-7.2 (m, 10H), 5.76 (d, 1H, J=15.9 Hz), 
5.57 (dt, 2H, J=15.8, 7.2 Hz), 5.22 (s, 2H), 4.31 (s, 2H), 3.64 (d, 1H, J=16.4 Hz), 3.37 (d, 1H, 
J=16.5 Hz), 2.90 (dd, 1H, J=14.6, 7.0 Hz), 2.80 (dd, J=14.5, 7.3 Hz), 1.31 (d, 6H, J=2.8 Hz); 13C 
NMR (125 MHz, CDCl3) δ 168.98, 165.50, 143.38, 139.56, 134.72, 128.97, 128.93, 128.56, 
128.45, 127.41, 127.35, 120.22, 75.82, 75.30, 68.14, 65.11, 46.01, 37.90, 26.49, 26.41; IR (neat 
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film) 3032 (m), 2976 (m), 1838 (s), 1743 (s), 1498 (m), 1455 (m), 1059 cm-1; HRMS (ESI) 
calcd. for C24H26O5Na (M + Na+) 417.1678, found 417.1673. 
Data for dimer 51: 1H NMR (400 MHz, CDCl3) δ 7.37 (m, 10H), 5.54 (m, 2H), 5.24 (s, 4H), 3.60 
(d, 2H, J=16.5 Hz), 3.32 (d, 2H, J=16.5 Hz), 2.8 (m, 4H) 
Dimer Recycle (II-JTW-272) 
A solution of dimer 51 (36.5 mg, 0.0786 mmol, 1.00 equiv) in benzyl ether 50 (576 mg, 3.27 
mmol, 41.6 equiv) was subjected to 2x freeze-pump-thaw cycles.  Grubbs catalyst, 2nd generation 
(6.9 mg, 0.00818 mmol, 0.10 equiv) was added and the resulting solution was subjected to one 
more freeze-pump-thaw cycle then allowed to stir at 20 ºC for 14 h.  Another portion of catalyst 
(7.1 mg, 0.00836, 0.11 equiv) was added and the solution was subjected to one freeze-pump-
thaw cycle then allowed to stir at 20 ºC for 9.5 h.  A third portion of catalyst (6.8 mg, 0.0080 
mmol, 0.10 equiv) was added and the solution was subjected to one freeze-pump-thaw cycle then 
allowed to stir at 20 ºC for 18.5 h.  The crude reaction mixture was loaded directly onto a pH 7.0 
buffered silica gel (10 wt% buffer) column which was eluted with a gradient eluant (1:1 
hex:CH2Cl2 to CH2Cl2) to yield 52 (40.2 mg, 65%) as a colorless oil. Data are identical to that 
reported above. 
 
 
(R,E)-2-(4-(benzyloxy)-4-methylpent-2-enyl)-4-oxooxetane-2-carboxylic acid (53) (II-JTW-
205) 
To a solution of benzyl ester 52 (52.8 mg, 0.134 mmol, 1.00 equiv.) in CH2Cl2 (500 μL) were 
added Et3N (3.0 μL, 0.0214 mmol, 0.16 equiv.), triethylsilane (32.1 μL, 0.201 mmol, 1.50 
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equiv.), and Pd(OAc)2 (1.6 mg, 0.0071 mmol, 0.053 equiv.).  The resulting black solution was 
stirred at 20 ºC for 1 h then partitioned between saturated NH4Cl solution (10 mL) and CH2Cl2 
(10 mL).  The phases were separated and the aqueous phase was extracted with CH2Cl2 (2x 10 
mL).  The combined aqueous phases were dried over MgSO4 and solvent removal by rotary 
evaporation left a brown oil that upon purification by silica gel column chromatography (4% 
HOAc in 1:1 hex:EtOAc) yielded acid 53 (34.4 mg, 85%) as a clear, colorless oil. 
Rf = 0.17 (4% HOAc in 1:1 hex:EtOAc); 1H NMR (500 MHz, CDCl3) δ 10.09 (br s, 1H), 7.33-
7.23 (m, 5H), 5.81 (d, 1H, J=15.9 Hz), 5.62 (m, 1H), 4.35 (s, 2H), 3.57 (d, 1H, J=16.6 Hz), 3.36 
(d, 1H, J=16.6, Hz), 2.87 (dd, 1H, J=14.6, 7.1 Hz), 2.74 (dd, 1H, J=14.7, 7.3 Hz), 1.35 (s, 6H); 
13C NMR (125 MHz, CDCl3) δ 173.48, 165.44, 143.27, 139.13, 128.48, 127.66, 127.53, 120.34, 
75.85, 65.24, 46.06, 37.57, 26.51, 26.29; IR (neat film) ~3500-2500 (br m), 3031 (w), 2977 (m), 
1843 (s), 1745 (s), 1497 (w), 1453 (w), 1149 (m) cm-1; LRMS (ESI) calc’d for C17H20O5Na 
327.1, found 326.9. 
 
(R,E)-2-(4-(benzyloxy)-4-methylpent-2-enyl)-4-oxooxetane-2-cephalotaxyl carboxylate (54) 
(II-JTW-145) 
To a solution of β-lactone 53 (34.5 mg, 0.114 mmol, 2.00 equiv) and triethylamine (52.4 μL, 
0.378 mmol, 6.6 equiv) in CH2Cl2 (570 μL) was added 2,4,6-trichlorobenzoyl chloride (19.6 μL, 
0.126 mmol, 2.20 equiv) via syringe.  The resulting dark purple solution was stirred at 20 ºC for 
1 h, then transferred via syringe to a solution of cephalotaxine (1) (18.0 mg, 0.0571 mmol, 1.00 
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equiv) and N,N-dimethylaminopyridine (DMAP) (7.8 mg, 0.063 mmol, 1.10 equiv) in CH2Cl2 
(570 μL).  This solution was then stirred for 25 minutes then loaded directly onto a pH 7.0 
buffered silica gel column.  The column was eluted with 1% Et3N in 9:1 toluene:EtOAc to yield 
54 (33.3 mg, 97%) as a light yellow oil. 
Rf = 0.24 (1% Et3N in 9:1 toluene:EtOAc on a TLC plate pretreated with 5% Et3N in pentane); 
1H NMR (500 MHz, CDCl3) δ 7.32-7.22 (m, 5H), 6.60 (s, 1H), 6.59 (s, 1H), 5.86 (m, 3H), 5.71 
(d, 1H, J=15.9 Hz), 5.47 (dt, 1H, J=15.8, 8.5 Hz), 5.08 (s, 1H), 4.31 (s, 2H), 3.80 (d, 1H, J=9.5 
Hz), 3.68 (s, 3H), 3.08 (m, 2H), 2.98 (d, 1H, J=16.4 Hz), 2.94 (m, 1H), 2.64 (d, 1H, J=16.5 Hz), 
2.59 (m, 3H), 2.43-2.34 (m, 2H), 2.02 (m, 1H), 1.90 (m, 1H), 1.75 (m, 2H), 1.32 (s, 6H); 13C 
NMR (125 MHz, CDCl3) δ 168.22, 165.58, 156.71, 147.19, 146.13, 143.19, 139.81, 133.73, 
128.49, 128.01, 127.52, 127.37, 120.57, 113.50, 109.98, 101.39, 101.24, 75.95, 75.67, 75.41, 
70.87, 65.17, 57.50, 56.66, 54.20, 48.74, 45.39, 43.72, 37.73, 31.70, 26.55, 26.39, 20.60; IR 
(neat film) 2972 (m), 2801 (w), 1842 (s), 1751 (s), 1654 (s), 1504 (s), 1223 (s) cm-1; LRMS 
(ESI) calc’d for C35H40NO8 602.3, found 602.5. 
 
(R,E)-1-cephalotaxyl 4-methyl 2-(4-(benzyloxy)-4-methylpent-2-enyl)-2-hydroxysuccinate 
(55) (II-JTW-146) 
To a solution of β-lactone 54 (33.0 mg, 0.0548 mmol, 1.00 equiv) in MeOH (550 μL) was added 
a freshly prepared solution of 0.5M NaOMe in MeOH (121 μL, 0.0603 mmol, 1.10 equiv).  After 
10 m the solution was quenched with sat’d NH4Cl solution (300 μL) and partitioned between 
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saturated NH4Cl solution (10 mL) and CH2Cl2 (10 mL).  The phases were separated and the 
aqueous phase was extracted with CH2Cl2 (2x 10 mL), the combined organic phases were dried 
over MgSO4, and concentrated by rotary evaporation to yield a yellow oil that was purified by 
silica gel column chromatography (1% Et3N in 9:1 toluene:EtOAc) to yield 55 (27.5 mg, 79%) 
as a clear, colorless oil. 
Rf = 0.18 (9:1 toluene:EtOAc on plates pretreated with 5% Et3N in pentane); 1H NMR (500 
MHz, CDCl3) δ 7.33-7.22 (m, 5H), 6.61 (s, 1H), 6.55 (s, 1H), 5.94 (d, 1H, J=9.7 Hz), 5.85 (app 
d, 2H), 5.62 (d, 1H), 5.51 (m, 1H), 5.05 (s, 1H), 4.33 (s, 2H), 3.77 (d, 1H, J=9.8 Hz), 3.66 (s, 
3H), 3.58 (s, 3H), 3.45 (s, 1H), 3.12 (m, 2H), 3.94 (m, 1H), 2.59 (m, 2H), 2.38 (dd, 1H, J=14.1, 
6.9 Hz), 2.29 (d, 1H, J=16.4 Hz), 2.20 (m, 2H), 2.01 (m, 1H), 1.96 (d, 1H, J=16.4 Hz), 1.90 (m, 
1H), 1.75 (m, 2H), 1.33 (d, 6H, J=3.1); 13C NMR (125 MHz, CDCl3) δ 173.72, 170.50, 146.98, 
146.07, 141.16, 140.02, 128.44, 127.66, 127.29, 123.16, 113.06, 109.86, 101.05, 100.50, 75.47, 
75.25, 74.61, 65.15, 57.49, 56.16, 54.15, 51.80, 48.81, 43.56, 41.92, 41.77, 31.63, 26.69, 26.52, 
20.50. 
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Homoharringtonine (4) (II-JTW-147) 
To a solution of allylic benzyl ether 55 (12.6 mg, 0.0199 mmol, 1.00 equiv.) in MeOH (200 μL) 
was added 10% Pd/C (2.4 mg, 20% by wt).  The atmosphere in the vessel was replaced with H2 
under balloon pressure and the suspension was stirred at 20 ºC until LRMS (ESI) showed 
complete reduction of the alkene (26 h). Glacial acetic acid (20 μL) was added via syringe and 
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the solution was stirred under H2 at 20 ºC for 21 h. Further 10% Pd/C (1.3 mg) and glacial acetic 
acid (20 μL) were added and the suspension was stirred under H2 for 24 h then filtered through a 
plug of celite.  The solvent was removed by rotary evaporation and the resulting film was 
purified by silica gel column chromatography (2% Et3N in 1:1 toluene:EtOAc) to yield 
homoharringtonine (4) (8.5 mg, 79%) as a colorless film. 
Rf = 0.25 (2% Et3N in 1:1 toluene:EtOAc on TLC plates pretreated with 5% Et3N in pentane); 1H 
NMR (500 MHz, CDCl3) δ 6.62 (s, 1H), 6.54 (s, 1H), 6.00 (d, 1H, J=9.8 Hz), 5.87 (app dd, 2H, 
J=2.9, 1.4), 5.05 (s, 1H), 3.77 (d, 1H, J=9.7 Hz), 3.67 (s, 3H), 3.57 (s, 3H), 3.52 (s, 1H), 3.10 (m, 
2H), 3.00 (m, 1H), 2.60 (m, 2H), 2.40 (dd, 1H, J=14.2, 6.9 Hz), 2.26 (d, 1H, J=16.5 Hz), 2.02 
(m, 1H), 1.90 (d, 1H, J=16.5 Hz), 1.89 (m, 1H), 1.75 (m, 2H), 1.45-1.36 (m, 5H), 1.27 (br s, 1H), 
1.19 (app d, 6H); 13C NMR (125 MHz, CDCl3) δ 173.62, 170.38, 157.63, 146.86, 145.96, 
141.06, 139.93, 133.44, 128.43, 128.33, 127.55, 127.18, 123.06, 112.95, 109.75, 100.94, 100.43, 
75.37, 75.16, 74.51, 70.66, 65.05, 57.38, 56.11, 54.06, 51.69, 48.73, 43.50, 41.82, 41.67, 31.56, 
26.59, 26.43, 20.42; IR (neat film) 3526 (br m), 2960 (s), 1744 (s), 1654 (s), 1503 (s), 1487 (s), 
1366 (s), 1225 (s), 932 (m), 754 (s) cm-1; LRMS (ESI) calcd for C29H40NO9 (M+ + H) 545.26 
found 545.7; [α]D = -112º (c 0.75, CHCl3). 
 
Homodeoxyharringtonine (5) (III-JTW-152) 
To a solution of allylic benzyl ether 55 (12.2 mg, 0.0192 mmol, 1.0 equiv) in glacial acetic acid 
(800 μL) was added degussa grade (E101 NE/W from Aldrich) Pd/C (10 wt % dry basis, 50% 
 43
water, 25.3 mg, 62 mol%).  The atmosphere in the vessel was replaced with H2 (1 atm) and the 
suspension was stirred for 20 h at 20 ºC, filtered through a plug of celite, flushed with glacial 
acetic acid, and the solvent was removed by azeotrope with toluene.  The crude product was 
purified by pH 7.0 buffered (10 wt %) silica gel column chromatography (2% Et3N in 1:1 
toluene:EtOAc) to yield homodeoxyharringtonine (5) (7.0 mg, 69%) as a colorless film as well 
as homoharringtonine (4) (2.8 mg 27%) as a colorless film. 
Rf = 0.66 (2% Et3N in 1:1 toluene:EtOAc on TLC plates pretreated with 5% Et3N in pentane); 1H 
NMR (500 MHz, CDCl3) δ 6.62 (s, 1H), 6.53 (s, 1H), 5.99 (d, 1H, J=9.8 Hz), 5.86 (dd, 2H, 
J=9.8, 1.5 Hz), 5.04 (s, 1H), 3.77 (d, 1H, J=9.8 Hz), 3.66 (s, 3H), 3.57 (s, 3H), 3.48 (s, 1H), 3.11 
(m, 2H), 2.95 (m, 1H), 2.59 (m, 2H), 2.38 (dd, J=14.8, 6.9, 1H), 2.31 (d, 1H, J=16.5 Hz), 2.05 
(m, 1H), 1.91 (m, 1H), 1.90 (d, 1H, J=16.5 Hz), 1.75 (m, 2H), 1.49 (m, 1H), 1.38 (m, 3H), 1.09 
(m, 3H), 0.85 (app t, 6 H, J=6.4 Hz); 13C NMR (125 MHz, CDCl3) δ174.24, 170.61, 157.95, 
146.82, 145.96, 133.48, 128.55, 112.81, 109.84, 100.96, 100.20, 74.84, 74.80, 70.75, 57.38, 
56.00, 54.09, 51.63, 48.75, 43.53, 42.79, 39.16, 39.08, 31.49, 27.93, 22.81, 22.51, 20.71, 20.44; 
IR (neat film) 3529 (br w), 2953 (s), 1748 (s), 1654 (m), 1504 (m), 1487 (s), 1224 (s), 932 (m) 
cm-1; LRMS (ESI) calcd for C29H40NO8 (M+ + H) 530.27 found 530.3;  [α]D = -112º (c 0.7, 
CHCl3). 
 
(R)-4-oxo-2-propyloxetane-2-carboxylic acid (56) (II-JTW-286) 
To a solution of benzyl ester 49 (30.3 mg, 0.123 mmol, 1.0 equiv) in EtOAc (1.5 mL) was added 
10% Pd/C (3.2 mg, 0.0030 mmol, 2.4 mol%).  The atmosphere in the vessel was replaced with 
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H2 under balloon pressure and the mixture was stirred at 20 ºC for 15 h.  The suspension was 
then filtered through a plug of celite and flushed with EtOAc (25 mL).  Solvent removal yielded 
carboxylic acid 56 (19.0 mg, 97%) as a yellow oil. 
1H NMR (500 MHz, CDCl3) δ 11.3 (br s, 1H), 3.73 (d, 1H, J=16.6 Hz), 3.45 (d, 1H, J=16.5 Hz), 
2.20-2.15 (m, 1H), 2.06-2.00 (m, 1H), 1.57-1.50 (m, 1H), 1.48-1.44 (m, 1H), 1.01 (t, 3H, J=7.3 
Hz); 13C NMR (125 MHz, CDCl3) δ 175.04, 165.78, 76.44, 47.07, 37.38, 17.20, 13.93; IR (neat 
film) 3500-3000 (br m), 2966 (m), 2878 (m), 1834 (s), 1736 (s), 1410 (w), 1143 (m), 960 (w) 
cm-1. 
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β-lactone 57 (III-JTW-006) 
To a solution of acid 56 (9.9 mg, 0.063 mmol, 2.0 equiv) and cephalotaxine (1) (9.9 mg, 0.031 
mmol, 1.0 equiv) in CH2Cl2 (630 μL) were added triethylamine (29 μL, 0.21 mmol, 6.6 equiv) 
and 2,4,6-trichlorobenzoyl chloride (10.9 μL, 0.0697 mmol, 2.20 equiv) via syringe and N,N-
dimethylaminopyridine (DMAP) (4.4 mg, 0.0360 mmol, 1.14 equiv) as a solid.  The resulting 
dark purple solution was stirred at 20 ºC for 15 m (TLC showed complete consumption of 
cephalotaxine after 5 m), then loaded directly onto a silica gel column.  The column was eluted 
with 2% Et3N in 9:1 toluene:EtOAc to yield 57 (11.7 mg, 81%) as a colorless oil. 
Rf = 0.48 (2% Et3N in 9:1 toluene:EtOAc on plates pretreated with 5% Et3N in pentane); 1H 
NMR (500 MHz, CDCl3) δ 6.61 (s, 1H), 6.59 (s, 1H), 5.90 (d, 1H, J=9.5 Hz), 5.86 (dd, 2H, 
J=7.8, 1.5 Hz), 5.08 (s, 1H), 3.81 (d, 1H, J=9.6 Hz), 3.69 (s, 3H), 3.14-3.07 (m, 2H), 3.02 (d, 1H, 
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J=16.5Hz), 2.96-2.90 (m, 1H), 2.85 (d, 1H, J=16.5Hz), 2.61-2.56 (m, 2H), 2.36 (dd, 1H, 
J=14.3,6.9 Hz), 2.05-2.00 (m, 1H), 1.92-1.88 (m, 1H), 1.84-1.72 (m, 3H), 1.64-1.58 (m, 1H), 
1.20-1.07 (m, 2H), 0.86 (t, 3H, J=14.8 Hz); 13C NMR (125 MHz, CDCl3) δ168.62, 166.26, 
156.79, 147.07, 145.99, 133.86, 127.89, 113.16, 110.02, 101.10, 76.48, 75.75, 70.85, 57.44, 
56.43, 54.08, 48.63, 46.35, 43.61, 37.36, 31.55, 20.45, 16.82, 13.94; IR (neat film) 2961 (m), 
1838 (s), 1743 (s), 1655 (s), 1487 (s), 1376 (w), 1037 (s), 731 (s) cm-1; LRMS (ESI) (calcd for 
C25H30NO7 (M+ + H) 455.19 found 455.96; [α]D = -120º (c 1.13, CDCl3). 
 
Bis-demethyldeoxyharringtonine (58) (III-JTW-008) 
To a solution of β-lactone 57 (9.5 mg, 0.021 mmol, 1.0 equiv) in MeOH (210 μL) was added a 
freshly prepared solution of 0.5M NaOMe in MeOH (4.2 μL, 0.0021 mmol, 0.1 equiv).  After 15 
min the solution was quenched with sat’d NH4Cl solution (10 mL) and extracted with CH2Cl2 
(3x 10 mL).  The combined organic phases were dried over MgSO4 and concentrated by rotary 
evaporation to yield 58 (9.5 mg, 93%) as a colorless oil without need for further purification. 
Rf = 0.40 (2% Et3N in 9:1 toluene:EtOAc on plates pretreated with 5% Et3N in pentane); 
1H NMR (500 MHz, CDCl3) δ 6.62 (s, 1H), 6.54 (s, 1H), 5.98 (d, 1H, J=9.8 Hz), 5.87 (d, 2H, 
J=5.7 Hz), 5.04 (s, 1H), 3.77 (d, 1H, J=9.8 Hz), 3.68 (s, 3H), 3.57 (s, 3H), 3.47 (s, 1H), 3.17-
3.07 (m,. 2H), 2.99-2.90 (m, 1H), 2.63-2.56 (m, 2H), 2.38 (dd, 1H, J=14.1,6.8 Hz), 2.29 (d, 1H, 
J=16.5 Hz), 2.07-2.00 (m, 1H), 2.00 (d, 1H, J=16.6), 1.93-1.87 (m, 1H), 1.80-1.71 (m, 2H), 1.44-
1.27 (m, 3H), 1.14-1.05 (m, 1H), 0.83 (t, 3H, J=7.2 Hz); 13C NMR (100 MHz, CDCl3) δ 174.15, 
170.63, 157.89, 146.83, 145.96, 133.51, 128.44, 112.81, 109.83, 100.95, 100.21, 74.96, 74.85, 
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70.76, 57.33, 56.06, 54.10, 51.62, 48.77, 43.58, 42.75, 41.16, 31.52, 20.45, 16.29, 14.22; IR 
(neat film) 3525 (w), 2958 (m), 1747 (s), 1654 (m), 1503 (m), 1487 (s), 1225 (s), 1037 (s), 731 
(w) cm-1; LRMS (ESI) calcd for C26H34NO8 (M+ + H) 488.22 found 487.84; [α]D = -124º (c 0.95, 
CDCl3). 
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CHAPTER 2. INTRODUCTION TO THE C19-DITERPENOID ALKALOIDS 
2.1 History and Characterization 
The Aconitum and Delphinium genera of plants have been used for centuries in traditional 
Chinese folk medicines. Although the raw leaves and especially the roots are quite toxic, 
preparations of these plants are known to have medicinal properties.1 The long documented 
history of the medicinal properties of these plants has piqued the interest of many natural product 
isolation chemists, leading to the identification of the Aconitum and Delphinium diterpenoid 
alkaloids (Figure 3).2 One diverse class of compounds is the C20-diterpenoid alkaloids that 
include the atisines, denudatines, hetidines, hetisines, vakognavines, and napellines. In addition  
to the C20-alkaloids, another class of compounds isolated from Aconitum and Delphinium plants 
includes some of the most potent biologically active members is the C19-diterpenoid alkaloids. 
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This class is further subdivided based on the presence (aconitines) or absence (lappaconitines) of 
the C18 carbon.* Although the structures in Figure 3 are drawn according to the traditional 
representations meant to highlight their terpene nature, an alternate representation that places 
emphasis on the C8-C7-C17-C1 backbone of the aconitines is depicted as structure 59 (Figure 4), 
along with a similar treatment for the atisines (60).†
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Figure 4. Diterpenoid numbering scheme.  
The biosynthesis of the C19-diterpenoid alkaloids was proposed by Wiesner to include a 
rearrangement from C20-atisine intermediate 61 (Scheme 17) to the aconitine skeleton (63) by a 
1,2-shift of C10 from C8 to C9 followed by formation of the C7–C17 bond to complete the F and 
B rings.3 Since the original isolation in the early 1900's4,5 and the first structural identification of 
the C19-diterpenoid alkaloids in 1959,6,7 hundreds of similar, but distinct, C19-diterpenoid 
alkaloids have been isolated and more are still being reported on an almost daily basis.2,8 The 
intriguing structure and biological activity of the plant preparations have made these compounds 
a popular subject of research. 
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* Although the lappaconitines lack the C18 carbon, historically these have also been denoted as C19-diterpenoid 
alkaloids. 
† The numbering scheme for the C20-alkaloids has been modified from the traditional scheme to more closely 
overlap with that of the C19-diterpenoid alkaloids for the purpose of clarity and to further highlight the similarities. 
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2.2 Biological Activity and Structure Activity Relationships 
Despite the structural similarity between C19-diterpenoid alkaloids, these compounds 
display a large variety of potent, yet at times, opposing biological effects. For example, aconitine 
(64, Figure 5) is a highly toxic sodium channel activator with arrhythmogenic cardiotoxicity. In 
contrast, lappaconitine (65), while sharing a similar structural skeleton, displays relatively low 
toxicity and is a sodium ion channel blocker with antiarrhythmic cardiovascular effect.9 In 
addition to the cardiovascular effects, these alkaloids are also analgesics.  Although aconitine 
(64) is a much more potent analgesic than lappaconitine (65), its much higher toxicity precludes 
its use in this capacity. 
LD50 (mg/kg)
Antinociceptive effect
ED50 (mg/kg)
Cardiovascular effect
Antiinflammatory effect
ED50 (mg/kg)
0.12-0.2 (s.c.) 5.9-11.5 (i.v.)
0.06 (s.c.) 1.2-3.8 (s.c.)
Arrhythmogenic Antiarrhythmic
0.1 (p.o.) 6-8 (s.c.)
(s.c.) subcutaneous; (i.v.) intravenous; (p.o.) per os.
High Toxicity
Na+ Channel Activator
Low Toxicity
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Figure 5. Biological activity of Aconitine and Lappaconitine
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The therapeutic potential of the C19-diterpenoid alkaloids has prompted the study of 
structure-activity relationships (SAR) to determine those structural features that contribute to 
potency and toxicity. Even though these SAR studies have been limited in scope to either 
naturally isolated C19-diterpenoid alkaloids or to those alkaloids attainable by post-isolation 
modifications, some relationships have been discovered. The high toxicity of aconitine (64) has 
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been attributed to the acyl groups at C8 and C14.  Alkaloids that lack these acyl groups, such as 
lappaconitine (65), are much less toxic. In traditional Chinese preparations of these plants for use 
in traditional folk medicine, they are first boiled or steamed to reduce the toxicity, an effect 
likely a result of the hydrolysis of these esters. 
2.3 Previous Synthetic Approaches to the Aconitum and Delphinium Alkaloids 
-diterpenoid 
alkaloid         
In addition to being the first group to fully elucidate the structure of the C19
s, Wiesner and co-workers succeeded in completing the first total synthesis of a  
C19-diterpenoid alkaloid, talatisamine (66, Figure 6).3,10 Their accomplishment was followed by 
the synthesis of chasmanine (67)11 and 13-desoxydelphonine (68).12 To date, these are the only 
published total syntheses for this class of compounds. 
 
The strategy Wiesner used to construct the C19-diterpenoid alkaloid skeleton centered on 
his hyp
biosynthetic approach was talatisamine (66, 
Scheme
othesis concerning the biosynthesis of these molecules (refer to Scheme 17). Based on 
their recently completed synthesis of atisine13, the foundation of the Wiesner strategy was to 
access an appropriate rearrangement precursor similar to 62, using the technology they had 
already developed, to execute a C20 to C19-diterpenoid alkaloid skeletal transformation. 
2.3.1 Total Synthesis of Talatisamine by Wiesner 
The first target to which Wiesner applied his 
 18).3,14 The synthesis closely followed that of atisine13 by accessing cyclobutanol 71 
from vinylnitrile 69 and bis(vinylacetate) 70. The atisine skeleton was then constructed using a 
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retroaldol/aldol rearrangement under acidic conditions to give ketone 72.  After several 
functional group installations they were able to access tosylate 73, an appropriate intermediate 
with which to test the biomimetic approach. A dilute solution of 73 was heated to 180 °C in the 
presence of 1,5-diazabicyclo[4.3.0]non-5-ene (DBN) to give rearranged olefin 74 via 1,2 shift of 
C10 onto C9 to give transient cation 75. The deprotonation of 75 was unselective, however, and 
gave a mixture of the desired product as well as its olefin isomer 76. This intermediate was 
advanced several steps to the penultimate olefin 77 that upon treatment with Hg(OAc)2, afforded 
talatisamine (66), presumably by nitrogen oxidation to an imminium that underwent nucleophilic 
attack by the C7 olefin. Water then trapped the resulting C8 cation to provide the necessary C8 
hydroxyl group to complete the first synthesis of a C19-diterpenoid alkaloid. This oxidation was 
not selective and resulted in only 40% yield of 66, but did validate this approach to these targets. 
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2.3.2 Total Synthesis of Chasmanine by Wiesner 
The successful synthesis of talatisamine validated Wiesner's approach to these alkaloids, 
however there were some non-ideal transformations that needed to be addressed.  Specifically, 
the key
               
o n  
enesulfonyl azide, 
acetic 
 rearrangement gave a mixture of isomeric olefins, and the final oxidation was also non-
selective. Wiesner addressed both of these problems during his synthesis of   
chasmanine (67)11,12,15 by forming the C7–C17 bond much earlier in the route. 
The synthesis of chasmanine (67) began with the advancement f be zyl ketone 78 
(Scheme 19) to olefin 79. This olefin was subjected to aziridination with benz
acid, and catalytic p-toluenesulfonic acid to give aziridine 80 that spontaneously 
rearranged via a strain-release bond migration of C8 onto C7 indicated by the red arrows, 
resulting in a 48% yield of ketone 81. This rearrangement was not selective and was 
accompanied by 32% of acetate 82, the product from migration of C10 onto C17, a 
transformation made favorable by the electron rich nature of C10 due to the presence of the C14 
methoxy substituent. This aromatic intermediate was advanced to migration precursor 83 over 
several steps. When this intermediate was heated to 180 °C in the presence of DBN, C10 
migrated to C9 as in the talatisamine synthesis; however, in this case the presence of the C7–C17 
bond precluded undesired C7–C8 olefin formation and therefore 84 was isolated as the sole 
product in 85% yield. Oxymercuration of the olefin with mercury(II)acetate then selectively 
installed the requisite C8 hydroxyl group to furnish alcohol 85. Several functional group 
manipulations then completed chasmanine (67). This synthesis addressed the selectivity issue in 
the key skeletal rearrangement from 83 to 84 as well as the final oxidation, but also introduced a 
new transformation with poor selectivity, i.e. the strain-release aziridine rearrangement from 80 
to 81 that would need to be dealt with in the next generation synthesis. 
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2.3.3 Total Synthesis of 13-Desoxydelphonine by Wiesner 
When Wiesner targeted 13-desoxydelphonine (68), he intended to solve the poor 
ipulation of the substitution on the 
aromat
selectivity of the aziridine rearrangement through a clever man
ic ring (Scheme 20).12,16,17 Benzyl ketone 86 was advanced to aziridine 87, an 
intermediate that had a methoxy substituent at C9 rather than C10 (compare with 80, Scheme 19) 
The presence of the C9 methoxy substituent provided increased electron density at C8, thus 
favoring the desired C8 shift onto C7 rather than the undesired C10 to C17 shift observed in the 
chasmanine (67) synthesis to give exclusively the intended product of the strain-release 
rearrangement (88, 70%). From here, Wiesner deviated further from his previous approach in 
that rather than the retro-aldol/aldol strain release rearrangement of a cyclobutanol (see 71, 
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Scheme 18), diene 89‡ was prepared for a Diels–Alder cycloaddition. Treatment of 89 with an 
excess of benzylvinyl ether at room temperature effected an inverse-electron demand Diels–
Alder to produce dioxolanone 90, thus efficiently completing the atisine skeleton more directly 
than the cyclobutanol rearrangement. This dioxolanone was transformed over several steps into 
C9 bromide 91, an intermediate poised to undergo Wiesner's key rearrangement. Similar to the 
talatisamine and chasmanine syntheses, when 91 was heated to 180 °C in the presence of DBN, 
the migration of C10 onto C9 took place to afford olefin 92 (89%), thus effecting the 
transformation of the atisine skeleton into the aconitine skeleton. Further manipulations 
completed 13-desoxydelphonine (68) as Wiesner's ultimate accomplishment in the synthesis of 
the C -diterpenoid alkaloids. This impressive achievement has yet to be matched in the decades 
since Wiesner's publications. 
19
 
 
 
                                                 
‡ Bromide 89b was an inconsequential side product from the oxidative dearomatization in the production of diene 
89. This mixture was taken without separation until convergence by dehalogenation in a subsequent reaction. 
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2.4 Summary 
Wiesner's synthesis of talatisamine, chasmanine, and 13-desoxydelphonine are truly 
watershed moments in the history of total synthesis.  That these syntheses have been unmatched 
in over 30 years is a testament both to Wiesner's skill as well as the challenge these targets pose. 
Despite this success, there are still issues that could be addressed in a modern approach to these 
alkaloids.  In particular, a large number of functional group manipulations and a linear approach 
combine to yield a relatively lengthy synthesis.  A more convergent approach to these targets that 
avoids excessive functional group interconversions would significantly shorten the length. 
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CHAPTER 3. RETROSYNTHETIC ANALYSIS OF THE ACONITINE SKELETON 
3.1 General Approach  
Our approach to the C19-diterpenoid alkaloids (henceforth referred to as the aconitine alkaloids) 
centers on a late-stage formation of the C7–C8 and C11–C17 carbon–carbon bonds (Figure 7). 
One method for the formation of these bonds begins with an appropriate radical 
precursor 93 (Scheme 21). Generation of a radical by homolysis of the C–X bond 
results in a cyclopropylcarbinyl radical (94) that would undergo endocylic bond 
cleavage* of the highly strained cyclopropane to give a radical at C8. Attack of this 
radical on an appropriately placed olefin at C7 would occur in a 7-exo manner to form the key 
C7–C8 bond. The resulting radical at C17 would then attack a second double bond at C11 in a 5-
exo manner to complete the cyclization as well as the skeleton of the aconitine alkaloids (95). 
While this is an inherently attractive strategy, several issues may emerge as challenges to 
overcome: (1) cyclopropylcarbinyl radical 94 could instead fragment the exocyclic C16–C15 
bond to give a primary radical at C15 rather than the desired C8 radical; (2) the conformation 
required for overlap between the C8 radical and C7–C17 π* orbital could be high enough in 
energy that direct reduction of the C8 radical is more favored than addition into the olefin; and 
(3) the possibility for attack of the C8 radical onto the C1 olefin in a 5-endo manner rather than 
the desired 7-exo attack onto C7. Although 7-exo-trig reactions are considered "favored" by 
                                                 
* "Endocyclic" refers to the ring-fusion bond (i.e. the C8–C16), whereas "exocyclic" refers to the C15–C16 bond. 
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Baldwin's rules while 5-endo-trig are considered "disfavored",1 5-endo-trig radical cyclizations 
have been well documented.2,3
 A complementary strategy would employ a cation–π cyclization beginning with similar 
intermediate 96 (Scheme 22). In contrast to homolysis, heterolysis of the C–X bond would give 
cyclopropylcarbinyl cation 97. This electron deficiency would be shared through the cyclopropyl 
σ-bond with C8. The olefin at C7 would then attack on C8, again in a 7-exo mode, to form the 
key C7–C8 bond with the resulting transfer of electron deficiency to C17 in the form of an 
iminium species. This iminium could then undergo an intramolecular Mannich-type cyclization 
of C11 onto C17 to complete the skeleton of the aconitine alkaloids. 
 
 An advantage of these approaches would be that both can be accessed from the same or 
similar intermediates 93 and 96. Should one mode of reactivity prove to be unworkable, minimal 
effort would need to be expended to explore the other. Also, while a one-pot cascade reaction 
would be ideal, each step could be performed separately if necessary.  Moreover, a stepwise 
strategy would also not be limited exclusively to a radical or ionic reaction mode, but could 
employ a radical process for one C–C bond construction and an ionic process for the other.   
3.2 Retrosynthetic Analysis 
 With an overall strategy in hand, we then turned our attention to the challenge of efficient 
access to key intermediate 101 (Scheme 23). Since 101 incorporates a cis-fused [5.4.0]-
bicylcoazepine system, it becomes apparent that a Diels–Alder cycloaddition comprising the 
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building blocks of azepine 103 and diene 104 becomes an attractive strategy. Though to our 
knowledge there are no examples of the use of a 2,5-dihydroazepine as a dienophile, we were 
drawn by the convergent nature of this approach. Further retrosynthetic analysis reveals the ring-
fused cyclopropane fragment within 104 could also be constructed efficiently though a Diels–
Alder cycloaddition; however, in this case the 2π and 4π components would be cyclopropene 105 
and 2,5-dioxycyclopenta-1,3-diene† 106, respectively. Again, this plan is not without risk as 
cyclopropenes have 56 kcal/mol4 of ring strain and are known to be unstable and reactive. 
Moreover, substituted cylopentadienes with at least one hydrogen in the five position tend to 
undergo 1,5–hydrogen shifts,5 scrambling the substitution pattern. These difficulties would have 
to be explored and overcome to acquire the desired cyclization precursor (vide infra). 
 
 
 
 
 
                                                 
† In the interest of clarity, the numbering scheme for unsubstituted cyclopentadiene will be used even in cases where 
additional substituents of higher priority, such as oxygen, would change the numbering priority. 
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CHAPTER 4. SYNTHESIS AND EXPLORATORY RADICAL CYCLIZATIONS OF A 
KEY CYCLOPROPYLCARBINYL RADICAL PRECURSOR 
4.1 Synthesis of the [2.1.1.0]-Tricylic Ring System 
 As proposed in Scheme 23 of chapter 3, a Diels–Alder reaction between a                        
2,5-dioxycyclopenta-1,3-diene* (106) and a suitable cyclopropene (105) would quickly construct 
a key portion of the aconitine structure. However, cyclopropenes have seen limited use as 
dienophiles in synthesis due to their high reactivity and instability. Despite these challenges, 
there are a number of methods for the generation of cyclopropenes,1-4 including 1,2-elimination 
from cyclopropanes,2,5 isomerization of vinyl carbenes,6-13 [2+1] cycloaddition,14-19 ring 
contraction of 5-membered rings with extrusion of N23,20 or CO2,3,21 1,3/1,2-elimination,22 ring 
contraction of 4-membered rings,3 addition to cyclopropylium salts,5 1,1-elimination/1,2-Si 
shift,5 retro-Diels–Alder cyclization,2 and cycloisomerization.4,5 Of these, the most suitable 
protocol followed the method explored by Baird and co-workers in which a 
tribromocyclopropane, easily prepared from an appropriate alkyl acrylate, is subjected to 
lithium-halogen exchange followed by 1,2-elimination (Scheme 24) to give cyclopropenes in 
good yields. For example, treatment of (1,2,2-tribromocyclopropyl)methanol (107, available in 
three steps from methyl acrylate) with two equivalents of methyllithium provided 
cyclopropenylmethanol (109) in 73% yield, presumably via initial formation and subsequent 
protonation of dianion 108 upon aqueous workup. As a hydroxyl group could be easily converted 
to an appropriate radical precursor such as a xanthate, thiocarbonate, selenide, or halogen, this 
approach proved to be most useful in that: (1) tribromocyclopropanes are easily prepared from 
methyl acrylate; (2) cyclopropene formation occurs quickly at –78 °C and (3) a latent 
                                                 
* In the interest of clarity, the numbering scheme for unsubstituted cyclopentadiene will be used even in cases where 
additional substituents of higher priority, such as oxygen, would change the numbering priority.  
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cyclopropylcarbinol group should serve as an appropriate radical precursor. In adapting this 
protocol, silyl protection of alcohol 107 (Scheme 25) was accomplished using TIPSCl and 
imidazole23 to give silyl ether 110 in 72% yield. It was confirmed that this protected derivative 
could in fact give the cyclopropene dienophile 112 after lithium-halogen exchange at –78 °C 
with two equivalents of methyllithium followed by 1,2-elimination and protonation of vinyl 
anion 111. Although cyclopropene formation was efficient, its susceptibility to decomposition 
precluded further purification.5 Therefore this dienophile was used directly for subsequent  
Diels–Alder reactions. The synthesis of the 2,5-dioxycyclopenta-1,3-diene component of the 
Diels–Alder cycloaddition then became a priority. 
 
 
 Substituted cyclopentadienes with at least one hydrogen at the 5-position are notoriously 
unstable due to facile 1,5–hydrogen shifts (Scheme 26).24-27 For example, the half-life for the 
isomerization of 5–methylcyclopenta-1,3-diene (113) to 1–methylcyclopenta-1,3-diene (114) is 
1.2 h at 20 °C.27 If the requisite 1,3-dioxycyclopenta-1,4-diene 106 were to undergo this 
hydrogen shift prior to cycloaddition (Scheme 27), the result would be scrambling of the 
substituents of 106 to deliver isomeric mixtures of Diels–Alder cycloadducts, including the 
undesired cycloadduct 116. Therefore, it was important to explore strategies that would limit the 
extent of this cycopentadiene isomerization.   
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 Overcoming the challenge of 1,5–hydrogen shift has previously been accomplished with 
several designs of Diels–Alder cyclopentadiene substrates. One includes 1,2,4-trichloro-3,5,5-
trimethoxycyclopenta-1,3-diene27, ,28 29 (118, Scheme 27), available in one step from 
commercially available 1,2,3,4-tetrachloro-5,5-dimethoxycyclopenta-1,3-diene.28 The lack of 
any allylic hydrogens in the 5-position due to the presence of a ketal precludes the possibility of 
hydrogen shift isomerization. Moreover, the trihalogen substitution attenuates the reactivity of 
the diene by reducing the electron density of the π system as well as increasing its steric bulk, 
thereby slowing unwanted dimerization. In fact, this diene is stable for months when stored at     
–10 °C and can be routinely handled at room temperature without incident. Despite its attenuated 
reactivity, it has been shown to readily react with cyclopropene (119) at room temperature to 
give cycloadduct 120 in 65% yield.29 Reductive removal of the chlorine atoms in 12030 affords a 
ring system (121) that closely resembles the requisite [2.1.1.0]-ring system 104 (Scheme 23). 
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The above example provides strong precedent for the key cycloaddition; only the 
regioselectivity of the Diels–Alder was in question as this diene had only been reported to react 
with unsubstituted cyclopropene. As a consequence, the chlorinated diene 118 was treated with 
cyclopropene 112 at 20 °C (Scheme 29), resulting in an efficient Diels–Alder cycloaddition to 
provide a mixture of cycloadducts in 76% yield over two steps from tribromocyclopropane 110 
as a 1 : 3.6 mixture of 122 and 123. Unfortunately, undesired isomer 123 was the major 
cycloadduct, relegating diene 118 to be non-viable in the synthesis.  
 
It is likely that the chlorine substituents on 118 significantly reduce the electron density 
of the diene, leading to an inverse-electron demand cycloaddition pathway31 to afford the 
unwanted regioselectivity. Accordingly, a similar diene, devoid of the chlorine substituents, was 
hypothesized to reverse the regiochemical outcome by proceeding through a normal electron 
demand pathway. At the time, there was no literature precedent for unchlorinated 2,5-
dioxycyclopenta-1,3-dienes (106) engaging in a Diels–Alder process; however, it seemed 
reasonable to be able to access this class of diene through enolization of an appropriate 
cyclopentenone precursor. Thus, cyclopentenone 124 (Scheme 30), available in one step from 
cyclopentenone ethylene ketal via a method reported by Corey and Yu,32 was chosen as a model 
diene precursor as the ethylene ketal group would preclude a 1,5–hydrogen shift. Unfortunately, 
when a solution of 124 was treated with tert-butyldimethylsilyl trifluoromethanesulfonate 
(TBSOTf) and Et3N in the manner reported by Forsyth and co-workers,33 only a complex 
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mixture of products was obtained. Mass spectral evidence suggested the presence of dimers that 
were possibly produced via a Diels–Alder process, presumably a consequence of diene 
concentration during the isolation process.  However, diene dimerization was suppressed when a 
solution of the freshly prepared diene 125, without prior solvent removal, was treated with para-
benzoquinone (126) to provide the cycloadduct 127 in 94% unpurified yield. This promising 
result suggested the possiblity of using a cyclopentenone-derived cyclopentadiene as a key early 
step in the construction of the structure of the aconitine alkaloid core. 
 
Emboldened by this success, a similar protocol was applied to 4-hydroxycyclopent-2-
enone (128, Scheme 31), previously prepared in one step from furfuryl alcohol,34 to generate 
cyclopentadiene 129. The added risk with 129 lies in the presence of an allylic proton that would 
be susceptible to hydrogen-shift isomerization. Despite this liability, the potential to directly 
install the C14 oxygen functionality, common to all aconite alkaloids, during this early       
Diels–Alder process would certainly enhance efficiency of the synthesis of the aconitine 
skeleton. Thus, when a solution of 128 was treated with TBSOTf and Et3N, followed again by 
addition of the model dienophile p-benzoquinone (126), cycloadduct 130 was obtained in 45% 
yield. Unfortunately, the facial selectivity of approach of the dienophile 126 on the diene 129 
was anti to the bulky silyl ether, confirmed by a strong nOe interaction between the C14 proton 
and the C8 and C16 protons of cycloadduct 130. Although highly selective, this stereoselectivity 
produced the undesired C14 configuration relative to the aconitine alkaloids. Nevertheless, this 
experiment validated the competency of 2,5-dioxycyclopenta-1,3-dienes such as 129 to proceed 
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in Diels–Alder reactions without diene isomerization. Notably, the reticence of diene 129 to 
undergo hydrogen shifts as compared to other cyclopentadienes like 5-methylcyclopenta-1,3-
diene (113) likely lies in the presence of the TBS-enol-ether. This effect was quantified by 
Gleason and co-workers shortly after our above-mentioned experiments.35 This report (Scheme 
32) revealed that 5-methylcyclopenta-1,3-diene (113, Scheme 26) had a t½ of 1.2 h at 20 °C, 
whereas the isomerization of diene 131, containing TBS-enol-ether, has a significantly longer 
half-life (t½ = 37 h at 23 °C). 
 
 
Having established the viability of cyclopentenone–derived cyclopentadienes as the 4π 
components in a Diels–Alder reaction with cyclopropene dienophiles, preparations were 
complete to investigate the key cycloaddition with building blocks directly relevant to the 
synthesis of the aconitine alkaloids. Toward this end, the γ-hydroxyl group of 4-
hydroxycyclopent-2-enone (128, Scheme 33) was methylated (MeI, Ag2O, 75%)33 to produce 
allylic methyl ether 133, which was subsequently converted to the cyclopentadienyl enol-ether 
134 with TBSOTf and Et3N. Without further manipulation, this solution was directly treated with 
cyclopropene 112 at 0 °C to give an inseparable mixture of isomeric cycloadducts 135, 136, 137, 
and 138 in a 9.5 : 5.4 : 1.5 : 1 ratio, respectively, and 99% overall yield, with no evidence of 
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products arising from hydrogen shift. Out of a host of potential isomeric Diels–Alder 
cycloadducts, the major product was the constitutional isomer 135, in which the cyclopropene 
engaged in an endo approach onto the diene in a contra-steric fashion, syn to the methyl ether. 
While this facial selection was opposite to the prior outcome with the p-quinone dienophile 
(compare from 130, Scheme 31), the resultant C14 configuration in 135 fortuitously coincides 
with that in the aconitine natural products. The structure of 135 was confirmed by subsequent 
hydrolysis of the silyl enol-ether (NaOH, H2O >99%) to provide ketone 139, which exhibited 
significant nOe correlations of the C14 and C15 protons with those of C12.  
 
 While the observed contra-steric approach of the cyclopropene dienophile 112 onto diene 
134 was initially surprising, this phenomenon is not without precedent. Approach of dienophiles 
onto cyclopentadienes with heteroatom substituents in the 5-position have been well studied.31,36-
48 For example, Jones has shown that when 7,9-dimethyl-8H-cyclopent[a]acenaphthylen-8-ol 
(143) was allowed to react with dimethylfumarate in a Diels–Alder cycloaddition (Scheme 34), 
the dienophile approached from the contra-steric face, syn to the hydroxyl substitutent, to afford 
adduct 144 in 73% yield, with no indication of the anti-addition product.36 Similarly, the      
Diels–Alder cycloadditions of 5-halogen substituted cyclopentadienes have been shown in the 
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literature to provide selectivity for the syn-cycloadduct, albeit with increasing amounts of the 
anti-cycloadduct as the identity of the heteroatom moves down the column of the periodic table. 
When 5-fluorocyclopenta-1,3-diene (145) was treated with dimethylacetylenedicarboxylate 
(DMAD), the only isolable product was adduct 146 in which the dienophile had approached 
from the face syn to the halogen substituent (Scheme 35).40 While a chlorine substituent at the 5-
position also provided the syn adduct as the major product, a small amount (21%) of the anti 
adduct was also observed in the cycloaddition between 5-chlorocyclopenta-1,3-diene (147) and 
N-phenylmaleimide (Scheme 6).45 In contrast to the 5-fluoro and 5-chloro derivatives, 5-bromo 
(148) and 5-iodocyclopenta-1,3-diene (149) gave the anti-cycloadducts as the major products, 
possibly due to steric effects resulting from increased size of these halogen atoms. Indeed, in the 
case of iodine, the Diels–Alder reaction exclusively provided the anti-product with no detectable 
quantities of the syn-cycloadduct.  
 
F
MeO2C CO2Me
146 (syn, 35%)145
F
H
CO2Me
CO2Me
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 The origin of this heteroatom influence remains a topic of debate. Based on calculations 
as well as on empirical evidence, several hypotheses have been put forth, including: (1) a  
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favorable non-bonding interaction between the heteroatom lone pair and the dienophile 
LUMO;49 (2) orbital mixing of the heteroatom n-orbitals with the π-HOMO through the carbon σ  
 
framework;50 (3) electrostatic interactions that allow the more nucleophilic face of the diene 
being more reactive toward an electrophilic dienophile;37 (4) lower deformation energy required 
to reach the syn transition state geometry;44,47 (5) stabilization of the syn transition state by 
hyperconjugative participation of the antiperiplanar σ-bonds into the σ*-orbitals of the newly 
forming bonds according to the Cieplak model.39,51 Nevertheless, while the origin for this 
selectivity remains elusive, the outcome, namely the production of the Diels–Alder cycloadduct 
135, is clearly advantageous to our synthetic approach toward the aconitine skeleton. 
4.2 Cyclopropylcarbinyl Radical Model Study 
 With the successful synthesis of the cyclopropane fragment 139 (Scheme 33), efforts 
were then focused on investigating the cyclopropylcarbinyl radical fragmentation to construct the 
aconitine core as shown in Scheme 37. A key concept of this process is the homolysis of the 
endocyclic† C8–C16 bond of the cyclopropane ring upon generation of a cyclopropylcarbinyl 
radical (152), as shown in Path A. This ring expansion results in the formation of a radical at C8 
that can then attack the olefin at C7 in a 7-exo cyclization, followed by a 5-exo radical addition 
from C17 to C11 to complete the radical cascade. An alternative, unproductive, pathway is that 
                                                 
† "Endocyclic" refers to the ring-fusion bond (i.e. the C8-C16), whereas "exocyclic" refers to the C15-C16 bond. 
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depicted by Path B, in which the exocyclic C15–C16 bond undergoes homolysis, resulting in a 
primary radical at C15 (154) rather than the productive secondary radical at C8. To our 
knowledge, the radical fragmentation of a [2.1.1.0]-tricyclic ring system 152 has not previously 
been reported, so it was unclear whether fragmentation by Path A or by Path B would occur. 
 
It has been shown that in the case of cyclopropylcarbinyl radical 156 (Scheme 38) the 
desired pathway to secondary radical 157 is 120 times faster52 than the competing, undesired 
pathway to give primary radical 155. While this report was encouraging, a [4.1.0]-system has 
been reported to give different results. The cyclopropylcarbinyl radical derived from xanthate 
158 (Scheme 39) underwent exclusively undesired exocyclic bond cleavage to give 159.53 There 
was no evidence of the endocyclic bond cleavage product 160. Additionally, the radical derived 
from simple cyclohexyl xanthate 161 (Scheme 40) exhibited a tributyltin hydride concentration 
dependent result.54  While at high tribuytltin hydride concentration the 7-membered ring product 
from the desired pathway, 162, was favored. At lower concentrations the reaction was 
unselective, affording a 1 : 1 mixture of 162 along with the 6-membered ring 163.   
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 The above-mentioned examples provide a somewhat conflicting indication of what could 
be expected from the radical fragmentation of the [2.1.1.0]-tricyclic ring system in 152 (Scheme 
37). Consequently, the synthesis of a model cyclopropane was embarked upon to determine 
whether the endocyclic or exocyclic bond would cleave. Toward this end, Diels–Alder 
cycloadduct 164 (Scheme 41) was advanced to radical precursor 165 beginning with fluoride 
mediated cleavage55,56 of the TIPS-ether with concomitant TBS enol-ether removal. This was 
followed by conversion of the resultant alcohol to thiocarbonate57 165 (63%, two steps) by 
nucleophilic attack onto phenylchlorothionoformate. Thiocarbonate 165 was an ideal 
intermediate with which to test the selectivity of the fragmentation of a [2.1.1.0]-tricyclic 
cyclopropylcarbinyl radical. In the event, a benzene solution of 165, tributyltin hydride, and 
AIBN was heated to reflux to give a mixture of two products, neither of which was the result of 
the undesired exocylic bond cleavage of 166 (refer to Path B, Scheme 37) that would have given 
[2.2.1]-bicyclic product 167. The minor product was readily identifiable as the [3.2.1]-bicyclic 
compound 168 (30%), derived from the desired fragmentation of the endocyclic bond (refer to 
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Path A, Scheme 37) to give transient secondary radical 169 followed by reduction with 
tributyltin hydride. However, the major product was [2.2.2]-bicyclic compound 170 (47%), the 
origin of which was immediately less obvious. Fortunately, it too was likely the result of the 
desired endocyclic bond cleavage to give secondary radical 169, but instead of direct reduction, 
attack of the radical onto the ketone gave transient cyclopropyl alcoxy radical 171 that then 
fragmented via a Dowd-Beckwith58,59 pathway to provide 170. It is interesting to note that this 
process is essentially the single electron reverse of Weisner's biosynthetic transformation (See 
Scheme 20, Chapter 2), and warrants further study following the successful synthesis of the 
aconitine alkaloids. The above results show the cyclopropylcarbinyl radical of the [2.1.1.0]-
skeleton undergoes fragmentation through the ring-expansive endo-cyclic bond cleavage that is 
necessary for the first step in the proposed radical cascade (Path A, Scheme 37). Therefore, the 
cyclopropylcarbinyl fragmentation to give a secondary radical at C8 should proceed as planned. 
It was then necessary to prepare the fully functionalized precursor for cyclopropylcarbinyl 
radical 152 in order to conduct the synthesis of the aconitine alkaloids. 
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4.3 Synthesis of the [5.4.0]-Bicycloazepine System 
 Confident the cyclopropylcarbinyl radical fragmentation should occur via the desired 
endocyclic bond scission, an expedient route to prepare the 2π and 4π components for the second 
Diels–Alder reaction was developed (Scheme 42), continuing from the inseparable isomeric 
mixture of [2.1.1.0]-tricyclic cyclopropanes 139 and 140. The ketone groups of 139 and 140 
were reacted with the potassium salt of methyl diethylphosphonoacetate anion in refluxing THF 
to effect a Horner–Wadsworth–Emmons olefination,60 affording a complex mixture of four 
isomers, the result of unselective olefination of each constitutional isomer (139 and 140).  Rather 
than attempting to separate this mixture, the olefin isomers were converged by stereoselective 
hydrogenation with palladium on carbon that delivered hydrogen from the sterically less 
encumbered convex face to afford the constitutionally isomeric methyl esters 172 and 173. 
Although the reduction of the olefin group simplified the mixture composition, the remaining 
two isomers were still inseparable by silica gel column chromatography. Therefore, the methyl 
esters were advanced via trimethylaluminum mediated amidation61-63 with N,O–
dimethylhydroxylamine hydrochloride to give the separable Weinreb amides 174 and 175 in 
20% and 39% yield, respectively, over six steps from tribromocyclopropane 110. Now pure, the 
single isomer 175 was subjected to nucleophilic addition of vinylmagnesium bromide into the 
Weinreb amide carbonyl64 to give the tetrahedral magnesium salt 176. After hydrolysis during 
acidic work-up, enone 177 emerged as the principal product, which was not purified, but used 
directly for the next transformation. The enone carbonyl was immediately enolized by treatment 
with TBSOTf and KHMDS at –78 °C65 to generate diene 178 as a >25 : 1 mixture of isomers in 
77% yield over two steps, favoring the Z-isomer. This final step marked the completion of the 4π 
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component required for the Diels–Alder cycloaddition to prepare the [5.4.0]-bicycloazepine ring 
system. Subsequent efforts were focused on constructing the remaining 2π azepine component. 
 An efficient synthesis of novel azepine dienophile 186 (Scheme 43) was developed to 
continue the construction of the [5.4.0]-bicycloazepine system. The synthesis began with 
commercially available and inexpensive ε-caprolactone (179) as the carbon source. A mixture of 
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179 and two molar equivalents of benzylamine was heated, without solvent, to 120 °C to affect 
nucleophilic attack onto the lactone carbonyl.66 The acyclic hydroxyl-amide 180 was isolated by 
direct crystallization (ethyl acetate, 78%). Oxidation of the primary alcohol was performed under 
Parikh–Doering conditions67 to provide aldehyde 181 (93%). Acid catalyzed condensation of the 
secondary amide onto the newly-formed aldehyde was accomplished in refluxing toluene with 
azeotropic removal of water via a Dean–Stark apparatus68 to afford enamide 182 (77%). The 
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requisite methyl ester as well as the selenide was installed in a one-pot double addition 
procedure. α-Deprotonation of the amide carbonyl with two equivalents of LHMDS was 
followed by the addition of one equivalent of methylchloroformate to give the intermediate 
enolate 183 that was then trapped with phenylselenyl chloride to deliver selenide 184.69  This 
product not purified, but was directly transformed into olefin 185 (60%, two steps) by oxidation 
of the selenide with aqueous hydrogen peroxide and spontaneous 1,2-syn elimination of the 
transient selenoxide.70 Further oxidation of the π-system with chromium (VI) oxide and 3,5-
dimethylpyrazole71 gave an appropriately activated dienophile (186). At this juncture, we had 
both the 4π and the 2π components in hand to perform the desired Diels–Alder cycloaddition to 
produce the [5.4.0]-bicycloazepine ring system. However, the use of an azepine-2,7-dione 
dienophile in a Diels–Alder reaction was unprecedented, so the outcomes of regio-, endo/exo-, 
and facial stereoselectivities were not clear.  
 
 Extensive experimentation by graduate researcher colleague Yuan Shi revealed that the 
Diels–Alder reaction could indeed be effected by addition of catalytic Yb(OTf)3 to a solution of 
the diene 178 with two equivalents of the dienophile 186 at 20 °C to produce an inseparable 
mixture of two isomers (Scheme 44), one of which incorporated the desired relative 
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stereochemistry (i.e. 102, Scheme 23, chapter 3).  Subsequent chemoselective hydrogenation of 
the enimide with palladium on carbon under an atmosphere of hydrogen gave the imides 187 
(45%, two steps) and 188 (38%, two steps) that could be separated by silica gel column 
chromatography. Notably, the above cycloaddition proceeded with complete regio and endo 
selectivity (relative to the 7-membered ring) as confirmed by the all syn nature of the C11 and 
C5 protons with the C4 ester. Although the facial approach of azepine 186 onto diene 178 was 
mildly selective for the undesired isomer 187, this process nonetheless produced a reasonable 
yield of the desired diastereomer 188. This strategy has provided 188 in quantities sufficient for 
further investigation (vide infra); however, efforts to improve the diastereoselectivity of this key 
Diels–Alder cycloaddition are ongoing. 
 
In order to explore our proposed radical cascade to access the aconitine alkaloids (see 
Scheme 37), it was necessary to transform the imide 188 to incorporate the C7–C17 and C1–C11 
olefins. This task was accomplished in five steps beginning with C7 deprotonation (Scheme 44) 
using KHMDS to provide the potassium enolate that underwent O-sulfonylation with Comins' 
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reagent72 to provide a vinyl triflate that was immediately reduced, without purification, with 
tributyltin hydride in the presence of catalytic Pd(PPh3)4 to afford enamide 189 in 62% yield 
over two steps. Selective cleavage of the TBS enol-ether in the presence of the more bulky TIPS 
ether was accomplished with one equivalent of TBAF at 0 °C to provide ketone 190 in 69% 
yield. Sodium borohydride reduction stereoselectively delivered hydride from the less hindered 
convex face to provide an 88% yield of alcohol 191 as a single diastereomer. The structure of 
this crystalline intermediate was unambiguously verified by x-ray structural analysis. A screen of 
reaction conditions revealed that the alcohol could be selectively transformed into the 
thermodynamically favored trisubstituted olefin 192 by activation of the hydroxyl group as an 
oxophosphonium under Hendrickson's conditions73-75 (triphenylphosphine oxide, triflic 
anhydride, Hünig's base, 42% yield). Although this intermediate did not contain the complete 
oxidation pattern of many of the aconitine alkaloids, it did have the required C7–C17 and C1–
C11 olefins to explore the key radical cyclization reaction. 
4.4 Undesired 5-Endo Cyclization of a C8 Radical onto C1 
With the installation of the C7–C17 and C1–C11 olefins as well as the 
cyclopropylcarbinol of 192, preparations were nearly complete to attempt the key radical 
cyclization cascade (see Scheme 37). However, the primary silyl ether needed to be converted to 
a more appropriate radical precursor. Therefore, the TIPS ether of 192 (Scheme 45) was first 
cleaved with TBAF to reveal the cyclopropylcarbinol 193 (88%). Activation of the newly 
revealed alcohol as an oxophosphonium and displacement with phenylselenylate nucleophile was 
accomplished with triphenylphosphine and N-(phenylseleno)succinimide (194) to give selenide 
195 in 39% yield over two steps. The resultant intermediate was ideal to explore the 
cyclopropylcarbinyl radical cleavage. Although the model cyclopropylcarbinyl radical (166, see 
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Scheme 41) underwent exclusive endocyclic C8–C16 bond scission, the behavior of the fully 
elaborated system was unknown. In the event, a benzene solution of selenide 195, tributyltin 
hydride, and catalytic AIBN were heated at 100 °C to produce a mixture of two compounds, both 
of which were the result of endocyclic C8–C16 fragmentation. Unfortunately, there was no 
indication of the productive attack of the secondary C8 radical (197) onto the C7 carbon.  The 
major product was that of direct C8 radical reduction to give 198 in 35% yield. Also isolated was 
cyclopentane 199 (29%), derived from C8 radical addition in a 5-endo fashion onto C1 rather 
than 7-exo addition onto C7. The empirical observations detailed by Baldwin76 suggest the 
observed 5-endo mode would be disfavored relative to the 7-exo pathway, so an alternate 
explanation was required. One possibility is the conformation in which the C8 radical is in close 
proximity to the C7 olefin must be higher in energy than that required for attack on the C1 olefin. 
Thus, the observed direct radical reduction and 5-endo cyclizations are left as the only observed 
reaction pathways. While this setback was disappointing, we reasoned this 5-endo pathway could 
be mitigated by the installation of an oxygen bearing a bulky protecting group at C1, which 
would sterically shield that position from attack by the C8 radical and increase the transition-
state energy such that the 7-exo reaction mode would be favorable relative to the 5-endo mode.   
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4.5 Summary 
Two novel Diels–Alder cycloadditions were developed in the synthesis of key radical 
precursor 195 (Scheme 46). One included a novel cyclopentenone-derived substituted 2,5-
dioxycyclopenta-1,3-diene (134) and a cyclopropene dienophile (112) that approached from the 
sterically more hindered face to rapidly construct the [2.1.1.0]-tricyclic ring system 135 with the 
appropriate C14 stereochemistry for the aconitine alkaloids. This product was rapidly elaborated 
to diene 178 that was reacted with azepine-2,7-dione dienophile 186 to install the [5.4.0]-
bicycloazepine ring system required for the successful synthesis of the aconitine alkaloids. The 
synthesis of the key radical cyclization precursor 195 was then completed in 18 steps from 
tribromocyclopropane 107. Although the initial cyclopropylcarbinyl radical fragmentation 
occurred by the intended endocyclic pathway, the only isolated products were 198 and 199, 
neither of which was the result of the desired C8 radical addition onto C7. Rather, 198 was the 
result of direct reduction of the C8 radical, while an undesired 5-endo cyclization of C8 onto C1 
formed cyclopentane 199. 
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4.6 Experimental 
General Procedures.  All reactions were performed in flame-dried modified Schlenk (Kjeldahl 
shape) flasks fitted with a glass stopper under a positive pressure of argon, unless otherwise 
noted.  Air- and moisture-sensitive liquids and solutions were transferred via syringe or stainless-
steel cannula.  Organic solutions were concentrated by rotary evaporation below 30 °C.  Flash 
column chromatography was performed employing 230-400 mesh silica gel under a positive 
pressure of nitrogen.  Automated silica gel column chromatography was performed employing 
an Isco Combiflash Rf with Isco brand columns. Gradient elutions were performed with a linear 
gradient. Thin-layer chromatography (analytical and preparative) was performed using glass 
plates pre-coated to a depth of 0.25 mm with 230-400 mesh silica gel impregnated with a 
fluorescent indicator (254 nm). Visualization was achieved using UV light, iodine, potassium 
permanganate (KMnO4), or ceric ammonium molybdenate (CAM).  
Materials.  Dichloromethane (CH2Cl2), tetrahydrofuran (THF), acetonitrile, diethyl ether, 
toluene, and benzene were purified by passage through two packed columns of neutral alumina 
under an argon atmosphere.  Methanol was distilled from magnesium turnings under a nitrogen 
atmosphere at 760 mm Hg. 1,2-Dichloroethane, N,N-dimethylformamide (DMF), 
dimethylsulfoxide, and 1,4-dioxane were dried over activated 4Å molecular sieves.  
Triethylamine, 2,6-lutidine, pyridine, Hünig's base, and diisopropylamine were distilled from 
CaH2 under a nitrogen atmosphere at 760 mm Hg.  Lithium bis(trimethylsilyl)amide (LHMDS) 
and potassium bis(trimethylsilyl)amide (KHMDS) were purchased as a solid from Aldrich and 
handled under an argon atmosphere. Trifluromethanesulfonic anhydride was distilled from P2O5 
under a nitrogen atmosphere at 760 mm Hg. All moisture and/or oxygen sensitive solids were 
handled and stored in a glove box. Organolithium solutions were titrated by known procedures77 
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immediately prior to use. All other reagents were used as purchased without further purification, 
unless otherwise noted. 
Instrumentation.  Infrared (IR) spectra were obtained using a Bruker Tensor 27 referenced to a 
polystyrene standard. Data are presented as the frequency of absorption (cm-1).  Proton and 
carbon-13 nuclear magnetic resonance (1H NMR or 13C NMR) spectra were recorded on a 
Bruker Avance III 500 or a Bruker Avance III 600 spectrometer; chemical shifts are expressed in 
parts per million (δ scale) downfield from tetramethylsilane and are referenced to the residual 
protium in the NMR solvent (CHCl3: δ 7.26 for 1H NMR, δ 77.16 for 13C NMR; C6D6: δ 7.16 for 
1H NMR, δ 128.06 for 13C NMR).  Data are presented as follows: chemical shift, multiplicity (s 
= singlet, bs = broad singlet, d = doublet, bd = broad doublet, t = triplet, dd = doublet of 
doublets, ddd = doublet of doublet of doublets, td = triplet of doublets, dt = doublet of triplets, m 
= multiplet and/or multiple resonances), integration, and coupling constant reported in Hz. X-ray 
crystallography was performed by Louis Todaro of Hunter College in New York City, NY. 
 
(1,2,2-tribromocyclopropyl)methanol (107) (V-JTW-006) 
To a solution of ester S2 (42.1 g, 125  mmol, 1.00 equiv) in CH2Cl2 (250 mL, 0.5 M) at –78 ºC 
was added a 1.0 M solution of diisobutylaluminum hydride in hexanes (256  mL, 256 mmol, 2.05 
equiv) and the solution was removed from the cooling bath for 45 min at which time the reaction 
was shown to be complete by TLC analysis.  The solution was cooled to –78 ºC and quenched 
with saturated Rochelle's salt solution (250 mL), diluted with Et2O (500 mL), removed from the 
cold bath, and stirred vigorously at room temperature until the phases became distinct and clear 
(1.5 h).  The phases were then separated and the aqueous phase was extracted with Et2O (2x 250 
mL) and the combined organic phases were dried over MgSO4, filtered, and the solvent was 
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removed to yield alcohol 107 (38.7 g, 100%) as a white solid.  NMR analysis indicated the 
presence of ~10% aldehyde.  This was used without purification. 
Rf = 0.28 (CH2Cl2, KMnO4 stain); all other spectral information was identical with the published 
values. 
 
triisopropyl((1,2,2-tribromocyclopropyl)methoxy)silane (110), (V-JTW-007) 
To a solution of alcohol 107 (38.7 g, 125 mmol, 1.00 equiv) in CH2Cl2 (420 mL, 0.3 M) were 
added imidazole (21.3 g, 313 mmol, 2.50 equiv) and triisopropylsilyl chloride (33.1 mL, 156 
mmol, 1.25 equiv).  A white precipitate quickly appeared and the mixture was stirred at 20 °C for 
16 h, at which time it was cooled in an icewater bath and quenched with ½ saturated NaHCO3 
solution (420 mL).  The phases were separated and the aqueous phase was extracted with CH2Cl2 
(200 mL).  The combined organic phases were washed with H2O (400 mL), dried over MgSO4, 
filtered, and the solvent was removed to yield a yellow oil.  This was purified by SiO2 column 
chromatography (hexanes) yielded triisopropylsilyl ether 110 (41.6g, 72%) as a clear, colorless 
oil as well as a 41 wt% mixture of aldehyde in triisopropylsilanol (12.8 g, containing 5.3 g 
aldehyde) 
Rf = 0.5 (hexanes, KMnO4 stain); 1H NMR (500 MHz, CDCl3) δ 4.23 (d, 1H, J=11.5 Hz), 4.12 
(d, 1H, J=11.5 Hz), 2.01 (d, 1H, J=9.3 Hz), 1.93 (d, 1H, J=9.3Hz), 1.11 (m, 21H); 13C NMR 
(125 MHz, CDCl3) δ 70.82, 45.16, 35.50, 30.50, 18.12, 18.05, 12.19, 12.08; IR (neat film) 2943 
(s), 2866 (s), 1462 (m), 1150 (s), 1119 (s) cm-1;  
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 Cyclopropanes 122 and 123 (II-JTW-251) 
To a solution of tribromocyclopropane 110 (113 mg, 0.243 mmol, 1.00 equiv) in diethyl ether 
(810 μL, 0.3 M) at –78 ºC was added a 1.6 M solution of methyllithium in diethyl ether (311 μL, 
0.498 mmol, 2.05 equiv). The resulting cloudy solution was removed from the cold bath for 10 
m, then re-cooled to –78 ºC, quenched with H2O (1 mL), then removed from the cold bath and 
allowed to melt. The aqueous phase was then re-frozen and the organic phase separated, then the 
aqueous phase allowed to melt and extracted with diethyl ether (2x 1 mL). The combined organic 
extracts were used added directly to a flask containing diene 118 (315 mg, 1.22 mmol, 5.00 
equiv) and stirred at room temperature for 18 h.  The solution was then concentrated and purified 
by silica gel column chromatography (2.5% diethyl ether in petroleum ether) to give a 1 : 3.6 
mixture of isomers 122 : 123 (90 mg, 76%) 
Major isomer 123: 
Rf = 0.27 (2 : 1 hexanes : CH2Cl2, KMnO4 stain); 1H NMR (500 MHz, CDCl3) δ 4.09 (d, 1H, 
J=9.5 Hz), 4.08 (s, 3H), 4.05 (d, 1H, J=9.5 Hz), 3.60 (s, 3H), 3.54 (s, 3H), 1.76 (dd, 1H, J=7.0, 
3.2 Hz), 1.26 (t, 1H, J=6.9 Hz), 1.11-1.04 (m, 21H), 0.61 (dd, 1H, J=6.3, 3.1 Hz) 
 
Dione 127 (II-JTW-259) 
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To a solution of enone 124 (21.0 mg, 0.150 mmol, 1.00 equiv) in CH2Cl2 (1.4 mL, 0.1 M) at 0 ºC 
were added triethylamine (30 μL, 0.22 mmol, 1.5 equiv) and tert-butyldimethylsilyl 
trifluoromethanesulfonate (41 μL, 0.179 mmol, 1.2 equiv). The resulting solution was stirred at 0 
ºC for 20 m, then benzoquinone (126) (30 mg, 0.28 mmol, 1.9 equiv) was added.  The solution 
was then stirred at room temperature for 20 m, diluted with H2O (10 mL), and extracted with 
CH2Cl2 (2x 10 mL).  The combined organic extracts were dried over Na2SO4, filtered, and 
concentrated to give dione 127 (48.6 mg, 94%) as a red oil.  
Rf = 0.65 (1 : 1 hexanes : ethyl acetate, KMnO4 stain); 1H NMR (500 MHz, CDCl3) δ 6.64 (d, 
1H, J=10.3 Hz), 6.61 (d, 1H, J=10.3 Hz), 4.72 (dd, 1H, J=3.5, 1.3 Hz), 3.95 – 3.86 (m, 4H), 3.49 
(dd, 1H, J=8.2, 4.1 Hz), 3.43 (dd, 1H, J=8.5, 4.1 Hz), 3.12 (m, 1H), 2.91 (m, 1H), 0.85 (s, 9H), 
0.12 (s, 3H), 0.02 (s, 3H). 
 
Dione 130 (III-JTW-077) 
To a solution of hydroxyl-enone 128 (20 mg, 0.20 mmol, 1.0 equiv) in CH2Cl2 (2.0 mL, 0.1 M) 
at 0 ºC were added triethylamine (124 μL, 1.22 mmol, 6.0 equiv) and tert-butyldimethylsilyl 
trifluoromethane sulfonate (140 μL, 0.612 mmol, 3.0 equiv). After 3 m, benzoquinone (126) (44 
mg, 0.41 mmol, 2.0 equiv) was added.  After 1 h, the solution was diluted with H2O (10 mL) and 
extracted with CH2Cl2 (3x 10 mL). The combined organic extracts were dried over MgSO4, 
filtered, and concentrated to give a dark brown oil. Purification by silica gel column 
chromatography (10 : 1 hexanes : ethyl acetate) gave dione 130 (40 mg, 45%) as a yellow oil. 
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Rf = 0.36 (10 : 1 hexanes : ethyl acetate, CAM stain); 1H NMR (500 MHz, CDCl3) δ 6.64 (d, 1H, 
J=10.3 Hz), 6.60 (d, 1H, J=10.3 Hz), 4.56 (dd, 1H, J=3.7, 1.5 Hz), 3.58 (m, 1H), 3.40 (dd, 1H, 
J=8.5, 4.4 Hz), 3.31 (dd, 1H, J=8.4, 4.0 Hz), 3.08 (m, 1H), 2.92 (m, 1H), 0.86 (s, 9H), 0.86 (s, 
9H), 0.10 (s, 3H), 0.07 (s, 6H), 0.01 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 201.32, 199.60, 
157.20, 142.75, 142.51, 100.61, 80.39, 56.93, 52.56, 48.36, 46.01, 25.85, 25.54, 18.02, 18.00, -
4.70, -4.72, -4.84. 
 
4-methoxycyclopent-2-enone ((±)133) (IV-JTW-161) 
To a solution of 4-hydroxycyclopent-2-enone (128) (13.8 g, 141 mmol, 1.00 equiv) in CH2Cl2 
(88 mL, 1.6 M) and iodomethane (88 mL, 1410 mmol, 10.0 equiv) was added Ag2O (44.1 g, 190 
mmol, 1.35 equiv).  The vessel was wrapped in foil and stirred vigorously for 13 d at room 
temperature.  The reaction was then filtered and the solvent was removed by rotary evaporation 
at 20 ºC and 150 torr, then purified by silica gel column chromatography (diethyl ether) and the 
solvent was removed at 20 ºC and 125 torr (CH2Cl2 was used for transfers) to yield 4-
methoxycyclopent-2-enone (133) as a yellow oil (16.3 g containing 27 wt% CH2Cl2; corrected 
yield: 11.9 g, 75%). 
Rf = 0.70 (ethyl acetate, KMnO4 stain); 1H NMR (500 MHz, CDCl3) δ 7.61 (dd, 1H, J=5.8, 2.4 
Hz), 6.26 (dd, 1H, J=5.7, 1.3 Hz), 4.59 (m, 1H), 3.43 (s, 3H), 2.67 (dd, J=18.2, 5.9 Hz), 2.30 (dd, 
1H, J=18.2, 2.2 Hz); 13C NMR (125 MHz, CDCl3) δ 205.92, 160.80, 135.90, 78.80, 57.16, 
41.24; IR (neat film) 2988 (w), 2934 (w), 2826 (w), 1720 (s), 1356 (m), 1112 (m), 794 (w); 
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Cyclopropene 112 (VI-JTW-070) 
To a solution of tribromocyclopropane 108 (37.7 g, 81.0 mmol, 1.00 equiv) in Et2O (400 mL, 
0.20 M) at –78 ºC was added a 1.6 M solution of methyllithium in Et2O (104 mL, 166 mmol, 
2.05 equiv).  The resulting solution was removed from the cold bath for 15 m, then re-cooled to  
–78 ºC, quenched with H2O (400 mL), removed from the cold bath, and allowed to melt.  The 
still cold phases were separated and the aqueous phase was extracted with Et2O (2x 200 mL) and 
the combined organic phases were dried thoroughly over MgSO4, filtered, and concentrated to 
give a light yellow oil (112) that was used immediately in the next step. 
Rf = 0.39 (hexanes, KMnO4 stain) 
Cyclopropane X (VI-JTW-071) 
To a solution of cyclopenteneone 133 (27.6 g of a 66 wt% solution in CH2Cl2 (18.2 g actual), 
162 mmol, 2.00 equiv) in CH2Cl2 (400 mL, 0.2 M) at 0 ºC were added cyclopropene 112 (18.4 g, 
81.0 mmol, 1.00 equiv) as a solution in CH2Cl2 (50 mL) followed by triethylamine (42.8 mL, 
308 mmol, 3.80 equiv) and tert-butyldimethylsilyl trifluoromethanesulfonate (35.3 mL, 154 
mmol, 1.90 equiv).  The resulting red solution was stirred at 0 ºC for 17 h then quenched with 
H2O (400 mL).  The phases were separated and the aqueous phase was extracted with CH2Cl2 
(2x 200 mL).  The combined organic phases were dried over Na2SO4, filtered, and the solvent 
was removed to give a bloodred oil that was purified by SiO2 column chromatography (packed 
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using 5% triethylamine in hexanes and eluted with 9:1 hexanes:CH2Cl2) to give cyclopropane 
135 (37.2 g, 101 %) as a 9.5:5.4:1.5:1 mixture of isomers 135 : 136 : 137 : 138 contaminated by 
a small amount of tert-butyldimethylsilanol. 
Rf = 0.63 (9:1 hexanes:CH2Cl2 on triethylamine pretreated plates); 1H NMR (500 MHz, CDCl3) 
(2 major isomers) δ 4.52 (dd, 10H, J=4.1, 1.6 Hz), 4.42 (dd, 6H, J=4.0, 1.7 Hz), 4.20 (d, 6H, 
J=9.8 Hz), 4.16 (d, 10H, J=9.9 Hz), 3.68 (m, 16H), 3.60 (s, 16H), 3.26 (s, 48H), 2.70 (m, 6H), 
2.64 (m, 10H), 2.59 (m, 16H), 1.35 (p, 10H, J=3.6 Hz), 1.30 (p, 6H, J=3.7 Hz), 1.09 (m, 336H), 
0.91 (m, 144H), 0.17 (s, 96H); 13C NMR (125 MHz, CDCl3) δ 155.47, 153.93, 102.65, 102.49, 
100.69, 99.50, 66.66, 66.46, 55.70, 50.56, 49.78, 44.25, 43.13, 30.46, 25.85, 25.82, 25.76, 21.97, 
21.54, 19.21, 18.24, 18.20, 18.11, 14.67, 12.27, 12.19, -4.21, -4.36; IR (neat film) 2942 (s), 2892 
(s), 2865 (s), 1611 (m), 1464 (m), 1254 (s), 1104 (s), 1067 (s) cm-1; HRMS (ESI) calc'd for 
C25H49O3Si2 (M+H) 453.3220 found 453.3214. 
 
Keto-cyclopropanes 139 and 140 (VI-JTW-073) 
A solution of silyl enol-ethers 135 and 136 (37.2 g, 81.0 mmol, 1.00 equiv) in 2:1 
tetrahydrofuran:1 M NaOH (810 mL, 0.1 M) was stirred vigorously at 20 °C for 3 h. The phases 
were then separated and the aqueous phase extracted with ethyl acetate (3x 250 mL).  The 
combined organic extracts were dried over Na2SO4, filtered, and the solvent was removed to 
yield a yellow oil.  Purification by SiO2 automated column chromatography (25g solid load 
cartridge, 330g column, 0-40% tert-butyl methyl ether in hexanes) gave keto-cyclopropanes 139 
and 140 (28.4 g, 104%) as a yellow oil contaminated with a small amount of tert-
butyldimethylsilanol. 
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Major isomer (139): Rf = 0.30 (4:1 hexanes : tert-butyl methyl ether, CAM stain); 1H NMR (500 
MHz, CDCl3) δ 4.18 (d, 1H, J=9.9 Hz), 3.96 (m, 1H), 3.64 (d, 1H, J=9.8 Hz), 3.35 (s, 3H), 2.79 
(m, 1H), 2.62 (m, 1H), 1.95 (dd, 1H, J=18.4, 4.4 Hz), 1.82 (d, 1H, 18.4 Hz), 1.69 (m, 1H), 1.21 
(ddd, 1H, J=8.5, 6.8, 2.2 Hz), 1.05 (m, 22H); 13C NMR (125 MHz, CDCl3) δ 212.54, 98.76, 
66.02, 56.82, 55.01, 42.55, 38.82, 34.12, 22.31, 18.60, 18.16, 18.13, 18.10, 12.17 
Minor isomer (140): Rf = 0.39 (4:1 hexanes : tert-butyl methyl ether, CAM stain); 1H NMR (500 
MHz, CDCl3) δ 4.06 (d, 1H, J=9.6 Hz), 3.95 (s, 1H), 3.66 (d, 1H, J=9.6 Hz), 3.35 (s, 3H), 2.69 
(m, 1H), 2.65 (s, 1H), 1.90 (dd, 1H, J=18.5, 4.1 Hz), 1.84 (d, 1H, J=18.3 Hz), 1.70 (m, 1H), 1.03 
(m, 22H); 13C NMR (125 MHz, CDCl3) δ 211.76, 98.87, 65.09, 56.67, 56.00, 41.80. 37.09, 
30.01, 22.23, 21.26, 18.12, 18.08, 12.12 
Mixture: IR (neat film) 2942 (s), 2865 (s), 1757 (s), 1463 (m), 1382 (m), 1142 (s) cm-1; HRMS 
(ESI) calc'd for C19H34O3SiNa (M+Na) 361.2175 found 361.2161. 
 
Cyclopropanes 164 and S4 (III-JTW-073, 074) 
To a solution of eneone S3 (884 mg, 6.31 mmol, 2.00 equiv) in CH2Cl2 (32 mL, 0.1 M) at 0 ºC 
were added triethylamine (1.32 mL, 9.47 mmol, 3.00 equiv) and tert-butyldimethylsilyl 
trifluoromethanesulfonate (1.81 mL, 7.89 mmol, 2.50 equiv).  This solution was stirred at this 
temperature for 20 m, at which time it was transferred to neat cyclopropene 112 (716 mg, 3.16 
mmol, 1.00 equiv).  The resulting yellow solution was then stirred at room temperature for 4 h, 
then quenched with H2O (30 mL) and the phases were separated.  The aqueous phase was 
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extracted with CH2Cl2 (2x 30 mL) and the combined organic phases were dried over MgSO4, 
filtered, and concentrated to give a red oil.  Purification by silica gel column chromatography 
(packed with 5% triethylamine in hexanes, eluted with 15-30% CH2Cl2 in hexanes, stepwise 
gradient) yielded desired cyclopropane isomer 164 (640 mg, 42%) as well as a 1:3 mixture of 
desired isomer 164 :  S4 (386 mg, 25%). 
Rf = 0.71 (4 : 1 hexanes : CH2Cl2, triethylamine pretreated plates, CAM stain, major isomer); 1H 
NMR (500 MHz, CDCl3) δ4.67 (dd, 1H, J=4.0, 1.7 Hz), 4.24 (d, 1H, J=10.0 Hz), 3.92~3.81 (m, 
4H), 3.69 (d, 1H, J=10.0 Hz), 2.54 (m, 1H), 2.47 (m, 1H), 1.23 (m, 1H), 1.06 (m, 21H), 0.92 (s, 
9H), 0.77 (dd, 1H, J=7.2, 5.7 Hz), 0.65 (m, 1H), 0.19 (s, 3H), 0.18 (s, 3H); 13C NMR (125 MHz, 
CDCl3) δ 157.78, 131.10, 100.43, 66.05, 64.64, 64.41, 51.86, 47.46, 26.48, 25.81, 18.22, 18.19, 
18.14, 15.14, 12.28, 11.45, -4.11, -4.14; IR (neat film) 2944 (s), 2867 (s), 1618 (s), 1466 (m), 
1324 (s), 1099 (s), 842 (s) cm-1; LRMS (ESI) 481.00 (M+H), 503.06 (M+Na). 
 
Hydroxyketone 164 (III-JTW-042) 
To a solution of silyl ether 164 (81 mg, 0.22 mmol, 1.0 equiv) in tetrahydrofuran (2.2 mL, 0.1 
M) was added a 1.0 M solution of tetrabutylammonium fluoride in tetrahydrofuran (0.44 mL, 
0.44 mmol, 2.0 equiv).  After stirring at room temperature for 1.25 h, the solution was diluted 
with H2O (10 mL) and extracted with ethyl acetate (3x 10 mL).  The combined organic extracts 
were dried over MgSO4, filtered, and the solvent was removed to give a yellow oil.  Purification 
by silica gel column chromatography (5 : 2 ethyl acetate : hexanes) yielded hydroxyketone S5 
(32 mg, 69%) as a clear, colorless oil. 
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Rf = 0.23 (5 : 2 ethyl acetate in hexanes, CAM stain); 1H NMR (500 MHz, CDCl3) δ 4.05 ~ 3.91 
(m, 5H), 3.51 (d, 1H, J=11.5 Hz), 3.01 (s, 1H), 2.64 (m, 1H), 2.54 ~2.48 (m, 2H), 1.79 (d, 1H, 
J=17.8 Hz), 1.60 (m, 1H), 0.94 (dd, 1H, J=7.4, 3.4 Hz), 0.81 (dd, 1H, J=7.7, 7.7 Hz); 13C NMR 
(125 MHz, CDCl3) δ 211.09, 126.43, 67.85, 65.50, 64.74, 55.82, 42.50, 42.41, 29.27, 17.61, 
16.71; IR (neat film) 3424 (br m), 2976 (m), 2892 (m), 1753 (s), 1410 (w), 1294 (m) cm-1; 
LRMS (ESI) 232.95 (M+Na) 
 
Thiocarbonate 165 (III-JTW-043) 
To a solution of hydroxyketone S5 (32 mg, 0.15 mmol, 1.0 equiv) in CH2Cl2 (1.5 mL, 0.1 M) 
were added N,N-dimethylamino pyridine (9.3 mg, 0.076 mmol, 0.5 equiv), pyridine (25 μL, 0.30 
mmol, 2.0 equiv), and phenylchlorothionoformate (41 μL, 0.30 mmol, 1.0 equiv).  The resulting 
bright yellow solution was stirred at room temperature for 16 h.  The reaction was quenched with 
H2O (10 mL) and extracted with CH2Cl2 (3x 10 mL).  The combined organic extracts were dried 
over MgSO4, filtered, and the solvent was removed to give a red oil.  Purification by silica gel 
column chromatography (5 : 2 hexanes : ethyl acetate) afforded thiocarbonate 165 (48 mg, 91%) 
as a brown oil. 
Rf = 0.38 (2 : 1 hexanes : ethyl acetate, CAM stain); 1H NMR (500 MHz, CDCl3) δ 7.42 (m, 2H), 
7.28 (m, 1H), 7.12 (m, 2H), 5.20 (dd, 1H, J=11.5, 1.3 Hz), 4.22 (d, 1H, J=11.5 Hz), 4.07 (m, 
1H), 3.99~3.92 (m, 3H), 2.64 (m, 1H), 2.57~2.51 (m, 2H), 1.83 (d, J=18.1 Hz), 1.70 (m, 1H), 
1.15~1.09 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 210.67, 195.40, 153.49, 129.63, 126.69, 
126.45, 122.02, 80.51, 65.53, 64.83, 54.98, 42.39, 42.26, 26.87, 19.10, 16.80; IR (neat film) 
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2979 (w), 2891 (w), 1756 (s), 1591 (w), 1490 (m), 1295 (s) 1197 (s), 1007 (m) cm-1; LRMS 
(ESI) 368.92 (M+Na), 715.01 (2M+Na) 
 
Olefins 168 and 170 (III-JTW-044) 
To a solution of thiocarbonate 165 (20 mg, 0.058 mmol, 1.0 equiv) in benzene (6 mL, 0.1M) 
were added tributyltin hydride (77 μL, 0.289 mmol, 5.0 equiv) and 2,2′-azobis(iosobutryonitrile) 
(1.0 mg, 0.0058 mmol, 0.10 equiv).  This solution was then heated to 90 ºC for 30 m, cooled to 
room temperature, and concentrated at 30 torr and room temperature.  The product was purified 
by silica gel column chromatography (2 : 1 to 1 : 1 petroleum ether : diethyl ether) to yield olefin 
168 (3.4 mg, 30%) as an oil and olefin 170 (5.3 mg, 47%) as an oil. 
Minor product 168: 
Rf = 0.30 (2 : 1 petroleum ether : diethyl ether, CAM stain); 1H NMR (500 MHz, CDCl3) δ 4.83 
(d, 1H, J=2.0 Hz), 4.82 (d, 1H, J=2.0 Hz), 4.07 – 3.94 (m, 4H), 2.99 (dd, 1H, J=7.0, 2.0 Hz), 
2.70 (dd, 1H, J=18.5, 7.1 Hz), 2.34 (br s, 1H), 2.26 (dd, 1H, J=15.5, 6.4 Hz), 2.18 – 2.10 (m, 
1H), 2.15 (d, 1H, J=18.4 Hz), 1.98 (tdd, 1H, J=12.7, 6.4, 3.0 Hz), 1.85 (m, 1H); 13C NMR (125 
MHz, CDCl3) δ 215.81, 147.50, 113.36, 110.39, 65.42, 64.28, 52.18, 50.28, 44.04, 26.38, 26.24; 
IR (neat film) 3075 (w), 2954 (m), 2891 (m), 1747 (s), 1346 (m), 1317 (m), 1146 (m), 1104 (m), 
1057 (m), 1012 (m), 947 (m), 894 (m) cm-1; LRMS (ESI) 216.95 (M+Na), 411.04 (2M + Na). 
Major product 170: 
Rf = 0.20 (2 : 1 petroleum ether : diethyl ether); 1H NMR (500 MHz, C6D6) δ 4.85 (s, 1H), 4.71 
(s, 1H), 3.41 – 3.20 (m, 4H), 2.67 (dd, 1H, J=18.6, 2.6 Hz), 2.35 (t, 1H, J=2.9 Hz), 2.28 (m, 1H), 
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2.20 (m, 2H), 2.05 (m, 1H), 2.01 (m, 1H), 1.83 (dd, 1H, J=14.7, 3.0 Hz); 13C NMR (125 MHz, 
C6D6) δ 211.01, 143.15, 110.96, 108.80, 64.18, 63.95, 47.39, 45.09, 40.41, 38.72, 30.98; IR (neat 
film) 3074 (w), 2955 (m), 2891 (m), 1730 (s), 1347 (m), 1121 (m), 1087 (m), 1085 (m), 1033 
(m), 1016 (m), 975 (m), 946 (m), 920 (m), 891 (m) cm-1; LRMS (ESI) 216.95 (M+Na), 410.98 
(2M+Na). 
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Methyl eneoates S6 and S7 (VI-JTW-074) 
To a solution of potassium bis(trimethylsilyl)amide (22.6 g, 113 mmol, 1.40 equiv) in 
tetrahydrofuran (350 mL) at 0 ºC was added methyl diethylphosphonoacetate (22.1 mL, 122 
mmol, 1.50 equiv) and the solution was removed from the cold bath and stirred at room 
temperature for 45 m.  A solution of ketones 139 and 140 (27.4 g, 81 mmol, 1.00 equiv) in 
tetrahydrofuran (30 mL) was added via cannula and the mixture was heated to reflux for 19 h.  
The solution was then cooled to room temperature, poured into H2O (400 mL) and extracted with 
ethyl acetate (3x 400 mL).  The combined organic extracts were dried over MgSO4, filtered, and 
the solvent was removed to yield a mixture of E/Z isomers of methyl eneoates S6 and S7 (35.4 g, 
>100%) that was used without purification.  
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 Methyl esters 172 and 173 (VI-JTW-077) 
A suspension of 10% Pd/C (4.31 g, 4.05 mmol, 0.05 equiv) and methyl eneoates S6 and S7 (32.0 
g, 81 mmol, 1.00 mmol) in ethyl acetate (400 mL, 0.2 M) was stirred at room temperature under 
an atmosphere of H2 at balloon pressure for 16 h. The suspension was filtered through a plug of 
celite (6 x 7 cm) and flushed with ethyl acetate (800 mL).  Solvent removal gave methyl esters 
172 and 173 (32.1 g, 100%) as a colorless oil. 
Data for 172: 
Rf = 0.63 (4 : 1 hexanes : ethyl acetate, CAM stain); 1H NMR (500 MHz, CDCl3) δ 4.06 (dd, 1H, 
J=9.8, 1.0 Hz), 3.89 (s, 1H), 3.65 (s, 3H), 3.33 (s, 3H), 3.26 (d, 1H, J=9.8 Hz), 2.61 (dd, 1H, 
J=16.3 Hz, 7.6 Hz), 2.46 (dd, 1H, J=16.2, 6.8 Hz), 2.32 (m, 1H), 2.27 (s, 2H), 1.74 (m, 1H), 1.53 
(m, 1H), 1.35 (s, 1H), 1.18 (s, 1H),  1.05 (m, 22 H), 0.88 (dd, 1H, J=13.3, 6.3 Hz); 13C NMR 
(125 MHz, CDCl3) δ 174.09, 102.12, 68.83, 56.89, 51.55, 45.08, 40.47, 34.79, 33.06, 32.27, 
28.73, 25.39, 25.00, 18.17, 18.15, 17.84, 12.15 
Data for 173: 
Rf = 0.63 (4 : 1 hexanes : ethyl acetate, CAM stain); 1H NMR (500 MHz, CDCl3) δ 4.11 (d, 1H, 
J=9.6 Hz) 3.88 (s, 1H), 3.65 (s, 3H), 3.52 (d, 1H, J=9.6 Hz), 3.31 (s, 3H), 2.60 (dd, 1H, J=15.7, 
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7.9 Hz), 2.44 (dd, 1H, J=16.1, 6.6 Hz), 2.27 (m, 2H), 2.24 (m, 1H), 1.79 (td, 1H, J=13.5, 4.7 Hz), 
1.30-1.19 (m, 3H), 1.10 (m, 22 H), 0.91 (dd, 1H, J=13.3, 6.0 Hz) 
Mixture: 
IR (neat film) 2944 (s), 2865 (s), 1741 (s), 1464 (w), 1169 (w), 1116 (m), 882 (w) 681 (w) cm-1; 
LRMS (ESI) 419.32 (M+Na). 
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Weinreb amides 174 and 175 (VI-JTW-079) 
To a suspension of N,O-dimethylhydroxylamine hydrochloride (23.7 g, 243 mmol, 3.00 equiv) 
in toluene (200 mL) at 0 ºC was added a 2 M solution of AlMe3 in heptane (121 mL, 243 mmol, 
3.00 equiv) very carefully and dropwise over 10 minutes, resulting in vigorous evolution of gas.  
The resulting solution was warmed to room temperature and stirred for 1 h.  This solution was 
then transferred via cannula to a solution of methyl esters 172 and 173 (32.1 g, 81.0 mmol, 1.00 
equiv) in toluene (200 mL) , resulting in a mild exotherm.  The resulting yellow solution was 
stirred at room temperature for 4 h, cooled to 0 ºC and very slowly and carefully quenched with 2 
M HCl (400 mL), resulting in vigorous evolution of gas and heat.  The product was then 
extracted with ethyl acetate (3x 200 mL) and the combined organic extracts were dried over 
MgSO4, filtered, and the solvent was removed to yield a black oil.  This was purified by 
automated silica gel column chromatography (25 g solid load cartridge, 330 g column, 5-10% 
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acetone in hexanes) to give weinreb amide 175 (13.4 g, 39% from tribromocyclopropane 110) as 
a yellow oil along with undesired isomer 174 (6.95 g, 20% from tribromocyclopropane 110). 
Major isomer (X): Rf = 0.21 (4 : 1 hexanes : ethyl acetate, CAM stain); 1H NMR (500 MHz, 
CDCl3) δ 4.11 (d, 1H, J=9.8 Hz), 3.90 (s, 1H), 3.69 (s, 3H), 3.53 (d, 1H, J=9.8 Hz), 3.30 (s, 3H), 
3.26 (s, 3H), 2.71 (dd, 1H, J=16.1, 7.7 Hz), 2.54 (dd, 1H, J=16.1, 6.2 Hz), 2.34 (m, 1H), 2.28 (br 
s, 1H), 2.22 (br d, 1H, J=4.8 Hz), 1.82 (td, 1H, J=13.2, 4.8 Hz), 1.35 (m, 1H), 1.23 (m, 2H), 1.04 
(m, 21 H), 0.91 (dd, 1H, J=13.3, 6.5 Hz); 13C NMR (125 MHz, CDCl3) δ 102.50, 67.21, 61.35, 
56.89, 43.77, 41.64, 36.41, 33.04, 30.10, 24.24, 21.37, 18.17, 18.16, 12.22;  
Minor isomer (X): Rf = 0.30 (4 : 1 hexanes : ethyl acetate, CAM stain); 1H NMR (500 MHz, 
CDCl3) δ 4.07 (dd, 1H, J=9.8, 1.0 Hz), 3.91 (m, 1H), 3.68 (s, 3H), 3.33 (s, 1H), 3.28 (d, 1H, 
J=9.9 Hz), 3.15 (s, 3H), 2.68 (dd, 1H, J=16.5, 7.2 Hz), 2.61 (br dd, 1H, J=16.4, 6.9 Hz), 2.39 (m, 
1H), 2.27 (m, 2H), 1.78 (td, 1H, J=13.2, 4.1 Hz), 1.52 (m, 1H), 1.43 (m, 1H), 1.19 (m, 1H), 1.04 
(m, 21H), 0.90 (dd, 1H, J=13.3, 6.5 Hz); 13C NMR (125 MHz, CDCl3) δ 102.20, 68.88, 61.27, 
56.87, 45.29, 40.56, 32.52, 32.26, 28.91, 25.46, 24.90, 18.17, 18.15, 12.21, 12.15, 11.91; IR (thin 
film) 2945 (s), 2867 (s), 1674 (s), 1110 (s), 884 (m), 682 (m) cm-1; LRMS (ESI) 426.38 (M+H), 
448.37 (M+Na) 
 
Vinyl ketone 177 (VI-JTW-120) 
To a solution of weinreb amide 175 (10.0 g, 23.5 mmol, 1.00 equiv) in tetrahydrofuran (235 mL, 
0.1 M) at 0 ºC was added a 1 M solution of vinylmagnesium bromide in tetrahydrofuran (35.3 
mL, 35.3 mmol, 1.50 equiv).  The solution was stirred at 0 ºC for 25 m when it was quenched 
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with ½ saturated aqueous NH4Cl solution (230 mL) and extracted with ethyl acetate (3x 230 
mL).  The combined organic extracts were dried over MgSO4, filtered, and the solvent was 
removed to yield 177 as an oil that was used directly without further purification. 
Rf = 0.69 (4 : 1 hexanes : acetone, CAM stain); 1H NMR (500 MHz, CDCl3) δ 6.33 (dd, 1H, 
J=17.7, 10.4 Hz), 6.23 (dd, 1H, J=17.7, 1.2 Hz), 5.81 (dd, 1H, J=10.5, 1.2 Hz), 4.10 (d, 1H, 
J=9.8 Hz), 3.90 (d, 1H, J=0.8 Hz), 3.54 (d, 1H, J=9.8 Hz), 3.30 (s, 3H), 2.92 (dd, 1H, J=17.0, 7.8 
Hz), 2.68 (dd, 1H, J=17.0, 6.3 Hz), 2.35 (m, 1H), 2.23 (m, 2H), 1.82 (td, 1H, J=12.1, 4.7 Hz), 
1.25 (m, 2H), 1.04 (m, 21H), 0.87 (dd, 1H, J=13.2, 6.3 Hz); 13C NMR (125 MHz, CDCl3) δ 
200.64, 136.92, 128.10, 102.48, 67.09, 56.92, 43.72, 41.57, 40.80, 36.43, 32.17, 30.30, 24.37, 
21.30, 18.19, 18.16, 12.21; IR (thin film) 3091 (w), 2943 (s), 2865 (s), 1702 (m), 1686 (m), 1616 
(w), 1464 (m), 1386 (m) 1114 (s) cm-1; LRMS (ESI) 415.35 (M+Na) 
 
Diene 178 (VI-JTW-121) 
To a solution of eneone 177 from above (9.20 g, 23.5 mmol, 1.00 equiv) in tetrahydrofuran (115 
mL, 0.2 M) at –78 ºC was added tert-butyldimethylsilyl trifluoromethanesulfonate (8.10 mL, 
35.3 mmol, 1.50 equiv) and stirred at this temperature of 5 m.  This solution was then transferred 
via cannula to a solution of potassium bis(trimethylsilyl)amide (7.03 g, 35.3 mmol, 1.50 equiv) 
in tetrahydrofuran (115 mL, 0.2 M) at –78 ºC over approximately 8 m and stirred at this 
temperature for 15 m.  The reaction was then quenched with ½ saturated NaHCO3 solution (230 
mL), removed from the cold bath and allowed to melt, then extracted with ethyl acetate (1x 230 
mL, 2x 100 mL) and the combined organic extracts were dried over MgSO4, filtered, and the 
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solvent was removed to give an oil that was purified by automated SiO2 column chromatography 
(25g solid load cartridge, 220 g column, 1-8% ethyl acetate in hexanes) to yield diene 178 (9.18 
g, 77% over 2 steps) as a light yellow oil favoring the Z isomer (>25:1 Z:E).   
Rf = 0.35 (4% diethyl ether in hexanes, CAM stain); 1H NMR (500 MHz, CDCl3) δ 6.16 (dd, 1H, 
J=17.2, 10.8 Hz), 5.28 (dd, 1H, J=17.1, 1.5 Hz), 5.15 (d, 1H, J=8.4 Hz), 4.96 (dd, 1H, J=10.8, 
1.4 Hz), 3.32 (s, 3H), 2.82 (m, 1H), 2.28 (m, 1H), 1.85 (dt, 1H, J=12.5, 4.4 Hz), 1.40 (dd, 1H, 
J=5.4, 3.3 Hz), 1.30 (m, 1H), 1.20 (m, 1H), 1.05 (m, 21H), 0.90 (s, 9H), 0.11 (s, 3H), 0.10 (s, 
3H); 13C NMR (125 MHz, CDCl3) δ 149.09, 135.88, 116.95, 112.49, 102.32, 67.45, 56.89, 
44.71, 41.31, 36.18, 33.34, 31.85, 26.15, 24.65, 21.62, 18.59, 18.22, 18.19, 12.26, -3.37, -3.39; 
IR (thin film) 2943 (s), 2864 (s), 1639 (w), 1602 (w), 1464 (m), 1365 (m), 1255 (m), 1116 (s) 
681 (m); HRMS (ESI) calc'd for C29H54O3Si2Na (M+Na) 529.3509 found 529.3508. 
 
Hydroxyamide 180 (VI-JTW-166) 
A mixture of ε-caprolactone (179) (5.0 mL, 45 mmol, 1.0 equiv) and benzylamine (10 mL, 90 
mmol, 2.0 equiv) was heated to 120 ºC for 20 h, cooled to room temperature, then dissolved in 
hot ethyl acetate (100 mL) and hot hexanes (100 mL). The solution was allowed to slowly cool 
to room temperature.  The resulting crystals were collected by filtration to give hydroxyamide 
180 (7.8 g, 78%) as a white crystalline solid. 
Rf = 0.29 (ethyl acetate, KMnO4 stain); 1H NMR (500 MHz, CDCl3) δ 7.28 (m, 5H), 5.74 (br s, 
1H), 4.44 (d, 2H, J=5.7 Hz), 3.64 (m, 2H), 2.23 (m, 2H), 1.69 (m, 2H), 1.59 (m, 2H), 1.41 (m, 
2H); 13C NMR (125 MHz, CDCl3) δ 172.92, 138.49, 128.85, 127.98, 127.66, 62.69, 43.75, 
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36.69, 32.41, 25.51, 25.40; IR (neat film) 3300 (s), 3084 (m), 3032 (m), 2937 (s), 2860 (s), 1636 
(s), 1545 (s), 1427 (s), 1382 (m), 1237 (m), 1060 (m) 728 (s), 629 (s) cm-1; LRMS (ESI) 221.9 
(M+H), 244.2 (M+Na), 465.2 (2M+Na). 
 
Aldehyde 181 (VI-JTW-190) 
To a solution of hydroxyamide 180 (1.37 g, 6.19 mmol, 1.00 equiv) in CH2Cl2 (12.9 mL) and 
dimethylsulfoxide (2.6 mL) was added triethylamine (3.45 mL, 24.8 mmol, 4.00 equiv) followed 
by SO3.pyridine (1.97 g, 12.4 mmol, 2.00 equiv) in 4 portions over 20 m, resulting in an 
exotherm. The solution was stirred at room temperature for 1.5 h, then poured into 10% aqueous 
citric acid solution (20 mL). The phases were separated. The aqueous phase was extracted with 
CH2Cl2 (20 mL). The combined organic phases were washed with 10% aqueous citric acid 
solution (20 mL), sat'd aqueous NaHCO3 solution (20 mL), sat'd aqueous NaCl solution (20 mL), 
dried over Na2SO4, filtered, and concentrated to give aldehyde 181 (1.26g, 93%) as an off-white 
solid. No further purification was performed. 
Rf = 0.54 (ethyl acetate, KMnO4 stain); 1H NMR (500 MHz, CDCl3) δ 9.70 (s, 1H), 7.26 (m, 
5H), 6.42 (br s, 1H), 4.38 (d, 2H, J=5.8 Hz), 2.41 (t, 2H, J=6.7 Hz), 2.20 (m, 2H), 1.63 (m, 4H); 
13C NMR (125 MHz, CDCl3) δ 202.47, 202.29, 172.49, 138.44, 128.78, 128.46, 127.85, 127.53, 
127.22, 43.68, 43.54, 43.52, 43.45, 43.39, 43.24, 36.27, 36.10, 35.92, 25.05, 21.56; IR (neat 
film) 3294 (br s), 3065 (m), 3031 (m), 2934 (m), 2866 (m), 2725 (w), 1721 (s), 1648 (s), 1545 
(s), 1497 (m), 1454 (s), 1390 (m), 1242 (m), 1080 (m), 1029 (m), 736 (s), 700 (s) cm-1; LRMS 
(ESI) 220.2 (M+H), 242.0 (M+Na), 461.3 (2M+Na). 
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 Enamide 182 (VI-JTW-192) 
A solution of aldehyde 181 (1.26 g, 5.75 mmol, 1.00 equiv) and p-toluenesulfonic acid (78 mg, 
0.41 mmol, 0.071 equiv) in toluene (29 mL) was heated to reflux with azeotropic removal of 
water by a Dean-Stark apparatus for 5 h, cooled to room temperature, and concentrated.  The 
residue was combined with a previous reaction on 2.77 mmol and purified by automated silica 
gel column chromatography (15-50% ethyl acetate in hexanes) to give enamide 182 (1.33 g, 
77%) as a clear, colorless oil. 
Rf = 0.40 (2 : 1 hexanes : ethyl acetate, CAM stain); 1H NMR (500 MHz, CDCl3) δ 7.26 (m, 5H), 
5.89 (d, 1H, J=9.0 Hz), 5.33 (m, 1H), 4.64 (s, 2H), 2.60 (m, 2H), 2.15 (m, 2H), 2.05 (m, 2H); 13C 
NMR (125 MHz, CDCl3) δ 174.20, 137.74, 129.77, 128.66, 127.98, 127.44, 117.88, 50.55, 
36.05, 26.63, 26.28; IR (neat film) 3031 (w), 2933 (m), 1657 (s), 1495 (m), 1452 (s), 1432 (s), 
1391 (s), 1364 (m), 1324 (m), 1285 (m), 1244 (m), 1198 (m), 970 (m), 739 (s), 701 (s) cm-1; 
LRMS (ESI) 224.0 (M+Na). 
 
Methyl enoate 185 (SY-VI-233 and SY-VI-234) – Yuan Shi 
To a solution of enamide 182 (1.19 g, 5.91 mmol, 1.00 equiv) in tetrahydrofuran (50 mL, 0.12 
M) at –78 °C was added a solution of lithium bis(trimethylsilyl)amide (2.49 g, 14.9 mmol, 2.50 
equiv) in tetrahydrofuran (15 mL). The resulting solution was removed from the cold bath for 10 
m, colled back to –78 °C at which time methylchloroformate (470 μL, 6.11 mmol, 1.00 equiv) 
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was added. The solution was again removed from the cooling bath for 15 m, then cooled to –78 
°C and phenylselenyl chloride (1.20 g, 6.27 mmol, 1.10 equiv) was added and the resulting 
solution removed from the cooling bath for 30 m, then quenched with ½ saturated aqueous 
NaHCO3 solution (40 mL), extracted with ethyl acetate (20 mL), and CH2Cl2 (2x 20 mL). The 
combined organic extracts were dried over MgSO4, filtered, and concentrated to give 184 as an 
oil that was used directly in the next reaction. 
To a solution of the above oil in CH2Cl2 at 0 °C was added a 30 wt% aqueous solution of H2O2 
(1.2 mL, 12 mmol, 2.0 equiv). The resulting mixture was stirred at 0 °C for 15 m, quenched with 
½ saturated aqueous NaHCO3 solution (20 mL) and extracted with CH2Cl2 (3x 10 mL). The 
combined organic extracts were dried over MgSO4, filtered, and concentrated. The crude product 
was purified by automated silica gel column chromatography (40 g column, 0 – 50% ethyl 
acetate in hexanes) to give methyl enoate 185 (822 mg, 54% over 2 steps). 
Rf = 0.18 (1 : 2 EtOAc : Hexane, KMnO4 stain); 1H NMR (600 MHz, CDCl3) δ 7.34-7.31 (m, 
5H), 7.27 (dd, 1H, J=8.5, 4.1 Hz), 6.05 (d, 1H, J=7.5 Hz), 5.51 (dd, 1H, J=14.1, 6.9 Hz), 4.88 (s, 
2H), 3.80 (s, 3H), 2.65 (t, 2H, J=7.1 Hz); 13C NMR (125 MHz, CDCl3) δ 165.54, 165.44, 148.80, 
137.26, 131.20, 130.47, 128.79, 127.76, 117.71, 52.54, 51.14, 24.38; IR (neat film) 2951 (w), 
1724 (s), 1687 (s), 1653 (m), 1437 (m), 1412 (m), 1263 (s), 1159 (w), 738 (m) cm-1; HRMS 
(ESI) calc'd for C15H15NO3Na (M+Na) 280.0950 found 280.0962. 
 
Dienophile X (SY-VI-041) – Yuan Shi 
To a mixture of CrO3 (12 g, 120 mmol, 9.68 equiv) in CH2Cl2 (100 mL) at – 20 oC (cooling bath 
of EtOH/H2O=3/7 and dry ice) was added 3,5-dimethylpyrazole (12.5 g, 130 mmol, 10.5 equiv) 
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in one portion.  The dark brown mixture was stirred at – 20 oC for 1 h before a solution of 185 
(3.20 g, 12.4 mmol, 1.00 equiv) in CH2Cl2 (20 mL) was added via cannula transfer, with a 
CH2Cl2 rinse (20 mL).  The resulting mixture was stirred at ambient temperature for 3.5 hours 
then filtered through a short silica gel plug (flushed with CH2Cl2).  The resulting solution was 
concentrated, and purified directly by automated SiO2 column chromatography (25 g solid load 
cartridge, 40 g column, 0-50% ethyl acetate in hexane) to yield diene 186 (2.45 g, 73%) as a pale 
yellow oil. 
Rf = 0.53 (1 : 20 ethyl acetate : CH2Cl2, KMnO4 stain);  1H NMR (500 MHz, CDCl3) δ 7.42 (d, 
2H, J=7.2 Hz), 7.31-7.25 (m, 3H), 7.22 (dd, 1H, J=3.5, 0.9 Hz), 6.66 (dd, 1H, J=11.9, 7.0 Hz), 
6.60 (dd, 1H, J=12.0, 0.9 Hz); 13C NMR (125 MHz, CDCl3) δ 165.54, 164.94, 164.55, 136.66, 
135.23, 134.25, 133.88, 130.68, 129.00, 128.53, 127.81, 53.23, 49.51; IR (neat film) 2902 (m), 
2255 (m), 1738 (m), 913 (s), 745 (s) cm-1; HRMS (ESI) calc'd for C15H13NO4Na (M+Na) 
294.0742 found 294.0747. 
 
Enimides S8 and S9 (SY-V-196) – Yuan Shi 
To a solution of 178 (2.54 g, 5.01 mmol, 1.00 equiv) and 186 (1.49 g, 5.49 mmol, 1.10 equiv) in 
toluene (50 mL) was added Yb(OTf)3 (217 mg, 0.350 mmol, 0.0699 equiv) in tetrahydrofuran 
(0.35 mL).  The resulting golden solution was stirred at ambient temperature for 4 h then 
quenched with saturated aqueous NaHCO3 solution (50 mL) and extracted with Et2O (3x 25 
mL).  The combined organic extracts were dried over MgSO4, concentrated, and purified by 
automated SiO2 column chromatography (25 g solid load cartridge, 120 g column, 0-10% ethyl 
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acetate in hexanes) to yield a 1.2 : 1 mixture of S8 and S9 (3.33 g, 85%, 95% brsm) as a white 
foam. Recovered diene 178 (264 mg, 10%) was also isolated.   
 
Imides 187 and 188 (SY-V-199) 
To a solution of the mixture of S8 and S9 (3.33 g, 4.28 mmol, 1.00 equiv) in ethyl acetate (80 
mL) was added 10% Pd/C (226 mg, 0.212 mmol, 0.0495 equiv).  The mixture was sparged three 
times with H2, and then stirred under balloon pressure H2 for 12 h then filtered through a short 
silica gel plug, and flushed with ethyl acetate.  The solution was concentrated and purified by 
automated SiO2 column chromatography (25 g solid load cartridge, 220 g column, 0-4% ethyl 
acetate in toluene) to yield 188 (731 mg, 22%) as a white foam and 187 (900 mg, 27%) as a 
white foam as well as a mixture of the two diastereomers (1.62 g 49%). The total yield from 178 
is 83%, so complete separation would give 38% of 188 and 45% of 187. 
Minor isomer (188) Rf = 0.36 (1 : 30 ethyl acetate : toluene, KMnO4 stain); 1H NMR (600 MHz, 
CDCl3) δ 7.35 (d, 2H, J=7.3 Hz), 7.30 (t, 3H, J=7.5 Hz), 7.25 (t, 1H, J=7.2 Hz), 4.90 (d, 1H, 
J=14.4 Hz), 4.86 (d, 1H, J=14.3 Hz), 4.74-4.73 (m, 1H), 4.13 (d, 1H, J=9.9 Hz), 3.82 (s, 1H), 
3.47 (d, 1H, J=9.9 Hz), 3.33 (s, 3H), 3.28 (s, 3H), 2.98 (dd, 1H, J=17.3, 3.7 Hz), 2.75-2.72 (m, 
2H), 2.87-2.82 (m, 2H), 2.41 (d, 1H, J=10.0 Hz), 2.34 (d, 1H, J=17.4 Hz), 1.93-1.86 (m, 2H), 
1.84-1.77 (m, 1H), 1.66 (dt, 1H, J=12.4, 4.4 Hz), 1.15-1.13 (m, 1H), 1.09-1.05 (m, 24H), 0.92 (s, 
9H), 0.19 (s, 3H), 0.16 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 178.56, 173.46, 170.19, 151.26, 
137.07, 129.08, 128.41, 127.54, 102.05, 99.71, 67.51, 60.63, 57.03, 52.83, 48.79, 45.26, 40.90, 
38.27, 38.58, 35.85, 35.74, 27.44, 26.39, 26.16, 23.60, 21.15, 20.75, 18.56, 18.21, 18.19, 12.21, -
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3.58, -4.03; IR (neat film) 2944 (s), 2863 (s), 1757 (m), 1718 (m), 1669 (s), 1207 (m), 1113 (m), 
880 (m), 838 (m) cm-1; HRMS (ESI) calc'd for C44H69NO7NaSi2 (M+Na) 802.4510 found 
802.4517. 
 
Enamide 189 (IV-JTW-208 and IV-JTW-210) 
To a solution of imide 188 (177 mg, 0.227 mmol, 1.00 equiv) and Comins' reagent (107 mg, 
0.272 mmol, 1.20 equiv) in tetrahydrofuran (2.3 mL, 0.1 M) at –78 ºC was added a 0.5 M 
solution of potassium hexamethyldisilazide in toluene (681 μL, 0.341 mmol, 1.50 equiv). This 
solution was stirred at –78 ºC for 25 m, quenched with 1 N aqueous NaOH solution (1.5 mL) and 
allowed to melt.  This mixture was diluted with ½ saturated aqueous NaCl solution (10 mL) and 
extracted with ethyl acetate (3x 10 mL). The combined organic extracts were dried over MgSO4, 
filtered, and concentrated to give an orange oil that was immediately dissolved in tetrahydrofuran 
(2.3 mL, 0.1 M). To this solution were added tributyltin hydride (90 μL, 0.34 mmol, 1.5 equiv) 
followed by Pd(PPh3)4 (13 mg, 0.011 mmol, 0.050 equiv). This solution was stirred at room 
temperature for 20 m, diluted with ½ saturated aqueous NaCl solution (10 mL), and extracted 
with ethyl acetate (3x 10 mL). The combined organic extracts were dried over MgSO4, filtered, 
and concentrated to give a brown oil. Purification by silica gel column chromatography (9 : 1 
hexanes : ethyl acetate) provided enamide 189 (113 mg, 65%) as a hard white foam. 
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Rf = 0.18 (9 : 1 hexanes : ethyl acetate, CAM stain); 1H NMR (500 MHz, CDCl3)‡ δ 7.26 (m, 
5H), 5.73 (dd, 1H, J=8.2, 1.4 Hz), 4.76 (d, 1H, J=14.3 Hz), 4.63 (s, 1H), 4.57 (d, 1H, J=14.6 
Hz), 3.94 (br d, 1H, J=8.7 Hz), 3.81 (s, 1H), 3.64 (br s, 3H), 3.30 (s, 3H), 2.23 (s, 1H), 2.10 (td, 
1H, J=14.3, 4.2 Hz), 2.03 (br s, 1H), 1.87 (br s, 1H), 1.54 (m, 2H), 1.20 (v br s, 1H), 1.17 (br s, 
1H), 1.03 (m, 21H), 0.93 (s, 9H), 0.18 (s, 3H), 0.14 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 
137.26, 128.60, 127.59, 56.76, 52.67, 35.63, 31.91, 26.10, 18.32, 18.19, 18.13, 18.06, 12.13; IR 
(neat film) 2944 (s), 2892 (m), 2863 (s), 1758 (m), 1738 (m), 1648 (s), 1462 (m), 1389 (m), 1254 
(s), 1210 (s), 1115 (s), 881 (m), 863 (m), 836 (s), 680 (m) cm-1; LRMS (ESI) 764.66 (M+H), 
786.71 (M+Na). 
 
 
Ketone 190 (VI-JTW-003) 
To a solution of enol-ether 189 (214 mg, 0.280 mmol, 1.00 equiv) in tetrahydrofuran (2.8 mL, 
0.1 M) at 0 ºC was added a 1 M solution of tetrabutylammonium fluoride in tetrahydrofuran (294 
μL, 0.294 mmol, 1.05 equiv).  After 30 m at this temperature, the yellow solution was poured 
into ½ saturated aqueous NaCl solution (10 mL) and extracted with ethyl acetate (3x 10 mL).  
The combined organic extracts were dried over Na2SO4, filtered, and concentrated to give an oil.  
Purification by automated silica gel column chromatography (5 g solid load cartridge, 12 g 
                                                 
‡ The 1H NMR and 13C NMR have very broad peaks.  The 13C NMR is missing many of the peaks due to excessive 
broadening. This effect could be due to hindered rotation about the N-benzyl bond. 
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column, 10-40% ethyl acetate in hexanes) afforded ketone 190 (126 mg, 69%) as a hard, white 
foam.   
Rf = 0.47 (2 : 1 hexanes : ethyl acetate, CAM stain); 1H NMR (500 MHz, CDCl3) δ 7.27 (m, 5H), 
5.82 (d, 1H, J=8.3 Hz), 5.40 (br m, 1H), 4.70 (br d, 1H, J=14.5 Hz), 4.60 (br d, 1H, J=14.5 Hz), 
4.09 (d, 1H, J=9.8 Hz), 3.86 (s, 1H), 3.74 (s, 3H), 3.55 (m, 1H), 3.48 (d, 1H, J=9.9 Hz), 3.30 (s, 
3H), 2.79 (br s, 1H), 2.65 (br s, 1H), 2.62 (m, 1H), 2.53 (m, 1H), 2.21 (m, 3H), 1.90 (m, 2H), 
1.51 (m, 1H), 1.19 (m, 3H), 1.04 (m, 21 H); 13C NMR (125 MHz, CDCl3) δ 211.23, 172.79, 
171.36, 136.91, 129.05, 128.72, 128.31, 127.79, 101.94, 67.30, 56.94, 53.11, 52.30, 43.31, 41.20, 
36.39, 34.02, 29.37, 26.14, 24.50, 21.49, 18.20, 18.17, 12.20; IR (neat film) 2943 (s), 2865 (s), 
1736 (s), 1717 (s), 1649 (s), 1462 (m), 1390 (m), 1263 (s), 1100 (s), 1066 (m), 883 (s), 734 (s), 
682 (m) cm-1; HRMS (ESI) calc'd for C38H55NO6SiNa (M+Na) 672.3696 found 672.3672 
 
Alcohol 191 (V-JTW-015) 
To a solution of ketone 190 (65.0 mg, 0.100 mmol, 1.00 equiv) in methanol§ (1.0 mL, 0.1 M) at 
0 ºC was added NaBH4 (18.4 mg, 0.487 mmol, 4.87 equiv).  The solution was stirred at 0 ºC for 
15 m, diluted with ½ saturated aqueous NH4Cl solution (10 mL), and extracted with CH2Cl2 (3x 
10 mL).  The combined organic extracts were dried over MgSO4, filtered, and concentrated to 
give alcohol 191 (62.9 mg, 96%) as a hard white foam.  This product required no further 
purification, though an X-ray quality crystal was grown from hexanes : ethyl acetate. 
                                                 
§ The methanol used for this reaction was undistilled. 
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Rf = 0.40 (4 : 1 CH2Cl2 : ethyl acetate, CAM stain); 1H NMR (500 MHz, CDCl3) δ 7.27 (m, 5H), 
5.89 (d, 1H, J=7.8 Hz), 5.62 (q, 1H, J=7.5 Hz), 4.74 (d, 1H, J=14.6 Hz), 4.51 (d, 1H, J=14.6 Hz), 
4.09 (d, 1H, J=9.8 Hz), 3.87 (s, 1H), 3.85 (s, 1H), 3.78 (s, 3H), 3.53 (d, 1H, J=9.8 Hz), 3.46 (q, 
1H, J=6.6 Hz), 3.31 (s, 3H), 2.68 (m, 1H), 2.37 (s, 1H), 2.24 (d, 1H, J=4.3 Hz), 2.20~2.00 (m, 
4H), 1.92 (m, 1H), 1.77 (dd, 1H, J=11.7, 5.6 Hz), 1.66 (m, 1H), 1.56 (td, 1H, J=13.0, 4.65 Hz), 
1.28 (m, 1H), 1.25 (s, 1H), 1.19 (m, 1H), 1.15 (m, 1H), 23.89 (m, 21H); 13C NMR (125 MHz, 
CDCl3) δ 173.95, 172.69, 137.30, 129.98, 128.67, 128.11, 127.59, 121.14, 102.36, 67.01, 56.91, 
52.83, 51.79, 41.89, 41.03, 39.51, 36.57, 36.34, 31.13, 29.84, 24.83, 23.97, 21.25, 18.21, 18.18, 
12.21; IR (neat film) 3502 (br m), 2943 (s), 2865 (s), 1737 (s), 1624 (s), 1458 (m), 1389 (m), 
1215 (s), 1112 (s), 1017 (s), 883 (m), 735 (m), 687 (m); HRMS (ESI) calc'd for C38H57NO6SiNa 
(M+Na) 674.3853 found 674.3848;  
 
Crystal Data and Structure Refinement for 191: 
 
data_x1666l 
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_audit_creation_method            SHELXL-97 
_chemical_name_systematic 
; 
 ? 
; 
_chemical_name_common             ? 
_chemical_melting_point           ? 
_chemical_formula_moiety          ? 
_chemical_formula_sum 
 'C38 H57 N O6 Si' 
_chemical_formula_weight          651.94 
  
loop_ 
 _atom_type_symbol 
 _atom_type_description 
 _atom_type_scat_dispersion_real 
 _atom_type_scat_dispersion_imag 
 _atom_type_scat_source 
 'C'  'C'   0.0033   0.0016 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'H'  'H'   0.0000   0.0000 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'N'  'N'   0.0061   0.0033 
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 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'O'  'O'   0.0106   0.0060 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'Si'  'Si'   0.0817   0.0704 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
  
_symmetry_cell_setting            Monoclinic 
_symmetry_space_group_name_H-M    C2/c 
  
loop_ 
 _symmetry_equiv_pos_as_xyz 
 'x, y, z' 
 '-x, y, -z+1/2' 
 'x+1/2, y+1/2, z' 
 '-x+1/2, y+1/2, -z+1/2' 
 '-x, -y, -z' 
 'x, -y, z-1/2' 
 '-x+1/2, -y+1/2, -z' 
 'x+1/2, -y+1/2, z-1/2' 
  
_cell_length_a                    42.060(8) 
_cell_length_b                    11.926(2) 
_cell_length_c                    15.447(3) 
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_cell_angle_alpha                 90.00 
_cell_angle_beta                  104.51(3) 
_cell_angle_gamma                 90.00 
_cell_volume                      7501(3) 
_cell_formula_units_Z             8 
_cell_measurement_temperature     100(2) 
_cell_measurement_reflns_used     10928 
_cell_measurement_theta_min       2.95 
_cell_measurement_theta_max       30.08 
  
_exptl_crystal_description        ? 
_exptl_crystal_colour             ? 
_exptl_crystal_size_max           0.32 
_exptl_crystal_size_mid           0.32 
_exptl_crystal_size_min           0.10 
_exptl_crystal_density_meas       ? 
_exptl_crystal_density_diffrn     1.155 
_exptl_crystal_density_method     'not measured' 
_exptl_crystal_F_000              2832 
_exptl_absorpt_coefficient_mu     0.106 
_exptl_absorpt_correction_type    integration 
_exptl_absorpt_correction_T_min   0.9668 
_exptl_absorpt_correction_T_max   0.9894 
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_exptl_absorpt_process_details    numerical 
  
_exptl_special_details 
; 
 ? 
; 
  
_diffrn_ambient_temperature       100(2) 
_diffrn_radiation_wavelength      0.71073 
_diffrn_radiation_type            MoK\a 
_diffrn_radiation_source          'fine-focus sealed tube' 
_diffrn_radiation_monochromator   graphite 
_diffrn_measurement_device_type   'Bruker-Nonius KappaaCCD' 
_diffrn_measurement_method        '\w scans' 
_diffrn_detector_area_resol_mean  ? 
_diffrn_standards_number          ? 
_diffrn_standards_interval_count  ? 
_diffrn_standards_interval_time   ? 
_diffrn_standards_decay_%         ? 
_diffrn_reflns_number             40381 
_diffrn_reflns_av_R_equivalents   0.0822 
_diffrn_reflns_av_sigmaI/netI     0.0650 
_diffrn_reflns_limit_h_min        -59 
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_diffrn_reflns_limit_h_max        59 
_diffrn_reflns_limit_k_min        -16 
_diffrn_reflns_limit_k_max        16 
_diffrn_reflns_limit_l_min        -21 
_diffrn_reflns_limit_l_max        21 
_diffrn_reflns_theta_min          2.95 
_diffrn_reflns_theta_max          30.08 
_reflns_number_total              10928 
_reflns_number_gt                 7383 
_reflns_threshold_expression      >2sigma(I) 
  
_computing_data_collection        'Bruker XSCANS' 
_computing_cell_refinement        'Bruker XSCANS' 
_computing_data_reduction         'Bruker SHELXTL' 
_computing_structure_solution     'SHELXS-97 (Sheldrick, 1990)' 
_computing_structure_refinement   'SHELXL-97 (Sheldrick, 1997)' 
_computing_molecular_graphics     'Bruker SHELXTL' 
_computing_publication_material   'Bruker SHELXTL' 
  
_refine_special_details 
; 
 Refinement of F^2^ against ALL reflections.  The weighted R-factor wR and 
 goodness of fit S are based on F^2^, conventional R-factors R are based 
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 on F, with F set to zero for negative F^2^. The threshold expression of 
 F^2^ > 2sigma(F^2^) is used only for calculating R-factors(gt) etc. and is 
 not relevant to the choice of reflections for refinement.  R-factors based 
 on F^2^ are statistically about twice as large as those based on F, and R- 
 factors based on ALL data will be even larger. 
; 
  
_refine_ls_structure_factor_coef  Fsqd 
_refine_ls_matrix_type            full 
_refine_ls_weighting_scheme       calc 
_refine_ls_weighting_details 
 'calc w=1/[\s^2^(Fo^2^)+(0.1134P)^2^+8.8305P] where P=(Fo^2^+2Fc^2^)/3' 
_atom_sites_solution_primary      direct 
_atom_sites_solution_secondary    difmap 
_atom_sites_solution_hydrogens    geom 
_refine_ls_hydrogen_treatment     constr 
_refine_ls_extinction_method      none 
_refine_ls_extinction_coef        ? 
_refine_ls_number_reflns          10928 
_refine_ls_number_parameters      468 
_refine_ls_number_restraints      6 
_refine_ls_R_factor_all           0.1187 
_refine_ls_R_factor_gt            0.0783 
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_refine_ls_wR_factor_ref          0.2307 
_refine_ls_wR_factor_gt           0.2035 
_refine_ls_goodness_of_fit_ref    1.055 
_refine_ls_restrained_S_all       1.055 
_refine_ls_shift/su_max           0.000 
_refine_ls_shift/su_mean          0.000 
  
loop_ 
 _atom_site_label 
 _atom_site_type_symbol 
 _atom_site_fract_x 
 _atom_site_fract_y 
 _atom_site_fract_z 
 _atom_site_U_iso_or_equiv 
 _atom_site_adp_type 
 _atom_site_occupancy 
 _atom_site_symmetry_multiplicity 
 _atom_site_calc_flag 
 _atom_site_refinement_flags 
 _atom_site_disorder_assembly 
 _atom_site_disorder_group 
Si Si 0.281455(14) 0.52851(5) 0.16517(4) 0.02843(16) Uani 1 1 d . . . 
O1 O 0.29486(4) 0.42446(14) 0.11362(12) 0.0340(4) Uani 1 1 d . . . 
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O6 O 0.32871(4) 0.21732(15) 0.31208(12) 0.0370(4) Uani 1 1 d . . . 
O11 O 0.45782(4) 0.0799(2) 0.25328(12) 0.0508(6) Uani 1 1 d . . . 
H11A H 0.4493 0.0846 0.2968 0.076 Uiso 1 1 calc R . . 
O20 O 0.43336(4) -0.11309(15) -0.09853(11) 0.0369(4) Uani 1 1 d . . . 
O21 O 0.44328(5) 0.14259(17) -0.09665(14) 0.0516(5) Uani 1 1 d . . . 
O22 O 0.39282(4) 0.10030(16) -0.08283(12) 0.0398(4) Uani 1 1 d . . . 
N19 N 0.46382(5) -0.17568(18) 0.03396(15) 0.0374(5) Uani 1 1 d . B . 
C1 C 0.29048(5) 0.3074(2) 0.12582(18) 0.0352(5) Uani 1 1 d . . . 
H1A H 0.2728 0.2784 0.0759 0.042 Uiso 1 1 calc R . . 
H1B H 0.2838 0.2951 0.1822 0.042 Uiso 1 1 calc R . . 
C2 C 0.32203(5) 0.2445(2) 0.12922(16) 0.0304(5) Uani 1 1 d . . . 
C3 C 0.34338(5) 0.2778(2) 0.06857(16) 0.0316(5) Uani 1 1 d . . . 
H3A H 0.3372 0.3458 0.0314 0.038 Uiso 1 1 calc R . . 
H3B H 0.3533 0.2171 0.0402 0.038 Uiso 1 1 calc R . . 
C4 C 0.35587(5) 0.29346(19) 0.16940(15) 0.0281(4) Uani 1 1 d . . . 
H4A H 0.3570 0.3717 0.1932 0.034 Uiso 1 1 calc R . . 
C5 C 0.37416(5) 0.20168(19) 0.23232(15) 0.0276(4) Uani 1 1 d . . . 
H5A H 0.3923 0.2306 0.2821 0.033 Uiso 1 1 calc R . . 
C6 C 0.34544(5) 0.1474(2) 0.26401(16) 0.0316(5) Uani 1 1 d . . . 
H6A H 0.3525 0.0756 0.2967 0.038 Uiso 1 1 calc R . . 
C7 C 0.32482(5) 0.1252(2) 0.16885(17) 0.0317(5) Uani 1 1 d . . . 
H7A H 0.3032 0.0886 0.1661 0.038 Uiso 1 1 calc R . . 
C8 C 0.34896(5) 0.0511(2) 0.13343(17) 0.0304(5) Uani 1 1 d . . . 
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H8A H 0.3454 0.0595 0.0679 0.036 Uiso 1 1 calc R . . 
H8B H 0.3466 -0.0289 0.1477 0.036 Uiso 1 1 calc R . . 
C9 C 0.38361(5) 0.09754(19) 0.18457(15) 0.0279(4) Uani 1 1 d . . . 
H9A H 0.3931 0.0418 0.2324 0.033 Uiso 1 1 calc R . . 
C10 C 0.40887(5) 0.11177(19) 0.12884(15) 0.0272(4) Uani 1 1 d . . . 
H10A H 0.3999 0.1698 0.0824 0.033 Uiso 1 1 calc R . . 
C11 C 0.44187(6) 0.1565(2) 0.18485(17) 0.0388(6) Uani 1 1 d . . . 
H11B H 0.4380 0.2288 0.2133 0.047 Uiso 1 1 calc R . . 
C12 C 0.46490(6) 0.1777(2) 0.12444(19) 0.0413(6) Uani 1 1 d . . . 
H12A H 0.4551 0.2346 0.0790 0.050 Uiso 1 1 calc R . . 
H12B H 0.4860 0.2075 0.1606 0.050 Uiso 1 1 calc R . . 
C13 C 0.47117(5) 0.0703(2) 0.07780(17) 0.0358(5) Uani 1 1 d . . . 
H13A H 0.4829 0.0159 0.1231 0.043 Uiso 1 1 calc R . . 
H13B H 0.4854 0.0873 0.0373 0.043 Uiso 1 1 calc R . . 
C14 C 0.43882(5) 0.01676(19) 0.02324(14) 0.0273(4) Uani 1 1 d . . . 
C15 C 0.41253(5) 0.00230(19) 0.07823(14) 0.0256(4) Uani 1 1 d . . . 
H15A H 0.3912 -0.0065 0.0325 0.031 Uiso 1 1 calc R . . 
C16 C 0.41736(6) -0.1089(2) 0.13133(17) 0.0365(5) Uani 1 1 d . . . 
H16A H 0.4051 -0.1033 0.1781 0.044 Uiso 1 1 calc R . . 
H16B H 0.4070 -0.1695 0.0900 0.044 Uiso 1 1 calc R . . 
C17 C 0.45159(7) -0.1443(3) 0.17549(18) 0.0479(7) Uani 1 1 d . . . 
H17A H 0.4588 -0.1435 0.2389 0.058 Uiso 1 1 calc R . . 
C18 C 0.47213(7) -0.1767(3) 0.12827(19) 0.0480(7) Uani 1 1 d . . . 
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H18A H 0.4934 -0.2018 0.1591 0.058 Uiso 1 1 calc R . . 
C20 C 0.44493(5) -0.09689(19) -0.01830(15) 0.0295(4) Uani 1 1 d . . . 
C21 C 0.42588(6) 0.0928(2) -0.05865(16) 0.0331(5) Uani 1 1 d . . . 
C22 C 0.37910(9) 0.1739(3) -0.1566(2) 0.0599(9) Uani 1 1 d . . . 
H22A H 0.3907 0.2459 -0.1473 0.090 Uiso 1 1 calc R . . 
H22B H 0.3557 0.1859 -0.1604 0.090 Uiso 1 1 calc R . . 
H22C H 0.3816 0.1399 -0.2123 0.090 Uiso 1 1 calc R . . 
C23 C 0.34544(8) 0.2264(3) 0.40311(19) 0.0487(7) Uani 1 1 d . . . 
H23A H 0.3498 0.1512 0.4290 0.073 Uiso 1 1 calc R . . 
H23B H 0.3319 0.2682 0.4351 0.073 Uiso 1 1 calc R . . 
H23C H 0.3663 0.2660 0.4085 0.073 Uiso 1 1 calc R . . 
C30 C 0.47356(7) -0.2756(2) -0.0087(2) 0.0484(7) Uani 1 1 d . . . 
H30A H 0.4978 -0.2823 0.0051 0.073 Uiso 0.50 1 calc PR A 1 
H30B H 0.4648 -0.2726 -0.0744 0.073 Uiso 0.50 1 calc PR A 1 
H30C H 0.4944 -0.3045 0.0301 0.073 Uiso 0.50 1 d PR A 2 
H30D H 0.4782 -0.2521 -0.0659 0.073 Uiso 0.50 1 d PR A 2 
C31 C 0.45816(14) -0.3762(5) 0.0325(5) 0.0479(13) Uani 0.50 1 d PD B 1 
C32 C 0.47327(18) -0.4411(6) 0.1067(5) 0.074(2) Uani 0.50 1 d PD B 1 
H32A H 0.4955 -0.4257 0.1361 0.088 Uiso 0.50 1 calc PR B 1 
C33 C 0.4573(2) -0.5272(7) 0.1394(6) 0.088(3) Uani 0.50 1 d PD B 1 
H33A H 0.4684 -0.5699 0.1898 0.105 Uiso 0.50 1 calc PR B 1 
C34 C 0.42444(18) -0.5496(7) 0.0962(6) 0.069(2) Uani 0.50 1 d PD B 1 
H34A H 0.4127 -0.6069 0.1177 0.083 Uiso 0.50 1 calc PR B 1 
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C35 C 0.4073(4) -0.4794(10) 0.0123(8) 0.085(4) Uiso 0.50 1 d PD B 1 
H35A H 0.3854 -0.4935 -0.0208 0.101 Uiso 0.50 1 calc PR B 1 
C36 C 0.4255(2) -0.3985(10) -0.0096(6) 0.058(3) Uani 0.50 1 d PD B 1 
H36A H 0.4153 -0.3516 -0.0584 0.070 Uiso 0.50 1 calc PR B 1 
C31B C 0.44825(11) -0.3722(4) -0.0300(4) 0.0344(10) Uani 0.50 1 d PD B 2 
C32B C 0.44417(19) -0.4359(7) -0.1029(6) 0.110(4) Uani 0.50 1 d PD B 2 
H32B H 0.4553 -0.4152 -0.1468 0.132 Uiso 0.50 1 calc PR B 2 
C33B C 0.4239(2) -0.5338(8) -0.1186(8) 0.133(5) Uani 0.50 1 d PD B 2 
H33B H 0.4212 -0.5778 -0.1712 0.160 Uiso 0.50 1 calc PR B 2 
C34B C 0.40832(17) -0.5602(6) -0.0508(7) 0.082(3) Uani 0.50 1 d PD B 2 
H34B H 0.3950 -0.6256 -0.0582 0.099 Uiso 0.50 1 calc PR B 2 
C35B C 0.4111(2) -0.4973(7) 0.0265(5) 0.0453(19) Uiso 0.50 1 d PD B 2 
H35B H 0.4002 -0.5156 0.0716 0.054 Uiso 0.50 1 calc PR B 2 
C36B C 0.4317(2) -0.4038(9) 0.0306(7) 0.067(3) Uani 0.50 1 d PD B 2 
H36B H 0.4344 -0.3573 0.0819 0.081 Uiso 0.50 1 calc PR B 2 
C40 C 0.30279(6) 0.6541(2) 0.13188(17) 0.0344(5) Uani 1 1 d . . . 
H40A H 0.2927 0.6659 0.0667 0.041 Uiso 1 1 calc R . . 
C41 C 0.33967(6) 0.6401(3) 0.1412(2) 0.0434(6) Uani 1 1 d . . . 
H41A H 0.3482 0.7065 0.1172 0.065 Uiso 1 1 calc R . . 
H41B H 0.3435 0.5735 0.1080 0.065 Uiso 1 1 calc R . . 
H41C H 0.3510 0.6312 0.2045 0.065 Uiso 1 1 calc R . . 
C42 C 0.29563(7) 0.7611(2) 0.17896(19) 0.0408(6) Uani 1 1 d . . . 
H42A H 0.3048 0.7537 0.2436 0.061 Uiso 1 1 calc R . . 
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H42B H 0.2718 0.7722 0.1667 0.061 Uiso 1 1 calc R . . 
H42C H 0.3056 0.8256 0.1567 0.061 Uiso 1 1 calc R . . 
C50 C 0.23579(5) 0.5477(2) 0.12129(17) 0.0329(5) Uani 1 1 d . . . 
H50A H 0.2292 0.6122 0.1543 0.039 Uiso 1 1 calc R . . 
C51 C 0.22632(6) 0.5778(3) 0.02117(19) 0.0465(7) Uani 1 1 d . . . 
H51A H 0.2330 0.5170 -0.0131 0.070 Uiso 1 1 calc R . . 
H51B H 0.2375 0.6473 0.0118 0.070 Uiso 1 1 calc R . . 
H51C H 0.2025 0.5884 0.0012 0.070 Uiso 1 1 calc R . . 
C52 C 0.21618(6) 0.4458(3) 0.1377(2) 0.0522(8) Uani 1 1 d . . . 
H52A H 0.1926 0.4614 0.1159 0.078 Uiso 1 1 calc R . . 
H52B H 0.2213 0.4296 0.2019 0.078 Uiso 1 1 calc R . . 
H52C H 0.2219 0.3809 0.1058 0.078 Uiso 1 1 calc R . . 
C60 C 0.29088(6) 0.5018(2) 0.28960(17) 0.0369(5) Uani 1 1 d . . . 
H60A H 0.2840 0.4228 0.2968 0.044 Uiso 1 1 calc R . . 
C61 C 0.32720(7) 0.5085(2) 0.33746(18) 0.0423(6) Uani 1 1 d . . . 
H61A H 0.3349 0.5859 0.3358 0.064 Uiso 1 1 calc R . . 
H61B H 0.3398 0.4592 0.3076 0.064 Uiso 1 1 calc R . . 
H61C H 0.3303 0.4848 0.3998 0.064 Uiso 1 1 calc R . . 
C62 C 0.27128(7) 0.5759(3) 0.3392(2) 0.0579(9) Uani 1 1 d . . . 
H62A H 0.2758 0.5525 0.4019 0.087 Uiso 1 1 calc R . . 
H62B H 0.2478 0.5680 0.3113 0.087 Uiso 1 1 calc R . . 
H62C H 0.2778 0.6544 0.3361 0.087 Uiso 1 1 calc R . . 
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loop_ 
 _atom_site_aniso_label 
 _atom_site_aniso_U_11 
 _atom_site_aniso_U_22 
 _atom_site_aniso_U_33 
 _atom_site_aniso_U_23 
 _atom_site_aniso_U_13 
 _atom_site_aniso_U_12 
Si 0.0209(3) 0.0338(3) 0.0305(3) 0.0016(2) 0.0062(2) 0.0008(2) 
O1 0.0290(8) 0.0347(9) 0.0387(9) 0.0007(7) 0.0094(7) 0.0036(6) 
O6 0.0330(8) 0.0459(10) 0.0381(10) -0.0032(8) 0.0201(7) 0.0025(7) 
O11 0.0248(8) 0.1010(17) 0.0258(9) -0.0153(10) 0.0047(7) 0.0029(9) 
O20 0.0406(9) 0.0460(10) 0.0261(8) -0.0079(7) 0.0124(7) -0.0057(8) 
O21 0.0634(13) 0.0479(11) 0.0521(12) 0.0121(9) 0.0308(10) -0.0038(10) 
O22 0.0418(9) 0.0479(10) 0.0292(9) 0.0101(8) 0.0081(7) 0.0111(8) 
N19 0.0345(10) 0.0410(11) 0.0394(12) -0.0017(9) 0.0144(9) 0.0074(9) 
C1 0.0210(9) 0.0365(12) 0.0476(14) -0.0046(11) 0.0077(9) -0.0010(9) 
C2 0.0200(9) 0.0349(11) 0.0366(12) -0.0021(9) 0.0076(8) -0.0004(8) 
C3 0.0258(10) 0.0367(12) 0.0317(12) 0.0001(9) 0.0061(8) 0.0001(9) 
C4 0.0224(9) 0.0328(11) 0.0301(11) -0.0045(9) 0.0082(8) -0.0036(8) 
C5 0.0202(9) 0.0383(12) 0.0252(10) -0.0032(9) 0.0070(7) -0.0007(8) 
C6 0.0262(10) 0.0370(12) 0.0359(12) 0.0005(9) 0.0159(9) 0.0026(9) 
C7 0.0206(9) 0.0349(12) 0.0417(13) -0.0024(10) 0.0113(9) -0.0033(8) 
 123
C8 0.0217(9) 0.0334(11) 0.0369(12) -0.0044(9) 0.0091(8) -0.0029(8) 
C9 0.0201(9) 0.0354(11) 0.0290(11) -0.0040(9) 0.0080(8) -0.0009(8) 
C10 0.0208(9) 0.0353(11) 0.0258(10) -0.0052(9) 0.0067(8) -0.0025(8) 
C11 0.0245(10) 0.0568(15) 0.0385(13) -0.0211(12) 0.0141(9) -0.0097(10) 
C12 0.0272(10) 0.0523(15) 0.0494(15) -0.0234(12) 0.0191(10) -0.0136(10) 
C13 0.0239(10) 0.0503(14) 0.0365(13) -0.0147(11) 0.0134(9) -0.0048(9) 
C14 0.0250(9) 0.0348(11) 0.0236(10) -0.0037(8) 0.0086(8) -0.0010(8) 
C15 0.0196(8) 0.0339(11) 0.0235(10) -0.0006(8) 0.0058(7) 0.0005(7) 
C16 0.0407(12) 0.0416(13) 0.0316(12) 0.0051(10) 0.0172(10) 0.0075(10) 
C17 0.0559(16) 0.0586(17) 0.0280(13) 0.0092(12) 0.0081(12) 0.0225(14) 
C18 0.0410(14) 0.0603(18) 0.0399(15) 0.0072(13) 0.0050(11) 0.0203(13) 
C20 0.0271(10) 0.0357(12) 0.0280(11) -0.0028(9) 0.0109(8) -0.0026(8) 
C21 0.0393(12) 0.0325(12) 0.0300(12) -0.0008(9) 0.0132(9) -0.0012(9) 
C22 0.076(2) 0.063(2) 0.0419(16) 0.0202(15) 0.0156(15) 0.0321(17) 
C23 0.0559(16) 0.0612(18) 0.0342(14) -0.0006(13) 0.0210(12) 0.0094(14) 
C30 0.0421(14) 0.0383(14) 0.073(2) -0.0094(13) 0.0293(14) 0.0037(11) 
C31 0.035(3) 0.051(3) 0.061(4) -0.002(3) 0.018(3) 0.009(2) 
C32 0.053(4) 0.079(5) 0.076(5) 0.026(4) -0.009(3) -0.014(4) 
C33 0.085(6) 0.100(7) 0.072(6) 0.025(5) 0.008(5) -0.025(5) 
C34 0.056(4) 0.071(5) 0.085(6) 0.005(4) 0.024(4) -0.009(3) 
C36 0.037(3) 0.054(4) 0.076(7) 0.003(5) 0.000(5) 0.000(3) 
C31B 0.029(2) 0.035(2) 0.038(3) -0.009(2) 0.005(2) 0.0041(19) 
C32B 0.120(8) 0.125(8) 0.103(8) -0.066(7) 0.064(7) -0.068(7) 
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C33B 0.136(10) 0.137(10) 0.138(11) -0.062(8) 0.058(9) -0.091(9) 
C34B 0.052(4) 0.068(5) 0.132(8) -0.034(5) 0.032(5) -0.020(4) 
C36B 0.085(8) 0.052(5) 0.073(7) -0.023(5) 0.036(6) -0.028(5) 
C40 0.0304(11) 0.0403(13) 0.0320(12) 0.0011(10) 0.0066(9) -0.0023(9) 
C41 0.0300(11) 0.0556(16) 0.0472(15) 0.0024(13) 0.0142(11) -0.0070(11) 
C42 0.0409(13) 0.0374(13) 0.0424(15) 0.0004(11) 0.0074(11) -0.0026(11) 
C50 0.0225(9) 0.0356(12) 0.0400(13) 0.0014(10) 0.0068(9) 0.0007(8) 
C51 0.0296(12) 0.0626(18) 0.0423(15) 0.0060(13) -0.0004(10) -0.0047(12) 
C52 0.0228(11) 0.0597(18) 0.071(2) 0.0181(16) 0.0068(12) -0.0044(11) 
C60 0.0317(11) 0.0443(14) 0.0342(13) 0.0038(10) 0.0077(9) -0.0008(10) 
C61 0.0377(13) 0.0525(16) 0.0326(13) -0.0037(11) 0.0008(10) 0.0062(11) 
C62 0.0401(14) 0.100(3) 0.0384(15) 0.0058(16) 0.0184(12) 0.0116(16) 
  
_geom_special_details 
; 
 All esds (except the esd in the dihedral angle between two l.s. planes) 
 are estimated using the full covariance matrix.  The cell esds are taken 
 into account individually in the estimation of esds in distances, angles 
 and torsion angles; correlations between esds in cell parameters are only 
 used when they are defined by crystal symmetry.  An approximate (isotropic) 
 treatment of cell esds is used for estimating esds involving l.s. planes. 
; 
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loop_ 
 _geom_bond_atom_site_label_1 
 _geom_bond_atom_site_label_2 
 _geom_bond_distance 
 _geom_bond_site_symmetry_2 
 _geom_bond_publ_flag 
Si O1 1.6482(18) . ? 
Si C40 1.883(3) . ? 
Si C50 1.884(2) . ? 
Si C60 1.890(3) . ? 
O1 C1 1.427(3) . ? 
O6 C23 1.410(3) . ? 
O6 C6 1.416(3) . ? 
O11 C11 1.430(4) . ? 
O20 C20 1.228(3) . ? 
O21 C21 1.204(3) . ? 
O22 C21 1.349(3) . ? 
O22 C22 1.439(3) . ? 
N19 C20 1.358(3) . ? 
N19 C18 1.410(4) . ? 
N19 C30 1.469(3) . ? 
C1 C2 1.514(3) . ? 
C2 C3 1.505(3) . ? 
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C2 C4 1.520(3) . ? 
C2 C7 1.542(3) . ? 
C3 C4 1.525(3) . ? 
C4 C5 1.536(3) . ? 
C5 C9 1.546(3) . ? 
C5 C6 1.554(3) . ? 
C6 C7 1.531(3) . ? 
C7 C8 1.546(3) . ? 
C8 C9 1.574(3) . ? 
C9 C10 1.535(3) . ? 
C10 C11 1.535(3) . ? 
C10 C15 1.549(3) . ? 
C11 C12 1.525(3) . ? 
C12 C13 1.525(3) . ? 
C13 C14 1.547(3) . ? 
C14 C21 1.541(3) . ? 
C14 C20 1.548(3) . ? 
C14 C15 1.564(3) . ? 
C15 C16 1.546(3) . ? 
C16 C17 1.491(4) . ? 
C17 C18 1.320(4) . ? 
C30 C31B 1.547(6) . ? 
C30 C31 1.573(7) . ? 
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C31 C36 1.390(11) . ? 
C31 C32 1.396(10) . ? 
C32 C33 1.389(11) . ? 
C33 C34 1.402(12) . ? 
C34 C35 1.559(15) . ? 
C35 C36 1.327(18) . ? 
C31B C32B 1.333(10) . ? 
C31B C36B 1.352(13) . ? 
C32B C33B 1.429(13) . ? 
C33B C34B 1.404(15) . ? 
C34B C35B 1.390(12) . ? 
C35B C36B 1.406(15) . ? 
C40 C41 1.531(3) . ? 
C40 C42 1.535(4) . ? 
C50 C52 1.525(4) . ? 
C50 C51 1.540(4) . ? 
C60 C61 1.523(4) . ? 
C60 C62 1.538(4) . ? 
  
loop_ 
 _geom_angle_atom_site_label_1 
 _geom_angle_atom_site_label_2 
 _geom_angle_atom_site_label_3 
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 _geom_angle 
 _geom_angle_site_symmetry_1 
 _geom_angle_site_symmetry_3 
 _geom_angle_publ_flag 
O1 Si C40 102.88(10) . . ? 
O1 Si C50 111.03(10) . . ? 
C40 Si C50 108.54(11) . . ? 
O1 Si C60 110.76(11) . . ? 
C40 Si C60 114.79(12) . . ? 
C50 Si C60 108.76(11) . . ? 
C1 O1 Si 126.99(15) . . ? 
C23 O6 C6 112.26(19) . . ? 
C21 O22 C22 116.1(2) . . ? 
C20 N19 C18 125.2(2) . . ? 
C20 N19 C30 118.8(2) . . ? 
C18 N19 C30 115.6(2) . . ? 
O1 C1 C2 110.39(18) . . ? 
C3 C2 C1 120.2(2) . . ? 
C3 C2 C4 60.58(14) . . ? 
C1 C2 C4 123.2(2) . . ? 
C3 C2 C7 119.54(19) . . ? 
C1 C2 C7 116.73(18) . . ? 
C4 C2 C7 102.85(18) . . ? 
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C2 C3 C4 60.20(15) . . ? 
C2 C4 C3 59.22(15) . . ? 
C2 C4 C5 104.71(18) . . ? 
C3 C4 C5 123.27(19) . . ? 
C4 C5 C9 114.73(18) . . ? 
C4 C5 C6 100.99(17) . . ? 
C9 C5 C6 97.38(17) . . ? 
O6 C6 C7 111.65(18) . . ? 
O6 C6 C5 116.57(19) . . ? 
C7 C6 C5 93.89(17) . . ? 
C6 C7 C2 100.96(19) . . ? 
C6 C7 C8 100.03(17) . . ? 
C2 C7 C8 112.23(18) . . ? 
C7 C8 C9 103.23(18) . . ? 
C10 C9 C5 118.38(18) . . ? 
C10 C9 C8 116.18(18) . . ? 
C5 C9 C8 101.88(16) . . ? 
C9 C10 C11 112.16(18) . . ? 
C9 C10 C15 111.11(17) . . ? 
C11 C10 C15 112.76(18) . . ? 
O11 C11 C12 107.8(2) . . ? 
O11 C11 C10 112.7(2) . . ? 
C12 C11 C10 109.6(2) . . ? 
 130
C13 C12 C11 111.2(2) . . ? 
C12 C13 C14 111.78(18) . . ? 
C21 C14 C13 106.62(19) . . ? 
C21 C14 C20 103.67(17) . . ? 
C13 C14 C20 111.84(18) . . ? 
C21 C14 C15 111.00(18) . . ? 
C13 C14 C15 113.25(17) . . ? 
C20 C14 C15 110.00(18) . . ? 
C16 C15 C10 118.16(18) . . ? 
C16 C15 C14 111.46(17) . . ? 
C10 C15 C14 110.76(17) . . ? 
C17 C16 C15 118.0(2) . . ? 
C18 C17 C16 121.4(3) . . ? 
C17 C18 N19 122.8(2) . . ? 
O20 C20 N19 121.1(2) . . ? 
O20 C20 C14 119.4(2) . . ? 
N19 C20 C14 119.5(2) . . ? 
O21 C21 O22 122.9(2) . . ? 
O21 C21 C14 123.9(2) . . ? 
O22 C21 C14 113.20(19) . . ? 
N19 C30 C31B 116.4(2) . . ? 
N19 C30 C31 104.3(3) . . ? 
C36 C31 C32 118.1(8) . . ? 
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C36 C31 C30 114.5(7) . . ? 
C32 C31 C30 127.3(5) . . ? 
C33 C32 C31 123.1(7) . . ? 
C32 C33 C34 118.5(8) . . ? 
C33 C34 C35 119.2(8) . . ? 
C36 C35 C34 115.2(11) . . ? 
C35 C36 C31 125.8(11) . . ? 
C32B C31B C36B 116.5(7) . . ? 
C32B C31B C30 122.7(6) . . ? 
C36B C31B C30 120.4(6) . . ? 
C31B C32B C33B 123.6(9) . . ? 
C34B C33B C32B 115.2(10) . . ? 
C35B C34B C33B 124.5(8) . . ? 
C34B C35B C36B 112.6(8) . . ? 
C31B C36B C35B 127.5(9) . . ? 
C41 C40 C42 111.1(2) . . ? 
C41 C40 Si 115.36(18) . . ? 
C42 C40 Si 111.60(17) . . ? 
C52 C50 C51 109.8(2) . . ? 
C52 C50 Si 112.88(17) . . ? 
C51 C50 Si 111.93(16) . . ? 
C61 C60 C62 109.0(2) . . ? 
C61 C60 Si 114.46(18) . . ? 
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C62 C60 Si 114.08(19) . . ? 
  
loop_ 
 _geom_hbond_atom_site_label_D 
 _geom_hbond_atom_site_label_H 
 _geom_hbond_atom_site_label_A 
 _geom_hbond_distance_DH 
 _geom_hbond_distance_HA 
 _geom_hbond_distance_DA 
 _geom_hbond_angle_DHA 
 _geom_hbond_site_symmetry_A 
O11 H11A O20  0.84 1.93 2.763(2) 172.2 6_556 
  
_diffrn_measured_fraction_theta_max    0.992 
_diffrn_reflns_theta_full              30.08 
_diffrn_measured_fraction_theta_full   0.992 
_refine_diff_density_max    0.984 
_refine_diff_density_min   -0.430 
_refine_diff_density_rms    0.074 
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Olefin 192 (V-JTW-014) 
To a solution of triphenylphosphine oxide (24.4 mg, 0.0876 mmol, 2.40 equiv) in CH2Cl2 (1.0 
mL) at 0 ºC was added trifluoromethanesulfonic anhydride (6.1 μL, 0.037 mmol, 1.0 equiv). This 
solution was stirred at 0 ºC for 30 m, then transferred via cannula to a solution of 
diisopropylethyl amine (14.0 μL, 0.0803 mmol, 2.20 equiv) and alcohol 191 (23.8 mg, 0.0365 
mmol, 1.00 equiv) in CH2Cl2 (1.2 mL, 0.03 M) at 0 ºC. The resulting solution was heated to 40 
ºC for 35 m, cooled briefly in an icewater bath, diluted with ½ saturated aqueous NaHCO3 
solution (10 mL), and extracted with CH2Cl2 (3x 10 mL). The combined organic extracts were 
dried over MgSO4, filtered, and concentrated to give a white solid.  Purification by silica gel prep 
TLC (4 : 1 hexanes : ethyl acetate) afforded desired olefin 192 (9.8 mg, 42%) as a colorless film 
along with undesired tetrasubstituted olefin S10 (3.6 mg, 16%) and recovered starting alcohol 
191 (4.6 mg, 19%). 
Desired isomer 192: 
Rf = 0.40 (4 : 1 hexanes : ethyl acetate, CAM stain); 1H NMR (500 MHz, CDCl3) δ 7.29 (m, 5H), 
5.80 (dd, 1H, J=7.2, 1.6 Hz), 5.59 (m, 2H), 4.80 (d, 1H, J=14.8 Hz), 4.51 (d, 1H, J=15.1 Hz), 
4.11 (d, 1H, J=9.6 Hz), 3.89 (s, 1H), 3.78 (br d, 1H), 3.59 (s, 3H), 3.45 (d, 1H, J=9.8 Hz), 3.33 
(s, 3H), 2.92 (br s, 1H), 2.49 (br s, 1H), 2.46 (s, 1H), 2.34 (m, 2H), 2.24 (m, 1H), 2.09 (br d, 1H, 
J=19 Hz), 1.91 (tdd, 1H, J=12.3, 7.2, 1.6 Hz), 1.72 (td, 1H, J=12.3, 4.5 Hz), 1.57 (m, 1H), 1.34 
(m, 1H), 1.24 (dd, 1H, J=12.6, 6.0 Hz), 1.12 – 1.02 (m, 21H), 0.98 (dd, 1H, J=5.5, 3.1 Hz) 
Undesired tetrasubstituted isomer S10: 
1H NMR (500 MHz, CDCl3) δ 7.29 (m, 5H), 5.81 (d, 1H, J=7.5 Hz), 5.64 (dd, 1H, J=15.1, 7.6 
Hz), 4.70 (d, 1H, J=14.8 Hz), 4.63 (d, 1H, J=14.5 Hz), 4.11 (d, 1H, J=9.5 Hz), 4.01 (dd, 1H, 
J=10.5, 5.9 Hz), 3.68 (s, 1H), 3.63 (s, 3H), 3.45 (s, 1H, J=9.5 Hz), 3.32 (s, 3H), 2.95 (s, 1H), 
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2.31 (s, 1H), 2.27 (m, 3H), 2.07 – 1.94 (m, 2H), 1.91 (br s 2H), 1.58 – 1.45 (m, 3H), 1.05 (m, 
21H), 0.95 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 172.65, 137.29, 132.19, 129.97, 128.63, 
128.37, 127.60, 121.82, 100.79, 67.49, 59.41, 56.75, 51.55, 50.99, 44.87, 39.63, 34.14, 32.32, 
31.09, 30.11, 29.85, 27.93, 24.86, 23.60, 22.22, 21.78, 18.22, 18.19, 12.22;  
MeO
H
OTIPS
NBn
MeO2C
H
O
MeO
H
OH
NBn
MeO2C
H
O
193192  
Alcohol 193 (V-JTW-061) 
To a solution of silyl ether 192 (41.8 mg, 0.0659 mmol, 1.00 equiv) in tetrahydrofuran (660 μL, 
0.1 M) was added a 1.0 M solution of tetrabutylammonium fluoride in tetrahydrofuran (165 μL, 
0.165 mmol, 2.5 equiv).  The resulting yellow solution was stirred at room temperature for 5.5 h, 
diluted with ½ saturated aqueous NaCl (10 mL), and extracted with ethyl acetate (3x 10 mL).  
The combined organic extracts were dried over MgSO4, filtered, and concentrated to give an oil.  
Purification by automated silica gel column chromatography (5 g solid load cartridge, 4 g 
column, 0 – 50% acetone in hexanes) afforded alcohol 193 (27.8 mg, 88%) as a hard white foam. 
Rf = 0.27 (2 : 1 hexanes : acetone, CAM stain); 1H NMR (500 MHz, CDCl3) δ 7.29 (m, 5H), 
5.82 (dd, 1H, J=7.3, 1.6 Hz), 5.60 (d, 1H, J=7.2 Hz), 5.57 (d, 1H, J=7.6 Hz), 4.79 (d, 1H, J=14.9 
Hz), 4.51 (d, 1H, J=14.8 Hz), 4.01 (m, 2H), 3.89 (s, 1H), 2.77 (br d, 1H), 3.59 (s, 3H), 3.41 (s, 
3H), 3.11 (d, 1H, J=10.5 Hz), 2.90 (br m, 1H), 2.58 (s, 1H), 2.49 (br s, 1H), 2.43 (m, 1H), 2.34 
(ddd, 1H, J=12.8, 5.6, 2.5 Hz), 2.24 (ddd, 1H, J=13.4, 8.0, 6.0 Hz), 2.08 (br d, 1H, J~17.7 Hz), 
1.91 (tdd, 1H, J=12.8, 7.2, 1.6 Hz), 1.80 (td, 1H, J=12.6, 4.7 Hz), 1.57 (m, 1H), 1.45 (m, 1H), 
1.26 (dd, 1H, J=12.8, 6.4 Hz), 1.07 (dd, 1H, J=6.0, 3.1 Hz), 0.89 (m, 1H); 13C NMR (125 MHz, 
CDCl3) δ 174.68, 171.82, 137.11, 133.55, 130.36, 128.61, 128.44, 127.60, 122.00, 121.93, 
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100.61, 68.84, 57.07, 56.91, 52.67, 50.42, 48.04, 43.09, 42.77, 39.56, 35.85, 30.73, 28.68, 28.59, 
27.09, 24.05, 23.10; IR (neat film) 3429 (br m), 2951 (m), 1734 (s), 1650 (s), 1433 (m), 1389 
(m), 1245 (s), 1220 (s), 1110 (m), 914 (m), 733 (s) cm-1; HRMS (ESI) calc'd for C29H36NO5 
(M+H) 478.2593 found 478.2604 
 
Selenide 195 (V-JTW-058) 
To a solution of alcohol 193 (3.1 mg, 0.0065 mmol, 1.0 equiv) in tetrahydrofuran (150 μL) were 
added a 1 M solution of Me3P in tetrahydrofuran (19.5 μL, 0.0195 mmol, 3.0 equiv) and            
N-(phenylseleno)phthalimide (194) (3.9 mg, 0.013 mmol, 2.0 equiv).  The yellow solution was 
stirred for 45 m, then more Me3P solution (5.0 μL, 0.0049 mmol, 0.75 equiv) and 
N(phenylseleno)phthalimide (1.1 mg, 0.0032 mmol, 0.50 equiv) were added.  The solution was 
stirred for 75 m, quenched with ½ saturated aqueous NaCl solution (300 μL), and extracted with 
ethyl acetate (3x 300 μL).  The combined organic extracts were concentrated to give a film that 
by crude 1H NMR suggested about 75% conversion. Purification by silica gel column 
chromatography (4 : 1 hexanes : acetone) provided selenide 195 (1.8 mg, 44%) as a solid film. 
Rf = 0.52 (2 : 1 hexanes : acetone, CAM stain); 1H NMR (500 MHz, CDCl3) δ 7.50 (d, 2 H, 
J=7.7 Hz), 7.3 – 7.2 (m, 8H), 5.80 (d, 1H, J=7.3 Hz), 5.58 (q, 1H, J=7.4 Hz), 5.53 (s, 1H), 4.80 
(d, 1H, J=14.6 Hz), 4.50 (d, 1H, J=14.6 Hz), 3.87 (s, 1H), 3.75 (br d, 1H, J=13.3 Hz), 3.59 (s, 
3H), 3.59 (m, 1H), 3.32 (s, 3H), 2.90 (br s, 1H), 2.81 (d, 1H, J=11.8 Hz), 2.50 (s, 1H), 2.46 (br s, 
1H), 2.35 (s, 1H), 2.31 (dd, 1H, J=12.8, 3.4 Hz), 2.22 (m, 1H), 2.04 (m, 1H), 1.90 (td, 1H, 
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J=12.9, 7.1 Hz), 1.71 (td, 1H, J=12.5, 4.7 Hz), 1.54 (m, 1H), 1.39 (s, 1H), 1.19 (dd, 1H, J=12.7, 
6.6 Hz), 1.05 (m, 1H), 0.91 (t, 1H, J=6.6 Hz); 
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198 199  
Olefins 198 and 199 (V-JTW-068) 
A solution of selenide 195 (4.7 mg, 0.0074 mmol, 1.0 equiv) in benzene (1.5 mL, 0.005 M) was 
subjected to 3x freeze-pump-thaw cycles. To this solution were then added tributyltin hydride 
(7.9 μL, 0.030 mmol, 4.0 equiv) and 2,2′-azobis(isobutryonitrile) (0.4 mg, 0.002 mmol, 0.3 
equiv). The solution was heated to 100 ºC for 15 m, then cooled to 20 °C. Another portion of 
2,2′-azobis(isobutryonitrile) (0.4 mg, 0.002 mmol, 0.3 equiv) was added and the solution again 
heated to 100 ºC for 20 m, then the solvent was removed by vacuum. Purification by silica gel 
prep TLC (2 : 1 hexanes : ethyl acetate) provided triene 198 (1.2 mg, 35%) and cyclopentane 199 
(1.0 mg, 29%). 
Triene 198: 
Rf = 0.49 (2 : 1 hexanes : ethyl acetate, CAM stain); 1H NMR (500 MHz, CDCl3) δ 7.28 (m, 5H), 
5.84 (d, 1H, J=7.2 Hz), 5.55 (dd, 1H, J=14.5 Hz), 4.70 (d, 1H, J=14.5 Hz), 4.64 (s, 1H), 4.62 (d, 
1H, J=14.5 Hz) 4.61 (s, 1H), 3.78 (br d, J=9.6 Hz), 3.61 (s, 3H), 3.57 (m, 1H), 3.35 (s, 3H), 2.91 
(m, 1H), 2.79 (m, 1H), 2.65 (m, 1H), 2.40 – 2.30 (m, 3H), 2.13 – 2.05 (m, 4H), 1.93 (m, 1H), 
1.80 (m, 1H), 1.60 (m, 2H); IR (neat film) 3062 (w), 3030 (w), 2932 (m), 1734 (s), 1650 (s), 
1389 (m), 1356 (m), 1245 (s), 1219 (s), 1118 (m), 1109 (m), 879 (w), 738 (m), 700 (m); LRMS 
(ESI) 462.23 (M+H), 484.19 (M+Na). 
Cyclopentane 199: 
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Rf = 0.42 (2 : 1 hexanes : ethyl acetate, CAM stain); 1H NMR (500 MHz, CDCl3) δ 7.30 (m, 5H), 
5.79 (dd, 1H, J=7.2, 1.9 Hz), 5.60 (dd, 1H, J=14.7, 7.2 Hz), 4.68 (d, 1H, J=14.3 Hz), 4.64 (d, 1H, 
J=14.3 Hz), 4.64 (s, 1H), 4.59 (s, 1H), 3.75 (t, 1H, J=5.0 Hz), 3.61 (s, 3H), 3.34 (s, 3H), 3.26 (td, 
1H, J=12.8, 5.1 Hz), 2.77 (m, 2H), 2.42 (m, 2H), 2.27 (m, 2H), 2.18 (m, 3H), 1.97 (m, 1H), 1.78 
(m, 1H), 1.71 (m, 1H), 1.62 (m, 1H), 1.44 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 174.91, 
171.88, 150.50, 137.22, 129.68, 128.79, 128.59, 128.51, 127.61, 123.41, 106.53, 83.30, 57.54, 
56.85, 52.53, 51.07, 49.14, 48.60, 45.81, 44.41, 43.65, 39.58, 38.54, 31.59, 29.38, 29.96, 28.28, 
18.99; IR (neat film) 3063 (w), 3031 (w), 2931 (s), 1732 (s), 1648 (s), 1456 (m), 1433 (m), 1401 
(m), 1390 (m), 1259 (s), 1213 (s), 1065 (m), 736 (m), 701 (m) cm-1; 
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CHAPTER 5. EXPLORATION OF A CATION-Π CYCLIZATION CASCADE TO 
ACCESS THE ACONITINE ALKALOIDS 
5.1 Addition of an Enol-ether onto an N-Acyliminium to Form the C11–C17 Bond 
An expedient strategy to install an oxygen at C1 while retaining the C11–C1 double bond 
and prevent the undesired 5-endo radical cyclization reaction mode would be to form the 
tetrasubstituted enol ether 201 from ketone 190 (Scheme 47). Unfortunately, a variety of 
standard methods failed to provide 201 (NaH/MeI, KH/Me2SO4,1 KOt-Bu/Me2SO4,2 
(CH3O)3CH/PTSA,3,4 TMSCl/Et3N,5 TMSCl/NaI/Et3N,6 MeOTf/DTBP7). The only isolable 
product was the kinetic enol-ether 200, formed by deprotonation at the most accessible position α 
to the ketone of 190 at C2. Isomerization8-10 of the kinetic C1–C2 enol-ether 200 to the more 
substituted C1–C11 201 also proved fruitless, possibly because the caged carbon structure 
disfavored the C1–C11 isomer, causing the C1–C2 isomer to be both kinetically and 
thermodynamically favored. One particular experiment that was intended to produce the C1–C11 
methyl enol-ether via an O-methyloxophosphonium gave an unanticipated, but highly beneficial, 
result (Scheme 48). Treatment of a solution of ketone 190 in CH2Cl2 with triphenylphospine 
oxide, triflic anhydride, and methanol resulted not in the formation of a methyl enol-ether as 
anticipated rather a complex mixture of products, from which the major product was isolated and 
identified as cyclic enol-ether 202 (26%). Under these conditions, an equivalent of triflic acid 
was generated that effected protonation of the silyl-ether to form cyclopropylcarbinyl cation 203 
that can also be represented by its resonance structure 204.  Attack of the cation at C8 by the 
oxygen of the C1 ketone with subsequent deprotonation at C11 resulted in cyclic enol-ether 205.  
Further protonation of enamide 205 produced N-acyliminium 206 that underwent intramolecular 
attack by the newly-formed enol-ether to complete the observed product 202. Although the 
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original intention was to simply form a C1–C11 methyl enol-ether, it was recognized that this 
transformation had formed the key C11–C17 bond and so could be employed to complete the 
synthesis of the aconitine alkaloid skeleton, though there were several challenges to overcome. 
 
 
In order to capitalize on this N-acyliminium addition result to access the aconitine 
alkaloids, there were several issues that needed to be considered when advancing an intermediate 
such as 202. First, hydrolysis of the enol-ether would be required, providing hydroxy-ketone 207 
(Scheme 49), which when redrawn as the conformational representation 208 maps very well onto 
the aconitine carbon-nitrogen skeleton in 209. Second, construction of the C7–C8 bond from 
intermediate 208 would then complete the aconitine skeleton. This task would be challenging, 
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however, due to the lack of a chemical handle at C7 to facilitate the coupling. Third, the yield of 
the cylization in the conversion of 190 to 202 was a paltry 26% and would require significant 
improvement to be synthetically viable. With these concerns in mind, we envisioned 
intermediate 210, incorporating a heteroatom functional group handle at C7, as a suitable 
cyclization substrate. To address the issue of the low yield of the N-acyliminium cyclization, it 
was hypothesized that deleterious side reactions might arise from the formation of a transient 
highly reactive cyclopropylcarbinyl cation such as 203 (see Scheme 48). Thus, the introduction 
of an aldehyde functionality at C16 would likely mitigate potential unproductive side reactions, 
in which a more stable cyclopropylcarbinyl oxocarbenium, as opposed to a cyclopropylcarbinyl 
carbocation, would serve as the initial electron-deficient reactive intermediate formed in the 
cyclization cascade.  
 
To address the second of these concerns, namely the installation of a C7 functional 
handle, a bromine atom was installed at C7 early in the synthesis by its incorporation into 
azepine dienophile 213 (Scheme 50). Treatment of enamide 182 with bromine gave an 
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intermediate dibromide that was not isolated, but subjected to triethylamine mediated  
regioselective elimination of the bromine α to the amide nitrogen.  This selectivity is likely due 
to nitrogen stabilization of the positive charge resulting from E1 bromide elimination and 
deprotonation α to the resulting N-acyliminium to produce bromoenamide 211 in 86% yield. The 
previously developed strategy for the construction of azepin-2(5H)-one 186 (refer to Scheme 43) 
was then applied to advance bromoenamide 212 to dienophile 213. Deprotonation of 211 with 
two equivalents of LHMDS followed by sequential addition of methylchloroformate and 
phenylselenyl chloride gave selenide 212 that was used without purification. Oxidation of the 
selenide with H2O2 proceeded with spontaneous 1,2-syn elimination of the resultant selenoxide 
to provide the modified Diels–Alder 2π-component 213 (99%, two steps). 
 
Halogenated dienophile 213 was then used to prepare the cyclization precursor 218 
(Scheme 51). Under conditions similar to the cycloaddition with unhalogenated dienophile 179 
(see Scheme 44, chapter 4), a solution of diene 178 and dienophile 213 was treated with catalytic 
Sc(OTf)3 at 20 °C to effect a Diels–Alder cycloaddition with complete regio and endo 
selectivity, but gave an inseparable 1 : 1.8 mixture of desired facial isomer cycloadduct 214 to 
undesired adduct 215 in 69% combined yield (87% based on recovered 178). This Diels–Alder 
reaction compares favorably with the one described in the previous chapter (See Scheme 44, 
Chapter 4). Although the facial selectivity will require further optimization, the high combined 
yield provided sufficient material for exploration of the latter stages of the synthesis. Desilylation 
of both the TBS enol-ether and the TIPS ether with two equivalents of TBAF provided keto-
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alcohols 216 and 217 in 71% yield.  Oxidation of the sensitive cyclopropylcarbinol was effected 
with 2-iodoxybenzoic acid (IBX) activated by ultrasonication. Separation of the resulting 
aldehydes by silica gel column chromatography produced desired diastereomer 218 (31%) along 
with the undesired diastereomer 219 (56%). Aldehyde 218 contained all the requisite 
functionality to test whether activation of cyclopropylcarbinyl aldehyde 218 as an oxocarbenium 
precursor would in fact increase the yield relative to that of the comparatively unstabilized 
cyclopropylcarbinyl carbocation 203. 
 
This hypothesis was tested by protonation of aldehyde 218 (Scheme 52) with one 
equivalent of triflimide at 0 °C. Subsequent warming of the reaction mixture to 23 °C did in fact 
provide the desired N-acyliminium adduct 219 as a single diastereomer in 71% yield,* a result 
consistent with the hypothesis of yield augmentation through increasing cation stability via a 
cyclization with a cyclopropylcarbinyl oxocarbenium intermediate.† The likely mechanism of 
                                                 
* A small amount (<5%) of the opposite C(7) diastereomer (226) was also obtained as an inseparable mixture of 
other unidentifiable products. 
† TfOH initially provided the product in a 73% yield, but was found to be dependent on the source and purity of 
TfOH, while Tf2NH provided more consistent results. 
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this transformation begins with initial protonation of the aldehyde to give oxocarbenium 220 that 
can also be represented as alternate resonance form 221.  Intramolecular attack of electron 
deficient C8 in 221 by the C1 ketone with subsequent C11 deprotonation gave cyclic enol-ether 
222. This portion of the reaction occurred very quickly and could be halted at this point to isolate 
intermediate tetrasubstituted cyclic enol-ether 222. However, if the reaction was warmed to 20 
°C for several hours, protonation of the bromoenamide then occurred to produce transient N-
acyliminium 223. Nucleophilic attack of the electron rich C17 onto the N-acyliminium was 
followed by deprotonation α to the newly-formed oxocarbenium ion to give the observed product  
219 in which the key C11–C17 bond had been successfully formed.  
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Notably, the observed C7–Br configuration in 219 differed from what was expected from 
this transformation. Based on the topology of the [5.4.0]-bicycloazepine ring system, it was 
anticipated that protonation of the ene-lactam π-system would occur from the less hindered 
convex face (Scheme 53). However, the initially formed N-acyliminium (224) likely exists as 
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endo bromonium ion 225. In this configuration, the σ* orbital of the C17–Br bond is oriented 
into the exo face and is therefore inaccessible for attack from C11 of the enol-ether. This process 
is almost certainly reversible, so protonation from the more hindered concave face would also 
occur, at least to a minor extent. The electrophilic σ* orbital of the C17–Br bond in the resulting 
bromonium 227 is much more accessible to the C11 π-nucleophile. Invertive ring opening  
of the bromonium intermediate 227 would then close the ring, thus securing the observed C7–Br 
stereochemistry via a Curtin–Hammett reactivity profile. The successful installation of a C7 
heteroatom as well as the formation of the C11–C17 bond in 219 was a significant step toward 
the synthesis of the aconitine skeleton. 
 
 
5.2 Attempts at Enol-ether Hydrolysis 
The successful construction of the C11–C17 bond left only the C7–C8 bond to complete 
the aconitine skeleton. The first step in this effort to bond C7 and C8 was the seemingly routine 
hydrolysis of enol-ether 219 (Scheme 54), formed from the N-acyliminium cyclization. 
Unfortunately, the stability of this enol-ether toward acidic hydrolysis was much greater than 
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anticipated. Standard hydrolysis conditions using a variety of aqueous acids (HCl, HBr, HClO4) 
in many cosolvents (THF, DME, DMF, dioxane, CH3CN) proved ineffective. In all cases, methyl 
ester hydrolysis to carboxylic acid 228 was the only observed reaction mode. Harsher reaction 
conditions resulted in co-solvent decomposition; therefore, the use of co-solvents was 
abandoned. When enol-ether 219 was heated in concentrated 12 N aqueous HCl to 60 °C, the 
initially formed acid 228 was consumed. The only recovered product, however, was acetal 229, 
resulting from hydrolysis of the C14 methyl ether. Even under these harsh conditions, the enol-
ether remained intact. One possible explanation for this unusual lack of reactivity is steric 
shielding of the enol-ether by the aldehyde. To address this possible complication, the aldehyde 
was removed by a two-step process beginning with transformation into the TBS enol-ether using 
TBSOTf and Et3N (Scheme 54). At this point, the unreactivity of the cyclic alkyl enol-ether 
worked to our advantage as chemoselective oxidative cleavage of the silyl enol-ether was 
accomplished using a Nicolaou modification of the Lemieux-Johnson conditions11 (OsO4, 
PhI(OAc)2, 2,6-lutidine) to provide ketone 230 in 64% yield over two steps, with no evidence of 
oxidative cleavage of the endocyclic enol-ether. Unfortunately, upon subjecting the enol-ether 
230 to progressively harsh conditions, it proved as unreactive toward hydrolysis as aldehyde 219.  
In one attempt, briefly heating a solution of 230 in concentrated 12 N aqueous HCl to 150 °C did 
in fact result in C8–O cleavage, but was accompanied by an undesired skeletal fragmentation to 
give keto-aldehyde 231 that could not easily be advanced to the aconitine alkaloids. We believe 
this fragmentation is initiated by carbocation formation at C8 instead of initial enol-ether 
hydrolysis followed by fragmentation. This hypothesis was substantiated by heating a solution of 
230 in 33% HBr in HOAc to 75 °C to provide bromide 232. Likely, 232 was obtained by 
ionization to form a carbocation at C8 that was trapped by bromide. 
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Although a cursory examination of the structure reveals the enol-ether exists within in a 
highly sterically congested pocket, the unprecedented stability of the enol-ether was surprising 
and warranted a closer investigation. We rationalized there are two possible explanations for this 
difficulty: (1) initial protonation of the olefin is retarded due to stereoelectronic factors or (2) 
protonation of the olefin does occur, but nucleophilic addition of water into the resultant 
oxocarbenium is retarded due to steric blockage of the oxocarbenium π* orbitals.  The former 
possibility was tested by a deuterium-exchange experiment in which a solution of 230 (Scheme 
55) in d8THF : 3N DCl was heated to 65 °C, at which temperature the d8THF began to hydrolyze, 
but there was no indication of any deuterium exchange; therefore, the problem seemed to lie with 
the protonation step of hydrolysis.  
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 Close inspection of models of 230 suggested that as a result of the rigid ring structure, the 
oxygen lone pair electrons are oriented in such a way that alignment with the π* orbitals of the 
olefin is disfavored. The result is decreased electron density and basicity of the olefin that further 
attenuates the protonation required for oxocarbenium formation and subsequent hydrolysis. This 
analysis was corroborated spectroscopically by the observation that the enol-ether vinyl proton 
was electronically de-shielded relative to less-strained enol-ether vinyl protons (Figure 8). For 
example, the 1H NMR resonance for vinyl proton of methyl enol-ether 234 occurs at δ 4.12. In 
contrast, the resonance for the vinyl proton of the unreactive cyclic enol-ether 230 is relatively 
deshielded (δ 5.42), indicating a much lower electron density than the acyclic methyl enol-ether. 
This observation further substantiates our hypothesis of poor orbital overlap between the oxygen 
lone-pair electrons and the olefin π*.  
 
 The failure of enol-ether hydrolysis by aqueous acid prompted a screen of alternate 
electrophiles. The results of these efforts included either no observed reaction (Hg(OAc)2, I2), or 
an unidentified mixture of products (mercury-(II)-trifluoroacetate, Br2, 1,3-dibromo-5,5-
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dimethylhydantoin). One notable exception was observed when 230 (Scheme 56) was treated 
with ten equivalents of dimethyldioxirane (DMDO). Typically, enol-ethers will react with 
DMDO at –78 °C,12-14 however in this case, appreciable conversion was only observed when the 
reaction was warmed to 20 °C. Even under these relatively forcing conditions, 4.5 hours were 
required to completely convert 230 into epoxide 235 (>99%). This result further exemplifies the 
reticence of 230 to undergo typical electrophilic reactions of the π electrons due to the high steric 
encumberance combined with the low electron density of the olefin. Clearly, an alternative 
strategy that does not rely directly upon enol-ether hydrolysis was required in order to advance 
230 to the aconitine alkaloids. 
 
 A breakthrough in the project came when graduate student co-worker Yuan Shi 
hypothesized that the enol-ether could be more easily cleaved via an elimination reaction rather 
than hydrolysis. To test this theory, an allylic leaving group was installed by allylic oxidation of 
230 to alcohol 236 (Scheme 57) with ceric ammonium nitrate followed by activation of the 
hydroxyl group as a mesylate with methanesulfonyl chloride and Et3N. The product of this 
reaction was not the mesylate as anticipated, rather only di-enone 238 was isolated in 72% yield 
over two steps. Likely, in situ ionization of the mesylate provided allyl cation 237 that is an 
excellent leaving group for cleavage of the C8–O bond β to the ketone to provide the observed 
di-enone 238. Representation of 238 as its conformational isomer 239 highlights its similarity to 
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the aconitine alkaloids. Thus, 239 was advanced further toward the completion of the aconitine 
skeleton by C7–C8 bond formation. 
Analysis of models of bis-enone 239 suggested the C7 bromine to be in close proximity 
to the C8 olefin, suggesting a radical or carbanion addition onto C8 would be facile.  Indeed, 
when the C7 radical was generated under thermal conditions with AIBN as the radical source 
and tributyltin hydride as the propagator, radical conjugate addition onto C8 completed the 
aconitine skeleton in the form of 240 (86%). Installation of the C8 oxygen, a necessary 
component for the majority of aconitine alkaloids, was accomplished by a three-step protocol 
that consisted of: (1) α-selenylation of the ketone using LHMDS and PhSeCl; (2) selenide 
oxidation with concomitant 1,2-syn elimination of the resulting selenoxide to give di-enone 241; 
and (3) selective conjugate addition of water into the highly strained anti-Bredt olefin at C8 to 
give alcohol 242 in 52% yield over the three steps. 
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5.3 Summary 
 Ultimately, the first synthesis of the aconitine skeleton in over three decades was 
accomplished through a stepwise ionic and radical manner, beginning with diene 178 (Scheme 
58), an intermediate intercepted from the radical pathway synthesis (see Chapter 4). A Diels–
Alder cycloaddition with 213 as the 2π component and 178 as the 4π component provided 
bromoenamide 214. This intermediate was advanced to steps to the key cyclopropylcarbinyl 
oxocarbenium precursor aldehyde 218 in 15% yield over the three steps. Acid catalyzed 
fragmentation of the cyclopropylcarbinyl aldehyde and addition of the C1 ketone oxygen into the 
resulting electron deficient C8 was followed by bromoenamide protonation and nucleophilic 
addition of C11 onto C17, completing one of the remaining carbon-carbon bonds via an ionic 
pathway. One carbon truncation of aldehyde 219 into ketone 230 was performed by a two-step 
oxidative cleavage protocol to give keto enol-ether 230. This enol-ether proved quite resistant to 
hydrolysis and so was instead fragmented to provide bis-enone 237. The final carbon-carbon 
bond forming reaction proceeded through a secondary radical generated at C7 from homolysis of 
the C–Br bond.  This radical then attacked the C8 enone to provide the completed aconitine 
skeleton 240. Installation of the C8 oxygen functionality was performed by a three-step process 
that hinged upon the selective addition of water into the highly strained anti-Bredt enone 241, 
providing alcohol 242. It is important to note that although intermediate 242 has not yet been 
advanced to a natural aconitine alkaloid, 242 is ideal for advancement to a number of natural and 
non-natural aconitine alkaloid analogues that have substituents at C1, C2, C3, C8, C14, C16, and 
C18. Once completed, these analogues will allow, for the first time, systematic study of the 
structure activity relationship of the aconitine alkaloids. 
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5.4 Experimental 
General Procedures.  All reactions were performed in flame-dried modified Schlenk (Kjeldahl 
shape) flasks fitted with a glass stopper under a positive pressure of argon, unless otherwise 
noted.  Air- and moisture-sensitive liquids and solutions were transferred via syringe or stainless-
steel cannula.  Organic solutions were concentrated by rotary evaporation below 30 °C.  Flash 
column chromatography was performed employing 230-400 mesh silica gel under a positive 
pressure of nitrogen.  Automated silica gel column chromatography was performed employing 
an Isco Combiflash Rf with Isco brand columns. Gradient elutions were performed with a linear 
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gradient. Thin-layer chromatography (analytical and preparative) was performed using glass 
plates pre-coated to a depth of 0.25 mm with 230-400 mesh silica gel impregnated with a 
fluorescent indicator (254 nm). Visualization was achieved using UV light, iodine, potassium 
permanganate (KMnO4), or ceric ammonium molybdenate (CAM). 
Materials.  Dichloromethane (CH2Cl2), tetrahydrofuran (THF), acetonitrile, diethyl ether, 
toluene, and benzene were purified by passage through two packed columns of neutral alumina 
under an argon atmosphere.  Methanol was distilled from magnesium turnings under a nitrogen 
atmosphere at 760 mm Hg. 1,2-Dichloroethane, N,N-dimethylformamide (DMF), 
dimethylsulfoxide, and 1,4-dioxane were dried over activated 4Å molecular sieves.  
Triethylamine, 2,6-lutidine, pyridine, Hünig's base, and diisopropylamine were distilled from 
CaH2 under a nitrogen atmosphere at 760 mm Hg.  Lithium bis(trimethylsilyl)amide (LHMDS) 
and potassium bis(trimethylsilyl)amide (KHMDS) were purchased as a solid from Aldrich and 
handled under an argon atmosphere. Trifluromethanesulfonic anhydride was distilled from P2O5 
under a nitrogen atmosphere at 760 mm Hg. Powdered 4Å molecular sieves were purchased as 
activated and stored and handled under an Argon atmosphere. Organolithium solutions were 
titrated by known procedures15 immediately prior to use. All moisture and/or oxygen sensitive 
solids were handled and stored in a glove box. All other reagents were used as purchased without 
further purification, unless otherwise noted. 
Instrumentation.  Infrared (IR) spectra were obtained using a Bruker Tensor 27 referenced to a 
polystyrene standard. Data are presented as the frequency of absorption (cm-1).  Proton and 
carbon-13 nuclear magnetic resonance (1H NMR or 13C NMR) spectra were recorded on a 
Bruker Avance III 500 or a Bruker Avance III 600 spectrometer; chemical shifts are expressed in 
parts per million (δ scale) downfield from tetramethylsilane and are referenced to the residual 
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protium in the NMR solvent (CHCl3: δ 7.26 for 1H NMR, δ 77.16 for 13C NMR; C6D6: δ 7.16 for 
1H NMR, δ 128.06 for 13C NMR).  Data are presented as follows: chemical shift, multiplicity (s 
= singlet, bs = broad singlet, d = doublet, bd = broad doublet, t = triplet, dd = doublet of 
doublets, ddd = doublet of doublet of doublets, td = triplet of doublets, dt = doublet of triplets, m 
= multiplet and/or multiple resonances), integration, and coupling constant reported in Hz. 
 
Enol ether 202 (V-JTW-089) 
To a solution of triphenylphospine oxide (8.5 mg, 0.031 mmol, 3.3 equiv) in CH2Cl2 (450 μL) 
was added trifluoromethanesulfonic anhydride (2.3 μL, 0.014 mmol, 1.5 equiv).  This solution 
was stirred at room temperature for 45 m, then transferred via cannula to a solution of ketone 290 
(5.9 mg, 0.0091 mmol, 1.0 equiv) in CH2Cl2 (450 μL). Methanol (0.6 μL, 0.01 mmol, 1.5 equiv) 
was immediately added and the solution was stirred at room temperature for 2 h, quenched with 
saturated aqueous NaHCO3 solution (300 μL), and extracted with CH2Cl2 (3x 400 μL).  The 
combined organic extracts were dried over MgSO4, filtered, and the solvent was removed to give 
a film.  Purification by silica gel column chromatography (1 : 1 hexanes : ethyl acetate) afforded 
enol ether 202 (1.1 mg, 26%) as a film. 
1H NMR (500 MHz, CDCl3) δ 7.28 (m, 5H), 5.42 (d, 1H, J=6.2 Hz), 4.83 (d, 1H, J=14.9 Hz), 
4.66 (s, 1H), 4.64 (s, 1H), 4.35 (d, 1H, J=15.0 Hz), 4.33 (m, 1H), 3.79 (s, 3H), 3.53 (m, 2H), 3.27 
(s, 3H), 2.84 (m, 1H), 2.80 (s, 1H), 2.71-2.66 (m, 2H), 2.58 (dd, 1H, J=17.0, 9.1 Hz), 2.44 (dd, 
1H, J=9.7, 4.6 Hz), 2.34 (d, 1H, J=6.1 Hz), 2.06-1.68 (m, 6H), 1.45 (dd, 1H, J=13.2, 7.5 Hz); 13C 
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NMR (125 MHz, CDCl3) δ 172.64, 168.81, 147.50, 146.11, 136.83, 128.59, 128.52, 127.47, 
113.13, 107.45, 84.01, 72.76, 63.78, 57.54, 56.73, 52.49, 50.00, 49.94, 45.63, 43.97, 38.54, 
34.72, 33.71, 31.13, 31.00, 29.86, 27.90, 22.94; IR (neat film) 3056 (w), 2950 (m), 1733 (s), 
1648 (s), 1451 (m), 1359 (w), 1264 (m), 1141 (s), 1111 (s), 734 (s), 700 (m) cm-1; LRMS (ESI) 
476.25 (M+H), 498.14 (M+Na). 
 
Vinyl bromide 211 (SY-VII-092) – Yuan Shi 
To a solution of enamide 182 (14.0 g, 69.6 mmol, 1.00 equiv) in CH2Cl2 (500 mL) at 0 oC was 
added Br2 (3.6 mL, 70.1 mmol, 1.01 equiv) dropwise over 15 m.  The resulting pale brown 
solution was stirred at 0 oC for 20 m before triethylamine (29.0 mL, 208 mmol, 2.99) was added.  
After 10 m, the reaction was brought to 20 oC and stirred for additional 2 h.  The reaction was 
then quenched with saturated aqueous NaHCO3 (300mL), separated, and the aqueous layer was 
extracted with CH2Cl2 (100 mL x 2).  The combined organic phases were dried over MgSO4, 
filtered and concentrated.  The residue was purified by automated silica gel column 
chromatography (25 g solid load cartridge, 220 g column, 0-30% EtOAc in hexane) to yield 
bromoenamide 211 (16.7 g, 86%) as a yellowish oil. 
Rf = 0.41 (1 : 2 ethyl acetate : hexanes, KMnO4 stain); 1H NMR (600 MHz, CDCl3) δ 7.34-7.24 
(m, 5H), 6.34 (s, 1H), 4.62 (s, 2H), 2.65-2.61 (m, 3H), 2.15-2.10 (m, 2H); 13C NMR (125 MHz, 
CDCl3) δ 173.26, 136.92, 129.96, 128.85, 128.12, 127.81, 115.91, 50.58, 36.90, 35.43, 26.54; IR 
(neat film) 2934 (w), 1663 (s), 1274 (m), 700 (m) cm-1; HRMS (ESI) calc'd for C13H15NO4Br 
(M+H) 280.0337 found 280.0332. 
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 Methyl enoate 213 (SY-VII-098, SY-VII-099) Yuan Shi 
To a solution of bromoenamide 211 (15.7 g, 56.0 mmol, 1.00 equiv) in tetrahydrofuran (500mL) 
at –78 oC was added lithium bis(trimethylsilyl)amide (19.2 g, 115 mmol, 2.05 equiv) as a solid in 
one portion.  The solution was stirred at –78 oC for 40 m, followed by dropwise addition of 
methylchloroformate (4.30 mL, 55.9 mmol, 1.00 equiv).  The reaction was stirred at –78 oC for 
additional 40 m before phenylselenyl chloride (11.5 g, 60.0 mmol, 1.07 equiv) was added in one 
portion.  The resulting solution was stirred at –78 oC for 20 m, and then the cooling bath was 
removed.  The reaction was stirred at 20 oC for 1.5 h before being quenched with saturated 
aqueous NaHCO3 (300 mL), separated, and the aqueous layer was extracted with CH2Cl2 (100 
mL x 2), dried over MgSO4, filtered and concentrated.  The yellow residue (212) was used in the 
next step without further purification. 
 
To a solution of the above phenylselenide 212 in CH2Cl2 (500 mL) at 0 oC was added aqueous 
H2O2 (30 wt%, 11.0 mL, 107 mmol, 1.91 equiv).  The reaction was stirred vigorously for 25 m 
before being quenched with saturated aqueous NaHCO3 (200 mL), and separated. The aqueous 
layer was extracted with CH2Cl2 (100 mL x 2), dried over MgSO4, filtered and concentrated. The 
residue was purified by automated silica gel column chromatography (25 g solid load cartridge, 
220 g column, 0-30% ethyl acetate in hexane) to yield 213 (18.8 g, 99% over 2 steps) as pale 
yellow crystals. 
Rf = 0.35 (1 : 2 ethyl acetate : hexanes, CAM stain); 1H NMR (600 MHz, CDCl3) δ 7.39-7.30 
(m, 6H), 6.35 (s, 1H), 4.83 (s, 2H), 3.81 (s, 3H), 3.16 (d, 2H, J=7.5 Hz); 13C NMR (125 MHz, 
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CDCl3) δ 164.88, 164.22, 146.82, 136.50, 131.36, 130.13, 128.95, 128.21, 128.06, 112.00, 52.72, 
51.23, 34.78; IR (neat film) 2951 (m), 1733 (s), 1722 (s), 1653 (s), 1620 (s), 1436 (s), 1407 (s), 
1264 (s), 1045 (m), 737 (m), 701 (m) cm-1; HRMS (ESI) calc'd for C15H15NO3Br (M+H) 
336.0235 found 336.0235. 
MeO
H
OTIPS
TBSO
NBn
O
MeO
O
Br
+
178
213
MeO
H
OTIPS
NBn
TBSO
MeO2C
H
H
O
Br
+
MeO
H
OTIPS
NBn
TBSO
MeO2C
H
H
O
Br
215
214  
Silyl ethers 214 and 215 (SY-VII-097) – Yuan Shi 
To a solution of diene 178 (4.02 g, 7.93 mmol, 1.00 equiv) and dienophile 213 (5.52 g, 16.4 
mmol, 2.07 equiv) in toluene (160 mL) was added powdered 4 Å molecular sieves (4.00 g) and 
Sc(OTf)3 (1.92 g, 3.90 mmol, 0.492 equiv).  The resulting mixture was stirred at ambient 
temperature for 4 h before a solution of dienophile 213 (2.60 g, 7.73 mmol, 0.975 equiv) in 
toluene (20 mL) was added via cannula transfer.  The reaction was stirred at 20 oC for additional 
4.5 h before being filtered through fritted funnel (Medium).  The filtrate was washed with 
saturated aqueous NaHCO3 (100 mL).  The aqueous layer was extracted with CH2Cl2 (3x 50 
mL), dried over MgSO4, filtered and concentrated.  The crude product was purified by automated 
silica gel column chromatography (25 g solid load cartridge, 80 g column, 0-50% ethyl acetate in 
hexane) to yield recovered diene (857 mg, 21%) and mixture of silyl ethers 214 and 215 (4.58 g, 
69%, 87% brsm) as white foam. 
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Alcohols 216 and 217 (SY-VII-100) – Yuan Shi 
To a solution of the diastereomeric mixture of cycloadducts 214 and 215 (4.58 g, 5.43 mmol, 
1.00 equiv) in tetrahydrofuran (100 mL) was added a 1.0 M solution of TBAF in tetrahydrofuran 
(17.0 mL, 17.0 mmol, 3.13 equiv).  The resulting brownish solution was stirred at 20 oC for 4.5 h 
before being quenched with saturated aqueous NaHCO3 (100 mL) and separated.  The aqueous 
layer was extracted with CH2Cl2 (3x 50 mL), dried over MgSO4, filtered and concentrated.  The 
crude mixture was purified by automated silica gel column chromatography (25g solid load 
cartridge, 40 g column, 0-100% ethyl acetate in hexanes) to yield alcohols 216 and 217 (2.22 g 
71%) as a white foam.  This mixture was used without further purification or characterization. 
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Aldehydes 218 and 219 (VII-JTW-017) 
To a solution of alcohols 216 and 217 (2.22 g, 3.88 mmol, 1.00 equiv) in acetonitrile (39 mL, 0.1 
M) was added 2-iodoxybenzoic acid (IBX) (2.18 g, 7.76 mmol, 1.00 equiv).  This mixture was 
subjected to sonication for 7 h without stirring.  At this time the IBX had transformed from a 
sandy dense solid to a milky suspension. Celite (4.4 g) was added, the mixture stirred for 50 m, 
filtered through a plug of celite (2.5 x 2.5 cm) that was then flushed with ethyl acetate (200 mL). 
Solvent removal gave a white crystalline solid that was purified by automated silica gel column 
chromatography (25 g solid load cartridge, 220 g column, 5 – 75% ethyl acetate in hexanes) to 
yield undesired aldehyde 219 (1.24 g, 56%) as a white solid and desired aldehyde 218 (677 mg, 
31%) as a white solid. 
Desired aldehyde 218 
Rf = 0.26 (1 : 1 hexanes : ethyl acetate, CAM stain); 1H NMR (500 MHz, CDCl3) δ 8.82 (s, 1H), 
7.30 (m, 5H), 6.15 (s, 1H), 4.66 (d, 1H, J=14.2 Hz), 4.55 (d, 1H, J=14.3 Hz), 3.85 (m, 2H), 3.72 
(s, 3H), 3.29 (s, 3H), 2.95 (s, 1H), 2.79 (m, 1H), 2.67 (m, 2H), 2.51 (t, 1H, J=13.8 Hz), 2.39 (m, 
1H), 2.24 (s, 1H), 2.2~2.0 (m, 5H), 1.94 (s, 1H), 1.56 (m, 1H), 0.91 (m, 1H); 13C NMR (125 
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MHz, CDCl3) δ 210.00, 199.80, 172.43, 170.29, 136.08, 128.97, 128.89, 128.73, 128.21, 101.13, 
56.99, 53.43, 51.67, 47.96, 46.02, 44.54, 37.59, 37.06, 34.06, 31.54, 30.16, 29.06; IR (neat film) 
3057 (w), 2952 (m), 2847 (w), 2725 (w), 1718 (s), 1697 (s), 1655 (s), 1436 (m), 1398 (m), 1265 
(s), 1218 (s), 1116 (m), 737 (s), 702 (m) cm-1; LRMS (ESI) 593.97 (M+Na). 
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Enol ethers 219 (VII-JTW-022) 
To a solution of aldehyde 218 (672 mg, 1.18 mmol, 1.00 equiv) in CH2Cl2 (24 mL, 0.05 M) at 0 
ºC was added bis(trifluoromethanesulfonimide) (332 mg, 1.18 mmol, 1.00  equiv) and the 
solution was removed from the cooling bath and stirred for 2 h.  The resulting brown solution 
was then poured into ½ saturated aqueous NaHCO3 solution (25 mL), the phases were separated 
and the aqueous phase was extracted with CH2Cl2 (2x 25 mL).  The combined organic phases 
were dried over MgSO4, filtered, and the solvent was removed to give a yellow oil that was then 
purified by automated silica gel column chromatography (5 g solid load cartridge, 24 g column, 
5-75% acetone in hexanes) to yield a mixture of aldehyde epimers 219 (476 mg, 71%) as a white 
solid. 
Major epimer: 
Rf = 0.14 (1 : 1 hexanes : ethyl acetate, CAM stain); 1H NMR (500 MHz, CDCl3) δ 9.58 (s, 1H), 
7.26 (m, 5H), 5.57 (d, 1H, J=15.0 Hz), 5.39 (dd, 1H, J=6.2, 1.7 Hz), 4.70 (m, 1H), 4.19 (td, 1H, 
J=8.5, 5.9 Hz), 4.02 (d, 1H, J=15.0 Hz), 3.81 (s, 3H), 3.71 (dd, 1H, J=4.4, 1.4 Hz), 3.55 (dd, 1H, 
J=5.5, 4.0 Hz), 3.32 (s, 3H), 2.93 (ddd, 1H, J=12.1, 6.6, 1.5 Hz), 2.84 (dd, 1H, J=17.2, 1.8 Hz), 
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2.70 (dd, 1H, J=17.2, 6.2 Hz), 2.66 (dd, 1H, J=6.6, 6.6 Hz), 2.50 (ddd, 1H, J=15.8, 10.3, 6.3 Hz), 
2.43 (dd, 1H, J=15.8, 4.8 Hz), 2.31 (d, 1H, 6.6 Hz), 2.27 (dd, 1H, J=9.9, 4.8 Hz), 2.03 (ddd, 1H, 
J=15.0, 12.1, 8.5 Hz), 1.89 (ddd, 1H, J=15.4, 7.7, 7.0 Hz), 1.78 (m, 1H), 1.68 (ddd, 1H, J=13.9, 
10.6, 7.7 Hz), 1.15 (dd, 1H, J=14.7, 8.5 Hz), IR (neat film) 2917 (w), 1720 (s), 1640 (s), 1460 
(m), 1263 (s), 1238 (s), 1144 (s), 1106 (s), 994 (m), 736 (s) cm-1; LRMS (ESI) 593.97 (M+Na). 
 
Silyl ether S11 (VII-JTW-023) 
To a solution of aldehyde 219 (476 mg, 0.834 mmol, 1.00 equiv) in CH2Cl2 (8.3 mL, 0.1 M) 
were added triethylamine (349 μL, 2.50 mmol, 3.00 equiv) and tert-butyldimethylsilyl 
trifluoromethanesulfonate (287 μL, 1.25 mmol, 1.50 equiv).  The resulting solution was stirred 
for 16 h, quenched with ½ saturated aqueous NaHCO3 solution (10 mL) and the phases were 
separated.  The aqueous phase was extracted with CH2Cl2 (2x 10 mL).  The combined organic 
phases were dried over Na2SO4 and concentrated to give a yellow oil.  Purification by automated 
silica gel column chromatography (5 g solid load cartridge, 25 g column, 5-90% ethyl acetate in 
hexanes) afforded silyl ether S11 (493 mg, 86%) as a hard white foam. 
Rf = 0.70 (minor isomer), 0.58 (major isomer); 1H NMR (8:1 mixture) (500 MHz, CDCl3) δ 7.26 
(m, 45H), 6.04 (d, 1H, J=2.2 Hz), 5.95 (d, 8H, J=2.0 Hz), 5.58 (d, 9H, J=14.9 Hz), 5.34 (dd, 8H, 
J=6.1, 1.9 Hz), 5.30 (m, 1H), 4.72 (m, 9H), 4.20 (m, 9H), 3.21 (s, 3H), 3.20 (s, 24H), 2.87 (dd, 
8H, J=17.6, 9.8 Hz), 2.77 (dd, 9H, J=17.2, 2.1 Hz), 2.69 (dd, 9H, J=17.1, 6.2 Hz), 2.58 (m, 9H), 
2.51 (m, 9H), 2.43 (dd, 9H, J=15.8, 4.7 Hz), 2.30 (m, 18H), 2.23 (m, 9H), 1.90 (m, 9H), 1.82 (m, 
 165
9H), 1.37 (dd, 9H, J=13.6, 8.0 Hz), 0.91 (s, 81H), 0.09 (s, 54H); IR (neat film) 2952 (s), 2930 
(s), 2856 (m), 1734 (s), 1654 (s), 1452 (m), 1286 (s), 1140 (s), 1114 (m), 1004 (w),  832 (s) cm-1; 
LRMS (ESI) 706.41 (M+Na). 
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Ketone 230 (VII-JTW-024) 
To a solution of silyl ether S11 (493 mg, 0.720 mmol, 1.00 equiv) in 10:1 tetrahydrofuran:water 
(7.2 mL) were added 2,6-lutidine (209 μL, 1.80 mmol, 2.50 equiv), 2.5 wt% OsO4 in tert-butanol 
(181 μL, 0.0144 mmol, 0.02 equiv), and PhI(OAc)2 (533 mg, 1.66 mmol, 2.30 equiv).  The 
resulting solution was stirred at room temperature for 1 h, at which time a white precipitate 
appeared. The suspension was then quenched with saturated aqueous Na2S2O3 solution (7 mL).  
This mixture was stirred vigorously for 20 m, diluted with H2O (20 mL) and extracted with 
CH2Cl2 (3x 20 mL).  The combined organic extracts were dried over MgSO4, filtered, and 
concentrated to give a brown solid.  Purification by silica gel column chromatography (2 : 1 
CH2Cl2 : hexanes followed by 1 : 1 CH2Cl2 in hexanes) afforded ketone 230 (294 mg, 74%) as a 
fluffy white solid. 
Rf = 0.6 (1 : 1 CH2Cl2 in hexanes, KMnO4 stain); 1H NMR (500 MHz, CDCl3) δ 7.26 (m, 5H), 
5.61 (d, 1H, J=14.9 Hz), 5.42 (m, 1H), 4.71 (m, 1H), 4.36 (m, 1H), 4.04 (d, 1H, J=14.9 Hz). 3.83 
(m, 1H), 3.81 (s, 3H), 3.79 (m, 1H), 3.25 (s, 3H), 2.90 (dd, 1H, J=6.6, 6.6 Hz), 2.74 (m, 2H), 
2.69 (m, 1H), 2.62-2.46 (m, 4H), 2.30 (d, 1H, J=6.4 Hz), 2.09 (m, 1H), 1.99 (m, 1H), 1.45 (dd, 
1H, J=14.4, 8.5 Hz); 13C NMR (125 MHz, CDCl3) δ 208.87, 172.01, 168.77, 144.77, 135.92, 
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129.40, 128.44, 127.66, 114.00, 84.58, 71.43, 65.34, 57.51, 57.26, 52.75, 52.24, 50.81, 50.42, 
50.29, 45.74, 39.69, 38.16, 36.09, 35.22, 33.86, 26.26; IR (neat film) 2930 (w), 1727 (s), 1649 
(s), 1452 (m), 1238 (m), 1210 (m), 1143 (m), 1107 (m), 913 (m), 729 (s) cm-1; HRMS (ESI) 
calc'd for C28H30NO6BrNa (M+Na) 578.1154 found 578.1154. 
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Epoxide 235 (VI-JTW-107) 
To a solution of enol ether 230 (4.5 mg, 0.0081 mmol, 1.0 equiv) in CH2Cl2 (900 μL) at 20 °C 
was added a 0.09 M solution of dimethyldioxirane in acetone (900 μL, 0.08 mmol, 10 equiv).  
The vessel was wrapped in aluminum foil and stirred at 20 °C for 4.5 h.  The solvent was 
removed by vacuum to give epoxide 235 as a film (4.6 mg, >99%). No purification was 
necessary. 
Rf = 0.50 (2 : 1 CH2Cl2 : ethyl acetate, CAM stain); 1H NMR (600 MHz, CDCl3) δ 7.30 (m, 5H), 
5.56 (d, 1H, J=14.5 Hz), 4.79 (m, 1H), 4.26 (t, 1H, J=8.8 Hz), 3.99 (d, 1H, J=14.5 Hz), 3.84 (d, 
1H, J=3.1 Hz), 3.81 (t, 1H, J=4.6 Hz), 3.78 (s, 3H), 3.28 (s, 3H), 3.11 (d, 1H, J=5.5 Hz), 2.91 
(m, 1H), 2.77 (dd, 1H, J=19.2, 10.3 Hz), 2.75 (m, 1H), 2.64 (d, 1H, J=18.7 Hz), 2.60 (dd, 1H, 
J=15.4, 5.6 Hz), 2.51 (m, 1H), 2.45 (dd, 1H, J=15.9, 4.2 Hz), 2.29 (d, 1H, J=15.4 Hz), 2.23 (m, 
2H), 2.17 (d, 1H, J=3.5 Hz), 1.92 (m, 1H); 13C NMR (150 MHz, CDCl3) δ 210.52, 171.18, 
169.06, 135.84, 129.84, 128.50, 127.98, 83.57, 82.14, 70.13, 64.72, 57.88, 56.05, 53.63, 53.17, 
52.86, 51.41, 50.82, 47.59, 44.25, 43.51, 36.60, 36.30, 35.66, 35.26, 24.39, 1.17; LRMS (ESI) 
572.1 (M+H), 594.1 (M+Na), 610.1 (M+K). 
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Allylic alcohol 236 (SY-VII-117) – Yuan Shi 
To a solution of enol-ether 230 (243 mg, 0.436 mmol, 1.00 equiv) in a mixed solvent of CH3CN 
and CH2Cl2 (v/v 4/1, 18 mL, 0.024 M) was added a 0.5 M aqueous solution of Cerium(IV) 
Ammonium Nitrate (2.60 mL, 1.30 mmol, 3.00 equiv).  The resulting cloudy solution was stirred 
at 50 oC in a sealed tube for 3 h. A second addition of 0.5 M aqueous solution of Cerium(IV) 
Ammonium Nitrate (800 μL, 0.400 mmol, 0.920 equiv) was added and the reaction was heated at 
50 oC for additional 30 m then cooled to 20 °C.  The reaction was diluted with H2O (20mL), 
extracted with CH2Cl2 (3x 20 mL), dried over MgSO4 and concentrated to give 236.  The residue 
was used in the next step without further purification. 
A purified sample was obtained by prep TLC for characterization purposes: 
Rf = 0.23 (1 : 1 ethyl acetate : CH2Cl2, KMnO4 stain); 1H NMR (500 MHz, CDCl3) δ 7.28-7.26 
(m, 3H), 7.22-7.20 (m, 2H), 5.60 (d, 1H, J=6.3 Hz), 5.52 (d, 1H, J=14.7 Hz), 4.78-4.74 (m, 2H), 
4.40-4.36 (m, 1H), 3.98 (d, 1H, J=14.7 Hz), 3.87 (s, 3H), 3.84 (dd, 1H, J=5.5, 4.5 Hz), 3.77 (dd, 
1H, J=4.5, 1.4 Hz), 3.25 (s, 3H), 2.91-2.89 (m, 2H), 2.69-2.62 (m, 4H), 2.55-2.52 (m, 1H), 2.13-
2.08 (m, 1H), 2.05-1.99 (m, 1H), 1.63 (dd, 1H, J=14.5, 8.4 Hz); 13C NMR (125 MHz, CDCl3) δ 
208.29, 173.61, 167.28, 149.61, 135.47, 129.52, 128.52, 127.85, 115.96, 85.54, 72.20, 69.05, 
64.35, 60.95, 57.46, 52.98, 52.33, 51.17, 50.99, 50.31, 39.78, 39.27, 38.11, 35.99, 34.59, 29.84, 
26.11; IR (neat film) 3436 (m), 2927 (s), 2854 (s), 1724 (s), 1646 (s), 1456 (m), 1242 (s), 1143 
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(m), 1106 (m), 910 (m), 733 (s) cm-1; HRMS (ESI) calc'd for C28H30NO7BrNa (M+Na+) 
594.1103 found 594.1110. 
 
Enone 239 (SY-VII-120) – Yuan Shi 
To a solution of alcohol 236 (crude product from above) in CH2Cl2 (20 mL) was added Et3N (1.8 
mL, 12.9 mmol, 29.6 equiv) and methanesulfonyl chloride (170 μL, 2.19 mmol, 5.02 equiv).  
The resulting solution was stirred at 50 oC in a sealed tube for 1.5 h then cooled 20 °C. Further 
methanesulfonyl chloride (35 μL, 0.45 mmol, 1,0 equiv) was added and the reaction was heated 
to 50 oC for additional 15 m then cooled to ambient temperature and quenched with saturated 
aqueous NaHCO3 (20 mL), extracted with CH2Cl2 (3x 10 mL), dried over MgSO4 and 
concentrated.  The residue was purified by automated silica gel column chromatography (5 g 
solid load cartridge, 4 g column, 0-50% ethyl acetate in CH2Cl2) to yield enone 239 (139 mg 
57% over 2 steps) as a pale purple solid along with recovered starting alcohol 236 (11.0 mg, 4.5 
%). 
Rf = 0.41 (1 : 1 ethyl acetate : CH2Cl2, KMnO4 stain); 1H NMR (500 MHz, CDCl3) δ 7.48 (d, 
1H, 9.5 Hz), 7.33-7.32 (m, 3H), 7.09-7.08 (m, 2H), 6.52-6.48 (m, 1H), 6.17 (d, 1H, J=9.5 Hz), 
6.07 (dd, 1H, J=9.8, 1.7 Hz), 5.47 (d, 1H, J=14.6 Hz), 4.43-4.40 (m, 1H), 3.94 (d, 1H, J=14.5 
Hz), 3.90 (s, 3H), 3.78 (m, 1H), 3.73 (m, 1H), 3.17 (s, 3H), 2.94 (m, 1H), 2.88 (m, 1H), 2.78-
2.74 (m, 1H), 2.71-2.64 (m, 2H), 2.55-2.51 (m, 1H), 2.30-2.27 (dt, 1H, J=14.0, 8.4 Hz), 1.31 (dd, 
1H, J=13.9, 9.2 Hz); 13C NMR (125 MHz, CDCl3) δ 199.89, 195.68, 170.00, 165.83, 150.28, 
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144.55, 135.32, 130.62, 129.48, 128.64, 128.25, 86.81, 68.79, 59.38, 57.89, 57.64, 53.72, 52.63, 
51.82, 48.57, 46.48, 44.25, 42.75, 37.05, 26.10; IR (neat film) 2918 (m), 1741 (m), 1661 (s), 
1199 (s), 1121 (s), 969 (m) cm-1; LRMS (ESI) calc'd for C28H28NO6BrNa (M+Na) 576.10, 
578.10 found 576.27, 578.22. 
 
Ketone 240 (SY-VII-123) – Yuan Shi 
A solution of enone 239 (130 mg, 0.234 mmol, 1.00 equivalent) in benzene (9.0 mL) was 
subjected to 1x freeze-pump-thaw cycle. To this solution was added a solution of AIBN (3.9 mg, 
0.024 mmol, 0.10 equiv) and Bu3SnH (70 μL, 0.26 mmol, 1.11 equiv) in benzene (1.20 mL).  
The resulting solution was heated at 80 oC for 30 m then cooled to 20 °C and concentrated.  The 
residue was purified by automated silica gel column chromatography (5 g solid load cartridge, 4 
g column, 0-100% ethyl acetate in hexanes) to yield ketone 240 (96.0 mg, 86%) as an off white 
solid. 
Rf = 0.20 (1 : 5 Acetone : Toluene, KMnO4 stain); 1H NMR (500 MHz, CDCl3) δ 7.43 (d, 1H, 
J=9.6 Hz), 7.32-7.30 (m, 3H), 7.14 (m, 2H), 6.17 (d, 1H, J=9.5 Hz), 4.61 (d, 1H, J=14.5 Hz), 
4.38 (d, 1H, J=14.6 Hz), 3.89 (s, 3H), 3.84 (t, 1H, J=5.0 Hz), 3.62 (s, 1H), 3.28 (s, 3H), 2.87-
2.82 (m, 2H), 2.59-2.52 (m, 1H), 2.41-2.35 (m, 2H), 2.28-2.23 (m, 2H), 2.18-2.12 (m, 3H), 1.85 
(dd, 1H, J=19.6, 3.9 Hz), 1.77 (dd, 1H, J=15.1, 7.5 Hz); 13C NMR (125 MHz, CD2Cl2) δ 211.51, 
211.25, 172.44, 168.47, 137.23, 129.29, 129.08, 129.02, 128.10, 83.67, 60.90, 59.69, 58.40, 
57.61, 52.98, 51.55, 51.10, 46.81, 46.61, 40.14, 39.09, 36.08, 34.83, 33.19, 30.65, 30.03, 29.74, 
28.18, 27.70, 27.19, 17.81, 13.72; IR (neat film) 2947 (s), 2895 (s), 2866 (s), 1757 (s), 1720 (s), 
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1672 (s), 1465 (m), 1216 (s), 1143 (s), 883 (m) 687 (m) cm-1; LRMS (ESI) calc'd for 
C28H29NO6Na (M+Na) 498.19 found 498.14. 
 
Phenylselenide S12 (SY-VII-132) – Yuan Shi 
To a solution of ketone 240 (85 mg, 0.18 mmol, 1.0 equiv) in tetrahydrofuran (1.8 mL) at –78 oC 
was added a 0.5 M solution of LHMDS in tetrahydrofuran (360 μL, 0.180 mmol, 1.00 equiv).  
The resulting enolate solution was stirred at –78 oC for 1 h then transferred via cannula to a 
solution of phenylselenyl chloride (67.8 mg, 0.354 mmol, 2.00 equivalent) in tetrahydrofuran 
(1.8 mL) at –78 oC and quantitated with additional tetrahydrofuran (500 μL).  The reaction was 
stirred at –78 oC for another 30 m then warmed to 20 °C over 10 m.  The reaction was then 
quenched with saturated aqueous NaHCO3 solution (10 mL), and extracted with CH2Cl2 (3x 10 
mL) The combined organic extracts were dried over MgSO4, filtered, and concentrated. The 
residue was purified by automated silica gel column chromatography (5 g solid load cartridge, 4 
g column, 0-60% acetone in hexane) to yield phenylselenide S12 (85.0 mg, 75%) as a pale 
yellow solid. 
Rf = 0.28 (1 : 5 Acetone : Toluene, KMnO4 stain); 1H NMR (500 MHz, CDCl3) δ 7.74 (dd, 2H, 
J=7.6, 1.3 Hz), 7.42 (d, 1H, J=9.6 Hz), 7.37-7.34 (m, 3H), 7.21-7.14 (m, 3H), 6.88 (d, 2H, J=7.2 
Hz), 6.15 (d, 1H, J=9.5 Hz), 4.78 (d, 1H, J=14.6 Hz), 3.88 (s, 3H), 3.83 (d, 1H, J=14.5 Hz), 3.80 
(t, 1H, J=4.9 Hz), 3.53 (s, 1H), 3.33 (d, 1H, J=5.7 Hz), 3.21 (s, 3H), 3.03 (m, 1H), 2.83 (d, 1H, 
J=7.5 Hz), 2.59-2.56 (m, 1H), 2.38-2.36 (m, 3H), 2.20-2.17 (m, 2H), 2.07-2.04 (m, 1H), 1.74 
(dd, 1H, J=13.6, 7.3 Hz); 13C NMR (125 MHz, CDCl3) δ 208.06, 197.92, 170.47, 165.81, 
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149.56, 135.96, 135.74, 130.72, 129.34, 129.03, 128.64, 128.25, 83.43, 60.20, 59.66, 57.16, 
54.20, 53.58, 53.48, 51.34, 49.73, 48.01, 45.00, 41.84, 37.43, 29.34; IR (neat film) 2953 (m), 
2931 (m), 1736 (s), 1724 (s), 1674 (s), 1654 (s), 1451 (m), 1437 (s), 1243 (s), 911 (m), 733 (s) 
cm-1; LRMS (ESI) calc'd for C34H33NO6SeNa (M+Na) 654.14 found 654.27. 
 
Alcohol 242 (SY-VII-135, SY-VII-156) – Yuan Shi 
To a solution of phenylselenide S12 (25.0 mg, 0.0396 mmol, 1.0 equiv) in CH2Cl2 (2.5 mL, 
0.016 M) at 0 oC was added a freshly diluted 1.0 M solution of H2O2 in H2O (105 μL, 0.105 
mmol, 2.70 equiv) in 4 equal portions slowly, one every 20 m.  20 m after the last addition, the 
reaction mixture was quenched with saturated aqueous NaHCO3 (10 mL), and extracted with 
CH2Cl2 (3x 10 mL). The combined organic extracts were dried over MgSO4, filtered, and 
concentrated.  The residue was quickly purified by a short pipette silica gel column (40% acetone 
in hexane) to give enone 241 (17.0 mg, 90%) as an off white solid. This was immediately used in 
the next step. 
Rf = 0.21 (1 : 5 Acetone : Toluene, KMnO4 stain). 
To a solution of enone 241 (16.0 mg, 0.0338 mmol, 1.00 equiv) in tetrahydrofuran (1.6 mL) was 
added a 33% acetic acid in H2O solution (400 μL diluted to 2.0 mL with H2O).  The resulting 
mixture was stirred at 20 °C for 23 h then quenched with aqueous 0.5 N aqueous HCl (10 mL) 
and extracted with CH2Cl2 (3x 10 mL). The combined organic extracts were dried over MgSO4, 
filtered, and concentrated.  The residue was purified by pipette column (16% acetone in toluene) 
to give alcohol 242 (12.8 mg, 77%) as an off white solid. 
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Rf = 0.22 (3 : 11 Acetone : Toluene, KMnO4 stain); 1H NMR (500 MHz, CDCl3) δ 7.45 (d, 1H, 
J=9.5 Hz), 7.32 (m, 3H), 7.13 (m, 2H), 6.18 (d, 1H, J=9.5 Hz), 4.69 (d, 1H, J=14.6 Hz), 4.36 (d, 
1H, J=14.6 Hz), 3.98 (t, 1H, 5.9 Hz), 3.90 (s, 3H), 3.57 (d, 1H, J=1.1 Hz), 3.32 (s, 3H), 3.30 (s, 
1H), 2.94 (m, 1H), 2.82 (m, 1H), 2.57 (d, 1H, J=20.3 Hz), 2.49 (d, 1H, J=20.3 Hz), 2.29-2.27 (m, 
4H), 2.17 (m, 1H), 2.13 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 208.86, 197.95, 170.63, 165.80, 
149.85, 138.02, 135.96, 130.83, 129.18, 129.14, 128.56, 128.44, 128.37, 125.44, 84.47, 73.44, 
62.32, 59.79, 57.81, 54.00, 52.38, 50.33, 50.27, 49.47, 48.72, 44.92, 40.45, 29.84, 28.31, 25.73, 
21.61; IR (neat film) 3531 (m), 2956 (s), 2925 (s), 1727 (s), 1656 (s), 1452 (s), 1242 (s), 913 (m) 
cm-1; LRMS (ESI) calc'd for C28H29NO7Na (M+Na) 514.18 found 514.08. 
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CHAPTER 6. CONCLUSIONS AND PROSPECTUS 
6.1 Innovations Resulting from the Cephalotaxus Esters Syntheses 
The development of a novel approach to the Cephalotaxus esters has enabled the 
synthesis of potent anti-leukemia agents deoxyharringtonine (2), anhydroharringtonine (3), 
homoharringtonine (4), and homodeoxyharringtonine (5), The construction of non-racemic 
strained β-lactone acyl chain derivatives allowed the direct C3-O-acylation of cephalotaxine (1), 
a longstanding challenge within the synthetic community. This technology also allowed the 
cytotoxicity screening of various natural and non-natural Cephalotaxus esters against an array of 
human hematopoetic and solid cancer cell lines, the results of which led to the discovery of 
several non-natural cytotoxic compounds. In addition, an unprotected hydroxyl group at the C2' 
position was found to be necessary for potent anti-tumor activity. Moreover, several members of 
these alkaloids were found to overcome the multi-drug resistance of the HL/60 RV+ cell line. 
These discoveries, when applied in concert with ready access to non-natural analogues via our 
novel strain accelerated acylation of cephalotaxine (1) (Scheme 59), should guide the design and 
construction of future anti-cancer agents capable of overcoming MDR in leukemia as well as 
other cancer types. 
 
 
 
 175
6.2 Innovations resulting from the Current Approach to the Aconitine Alkaloids 
Several innovations were developed during the synthesis of the carbon-nitrogen skeleton 
of the aconitine alkaloids. These include: (1) use of a cyclopropene as the 2π and a 2,5-
dioxycyclopenta-1,3-diene as the 4π components of a Diels–Alder cycloaddition; (2) Diels–
Alder cycloaddition with a azepin-2(5H)-one dienophile; (3) cyclopropylcarbinyl aldehyde 
fragmentation with subsequent N-acyliminium cyclization (Scheme 60). 
C5-hydrogen substituted cyclopentadienes are known to undergo substituent 
rearrangement via 1,5-hydrogen migrations. In spite of this possible limitation, it was shown that 
2,5-dioxycyclopenta-1,3-diene 134 would react with various dienophiles to produce the Diels–
Alder cycloadducts without evidence of hydrogen shift. Furthermore, cyclopropene 112 was 
shown to engage in endo approach to 134 stereoselectively in a contra-steric fashion syn to the 
methyl ether. The resultant C14, C13, and C9 configuration coincides with that in the aconitine 
alkaloids. A second Diels–Alder cycloaddition with novel azepin-2(5H)-one 213 as the 4π-
component constructed the [5.4.0]-bicycloazepine 214 and set the C4, C5, and C10 stereocenters. 
Dienophile 213 would have applications beyond that of the aconitine alkaloids in that it is a 
useful reagent for the introduction of a highly functionalized 7-membered nitrogen containing 
heterocycle. The successful implementation of the two above-mentioned Diels–Alder reactions 
installed all the requisite carbons and nitrogen atoms present in the aconitine alkaloid skeleton. 
However, there were two key carbon-carbon bonds left to be formed, namely the C11–C17 and 
C7–C8 bonds. The former was installed through the acid-catalyzed strain release fragmentation 
of a cyclopropylcarbinyl aldehyde followed by addition of electron-rich C11 onto the C17 
bromonium (227). The latter was installed via conjugate addition of a C8 radical onto an electron 
deficient olefin at C7. 
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 The above-mentioned innovations as applied to the synthesis of the aconitine alkaloids 
have resulted in a convergent synthesis of the carbon and nitrogen aconitine core. The work 
described herein marks the first successful construction of the complete acontine skeleton since 
the seminal accomplishments of the Wiesner group more than 30 years ago. This approach 
compares favorably with that of Wiesner in that it addresses the key concerns outlined in Chapter 
2. Specifically, this strategy is highly convergent in that the two Diels–Alder reactions outlined 
above collectively install four rings and set five stereocenters that are required for the aconitine 
alkaloids. A minimum of functional group manipulations should allow access to various natural 
aconitine alkaloids from alcohol 242. 
 Moreover, the advanced intermediate bis(enone) 241 is an ideal precursor for a number 
of both natural and non-natural aconitine alkaloids. The highly strained anti-Bredt nature of the 
C8–C15 olefin allows differentiation from the C2–C3 olefin, as demonstrated by the facile 
addition of water at C8. A variety of nitrogen, sulfur, halogen, and carbon nucleophiles could 
also undergo nucleophilic addition at C8 or C3. These modifications combined with a number of 
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potential C16, C1, and C18 carbonyl manipulations provide a pathway for any number of C1, 
C2, C3, C8, C15, C16, and C18 aconitine analogues. These analogues should not only be ideal to 
interrogate the neuropharmacology of aconitine alkaloids with Na+ ion channels, but also provide 
new tools to study ion channel structure and function in general. These advances hold the 
promise to develop to new therapies for antinociception, arrhythmia, inflammation as well as 
other cardiovascular and central nervous system diseases. 
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